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3Introduction
Liver transplantation has emerged over the past decades as a successful 
treatment option for patients with acute liver failure, end-stage liver disease, 
and hepatocellular carcinoma (1). After the kidney, the liver is the second most 
transplanted organ worldwide. Annually, around 6000 liver transplantations are 
performed in Europe, a number similar to that of the Unites States of America 
(1). One-year patient survival rate after transplantation is about 85-90% and 
the long-term survival rate is approximately 75-85% (1,2). Although the number 
of transplantations has increased progressively over the last three decades, the 
expanding demand of liver grafts is not balanced by an increase in donation of 
livers. The annual report of the Eurotransplant International Foundation 2013 
showed a growing difference between available donor livers and the number 
of patients on the waiting list. Currently, approximately 15% of patients die 
while waiting for a suitable donor organ (2). In the beginning of clinical liver 
transplantation, donor livers were recovered from relatively young and healthy 
donors who had suffered traumatic brain injury, typically in the context of a 
motor vehicle accident. However, the supply of these reference donors is not 
enough to expand the pool of available organs today. To minimize the current 
organ shortage, many centres try to reduce the present misbalance between 
organ demand and supply, with the use of domino liver grafts, living donations, 
and so-called extended criteria donor (ECD) livers. Today, around two-thirds of 
transplanted livers are derived from ECDs (3,4). Characteristics of ECD livers are 
donor age above 40 years, graft steatosis, grafts with underlying diseases (for 
example hepatitis B and C), donors derived from donation after circulatory death 
(DCD) procedures, donors with abnormal liver function tests, and causes of donor 
death different than trauma (5). ECD livers, previously called “suboptimal grafts”, 
are associated with an expected inferior tissue quality compared to reference 
donors. Due to this impaired quality, ECD livers are more prone to preservation 
and ischemia/reperfusion (I/R) related injuries (5-7). As a result, ECD livers are 
related to higher incidences of postoperative risks such as an increased rate of 
primary non-function (PNF), delayed graft function, and biliary complications 
(8,9). In particular, biliary complications, like non-anastomotic strictures (NAS), 
are a major reason for long-term morbidity. Patients with NAS may suffer from 
recurrent periods of cholangitis due to bile duct necrosis and fibrosis. In severe 
cases of NAS, injury to the bile ducts may cause biliary cirrhosis and unfortunately, 
a second episode of end-stage liver disease. For that reason, severe NAS can only be 
cured with a retransplantation (10). Therefore, NAS formation is one of the most 
troublesome complications after transplantation. In particular, the occurrence of 
NAS after DCD donation limits transplant centers to routinely accept DCD donor 
livers for transplantation (11).
1
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4Currently, the issue is not whether ECD livers should or should not be used in liver 
transplantation. ECD livers are immediately needed for increasing the pool of 
potential donor livers, even if their use is associated with an increased morbidity 
and mortality (5). One of the current strategies to deal with ECD donor livers is to 
only accept them for transplantation when additional donor and recipient related 
risk factors are limited (11,12). On the other hand, some studies have shown that 
also a survival benefit can be achieved if ECD donors are transplanted in patients 
with high model for end-stage liver disease (MELD) scores (13,14). Although both 
strategies will lead to a reduction of waiting list mortality, these strategies are 
not sufficient enough to make more ECD livers suitable for transplantation. For 
that reason, the aim of this thesis is to assess other strategies to improve outcome 
after transplantation of ECD livers. In particular, we studied the potential role of 
machine perfusion in reducing hepatobiliary preservation injury and its ability to 
enhance organ quality prior to transplantation. 
Part A: Strategies to Improve Outcome after Transplantation of ECD 
livers in Clinical and Animal Studies 
The aim of this section (Part A) is to study the effects of new potential strategies in 
handling ECD livers, as conducted in clinical and animal studies. One of the easiest 
strategies to lower the decline in quality of an ECD liver is reduction of the cold 
ischemia time. The cold ischemia time during a transplant procedure is defined as 
the time between cooling of a liver graft, subsequent cold storage on ice, and the 
start of implantation in the recipient. 
As mentioned previously, advanced age of the donor is an important ECD liver 
variable. Due to the aging process, the older liver has an impaired regenerative 
capacity and decreased synthetic function (15). Moreover, these livers have a 
reduced capacity to adequately respond to oxidative stress, to which the liver 
is exposed during preservation (16). Transplantation of livers from older aged 
donors has been associated with an impaired postoperative function and a higher 
incidence of biliary complications (17,18). On the other hand, one could hypothesize 
that acceptable postoperative outcomes can still be achieved if the cold ischemia 
time is kept short when elderly donor livers are transplanted. In chapter 2 we 
tested this hypothesis in a study focussing on postoperative outcomes, in particular 
incidences of biliary complications, after transplantation of elderly donor livers (≥ 
65 years) in a cohort of patients transplanted in the three transplant centers in the 
Netherlands. 
Another ECD liver variable is donor liver steatosis. From a histological perspective, 
steatosis can be categorised qualitatively and quantitatively. Qualitatively, there 
are two different histological varieties of hepatic steatosis: macrovesicular and 
microvesicular steatosis. Quantitatively, hepatic steatosis can be categorized 
1
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5according to the percentage of hepatocytes affected by fat vacuoles; < 30% mild, 
30-60% moderate, and > 60% severe steatosis (19). To what extent steatosis affects 
postoperative outcome depends on the type and grading. Macrovesicular steatosis 
is in general associated with higher susceptibility to I/R injury and poorer 
postoperative graft function, whereas microvesicular steatosis does not negatively 
influence outcome (20). In addition, mild macrovesicular hepatic steatosis is 
thought not to negatively affect outcome, on the other hand, the general consensus 
is that severe macrovesicular steatotic grafts should not be used for transplantation 
(20,21). Moderate steatosis is an important risk factor for poorer postoperative 
outcome. It is, however, unclear what the effects of moderate steatosis are on 
postoperative outcomes when the cold ischemia time is kept short (12). The 
aim of chapter 3 was therefore to examine if short cold ischemia times during 
transplantation of moderate (30-60%) macrovesicular steatotic donor livers can 
lead to similar postoperative outcomes compared to donor livers without steatosis. 
Nowadays, no tools are available to quickly and accurately evaluate the degree of 
hepatic steatosis (22). Assessment of the donor liver is mostly performed in a short 
period of time. Although histopathological assessment by the pathologist is still the 
gold standard, this technique is prone to intra- and interobserver variability and 
pathological expertise is not always available during off hours, especially not in a 
local donor hospital (23). In addition, inspection and palpation by the surgical team 
during the donation procedure has low predictive value and remains subjective, 
especially in grafts with higher degrees of steatosis (> 30%) (24,25). Moreover, 
ultrasound, computed tomography, magnetic resonance imaging, and magnetic 
resonance spectroscopy can visualize the hepatic fat content accurately, but none 
of these techniques can distinguish between different degrees of macrovesicular 
steatosis and they are all relatively time-consuming (22,26). Due to this lack of 
techniques, which can assess hepatic steatosis accurately and in real-time, there 
is a risk that the degree of steatosis is overrated and mild steatotic grafts are 
incorrectly declined for transplantation. In chapter 4 and 5 we, therefore, studied 
whether a new technique, diffuse reflectance spectroscopy (DRS) developed by 
Philips Healthcare, could measure the degree of hepatic steatosis accurately and in 
real-time. In particular, we assessed if the DRS system could discriminate between 
mild and moderate/severe steatosis, to help the transplantation team with a better 
evaluation of the degree of macrovesicular steatosis in potential donor livers. 
Intraoperative blood loss and transfusion requirements during liver 
transplantation have also been identified as risk factors for inferior postoperative 
outcome (27-29). The possible negative effects of blood transfusions include 
alloimmunization, transmission of viral diseases, graft-versus-host disease, and 
an increased postoperative infection rate (30). ECD livers are related to inferior 
graft quality and increased vulnerability for preservation injury (5). It is therefore 
conceivable that transplantation with ECD livers is associated with more blood 
1
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6loss and higher amounts of transfusion requirements. The purpose of the study 
described in chapter 6 is to determine whether ECD livers, defined as a donor risk 
index score of 1.7 or higher, are associated with increased intraoperative blood loss 
and transfusion requirements during transplantation.  
Part B: Machine Perfusion as a Strategy to Improve Hepatobiliary 
Viability in ECD Livers   
The aim of this section (Part B) is to study the effects of machine perfusion in 
its ability to reduce hepatobiliary preservation injury and improve function of 
ECD livers. Recently, machine perfusion during organ preservation has regained 
clinical interest for optimizing ECD liver organs prior to transplantation (31-
33). The advantages of machine perfusion over static cold storage (the current 
preservation method) include continuous perfusion of the liver with perfusion 
fluid enriched with oxygen and nutrients. As a result, the liver will less suffer from 
anaerobic conditions, which normally occurs during static cold storage (34,35). By 
providing oxygen and nutrients, the mitochondria can maintain a better functional 
state and more importantly, the effects of hepatobiliary preservation injury and 
I/R injury will be minimized compared to static cold storage alone (36). It is known 
that ECD livers are more prone to hepatobiliary preservation and I/R injury. As a 
consequence, the general hypothesis is that ECD livers will benefit the most from 
machine perfusion during organ preservation (37).   
In chapter 7 we provide an overview of the literature on the pathophysiology 
of NAS and the potential protective role of machine perfusion to lower biliary 
preservation injury. The aim of chapter 8 is to examine the role of the peribiliary 
glands in the pathophysiology of NAS and to find new starting points for future 
research with machine perfusion. 
Although various studies have been shown that with machine perfusion 
postoperative outcomes of ECD livers can be enhanced, knowledge is still limited 
about its working mechanism. The aim of chapter 9 is therefore, to examine the 
effects of machine perfusion at the end of the period of static cold storage (also 
called end-ischemic machine perfusion) on a variety of human (discarded) ECD 
livers. In this study, machine perfusion was conducted at a perfusion temperature 
of 10 0C (hypothermic machine perfusion). However, the optimal perfusion 
temperature and temperature strategy for end-ischemic machine perfusion is still 
under debate (4). In particular, the optimal perfusion temperature for protection 
of the vulnerable bile ducts in DCD donor livers is not known. It is the purpose of 
chapter 10 to examine the ideal perfusion temperature and temperature strategy 
during end-ischemic machine perfusion in DCD rat livers. 
1
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7Machine perfusion at 37 degrees (normothermic machine perfusion) has the 
benefit that the liver is fully metabolically active. As a result, during normothermic 
machine perfusion pharmacological compounds could be added to the perfusion 
solution to optimize graft quality and lower preservation injury (38,39). In 
chapter 11 we report on the results of a study on the pharmacological pre- and 
postconditioning effects of metformin during normothermic machine perfusion 
in rat donor livers.  
In chapter 12 the results as described in the thesis are summarized and future 
perspectives are discussed. 
Finally, this thesis ends with a Dutch summary (chapter 13).
1
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Abstract
Background: Liver transplantation with livers grafts from elderly donors has 
been associated with a higher risk of biliary complications. The aim of this study 
was to examine if our national protocol could contribute to a lower incidence of 
biliary complications.  
Methods: All adult transplant recipients in the Netherlands transplanted with a 
liver from an elderly donor (≥ 65 years; n = 68) in the period January 2000 – July 
2011 were matched with recipients of a liver from a donor < 65 years (n = 136). 
Outcome parameters were 90-day, 1- and 3-year patient/graft survival rates, biliary 
complications (non-anastomotic stricture, anastomotic stricture, biliary leakage 
and posttransplant cholangitis), and postoperative hepatic ischemic-injury serum 
markers (AST/ALT). 
Results: The median cold ischemia time was 7:25 (hr:min) in the group recipients 
of an elderly donor liver graft. Ninety-day, 1- and 3-year patient/graft survival 
rates were similar between the group with an elderly donor liver and their 
younger controls. Moreover, no differences were found in the incidence of biliary 
complications and postoperative levels of AST/ALT between the two groups. 
Conclusion: Transplantation of livers from elderly donors (≥ 65 years) is not 
associated with a higher incidence of biliary complications, in a national policy 
wherein the cold ischemia time is kept short. 
2
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Introduction
One of the main challenges in orthotopic liver transplantation (OLT) has become 
the widening gap between donor organ availability and the number of patients 
on the waiting list for OLT. One way to decrease the shortage of liver donor grafts 
is the use of extended criteria donor (ECD) livers, which carry a higher risk of 
graft failure. Advanced donor age is one of the criteria to classify a donor liver 
as ECD liver (1). Older livers have an impaired regenerative capacity (2-4) and 
are subsequently more susceptible for ischemia/reperfusion (I/R) injury (5-
7). Proposed mechanisms are a decline in liver volume, impaired response to 
oxidative stress, diminished rates of DNA repair, and a reduced expression of 
growth regulatory genes (2,7).  Donor livers with advanced age (≥ 65 years) are 
therefore not widely accepted for OLT, especially if other risk factors are present 
such as a (expected) prolonged cold ischemia time (CIT) (7), donation procedure 
after circulatory death (DCD) (8), graft steatosis (> 30% macrovesicular steatosis) 
(9), and recipients’ positive hepatitis C virus (HCV) status (10). 
In the Netherlands, the discrepancy between the number of donor livers and 
candidates for OLT remains a huge problem, resulting in a 15% mortality rate 
on the national waiting list in 2013 (11). The three liver transplant centers in 
the Netherlands, therefore, agreed to consider all potential donors for liver 
donation regardless donor age. Due to this national policy the average donor age 
has increased during the last decade and the percentage of elderly donors (≥ 65 
years) has increased in parallel with this. Allocation of all donor livers is based on 
a patient-oriented system in which priority is defined by the model for end-stage 
liver disease (MELD) score.  
Biliary complications, including non-anastomotic biliary strictures (NAS) are 
a major cause of mortality and morbidity after OLT (12). A single center report 
suggested that NAS are more frequent after transplantation of livers from donors 
with advanced age, especially when the CIT is longer than 10 hours (13). However, 
it remains unclear whether short cold ischemia times could contribute to a lower 
incidence of NAS when elderly donor livers are used for OLT. Moreover, data about 
the rate of other biliary complications, such as biliary leakage and posttransplant 
cholangitis after OLT with elderly donors, is not fully known. 
We, therefore, conducted a Dutch multicenter study to examine outcome after 
transplantation of liver grafts from elderly donors (≥ 65 years). We specifically 
focused on the incidence of biliary complications as NAS, anastomotic strictures 
(AS), biliary leakage, and posttransplant cholangitis, within a national policy 
ensuring short logistics. 
2




In this retrospective study, all adult recipients undergoing a full-size OLT in the 
period January 2000 till July 2011 were reviewed. All three Dutch transplant centers 
(Groningen, Leiden, and Rotterdam) participated in this national study. Pediatric 
transplants (age < 18 yr), retransplantations, living donations, and combined 
organ transplantations were excluded. Sixty-eight adult patients with a primary 
liver graft derived from a 65-year or older donor formed the basis of the current 
study. Of all 68 patients, 29 underwent OLT in Groningen, 26 in Rotterdam, and 13 
patients received a liver graft from an elderly donor in Leiden. All patients had a 
minimal follow-up period of 2 years and follow-up was complete for all patients 
until the first of June 2013. Characteristics of the patients, including donor and 
recipient variables, as well as surgical factors were obtained from a prospectively 
maintained computer database of the Dutch Transplantation Foundation (NOTR). 
When necessary, the original patient notes were reviewed for missing information. 
The percentage missing variables was 3%. According to national legislation, this 
type of retrospective analysis using anonymous data is allowed in the Netherlands 
and does not require informed consent from the individual patients.  
To examine the effect of advanced donor age on outcome after OLT, all recipients 
receiving a liver graft ≥ 65 years were matched at random in a 1:2 ratio with control 
recipients, who received a liver from a donor below 65 years in the same time 
period. To eliminate any confounding effect of a “center effect’’ (14), the matching 
process was stratified per transplant center. Matching was based on the following 
variables; type of donor graft (donation after brain death [DBD] or circulatory 
death [DCD]), MELD score (+/- 5 points), and recipient age (+/- 5 years). The MELD 
score was calculated on the day of OLT disregarding extra points for standard or 
non-standard exceptions.
National Policy for Allocation and Transplantation of Elderly Donor Livers
Donor liver allocation in the Netherlands is based on a patient-oriented, MELD 
score based system. The three transplant centers share one national waiting list 
and donor livers that come available are first offered to the patient with the highest 
MELD score (either based on laboratory values or exceptional MELD points). This 
allocation process is not different for ECD livers, however, centers are allowed to 
refuse a potential high risk donor liver (i.e. from an elderly donor) for a specific 
recipient. Reasons for declining an ECD liver may include a high recipient MELD 
score, positive HCV recipient status, or a large age difference between donor and 
recipient. The refused graft is subsequently offered to the next recipient on the 
waiting list. According to the Dutch national protocol for DCD donors, donor age 
above 60 years is a contraindication for liver donation, which resulted in a very 
sparse use of elderly DCD livers in this study. In general, elderly donors are accepted 
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for liver donation when there are no other major risk factors for early graft failure 
are present such as moderate or severe steatosis (> 30% macrovesicular steatosis), 
extensive co-morbidity in the donor, or a long (> 5 days) ICU admission of the 
donor. Assessment of graft steatosis in our study consisted of a combination of 
macroscopic inspection of the donor liver by the surgeon during organ procurement 
and clinical assessment based on the donor’s medical history, current condition, 
and laboratory studies. Frozen section liver biopsy was not standard part of donor 
evaluation in the Eurotransplant area. Additionally, ultrasonography or computer 
tomography scanning was not routinely performed prior to donation to evaluate 
liver steatosis in the donor, as described previously (15).
All three transplant centers had a general policy to try to keep the CIT as short 
as possible. Generally, the surgical procedure in the recipient was started as soon 
as quality aspects of the graft were discussed with the surgeon performing the 
donor procedure. In many cases the recipient operation had advanced that far, that 
the donor liver could be implanted immediately upon arrival after the back table 
procedure. The preferred recipient operation was the cava-sparing piggyback 
technique, which resulted in a shorter anastomosis time in comparison to the 
classical implantation technique (one versus two caval anastomoses). 
Donor and Recipient Characteristics and Surgical Variables 
The donor risk index (DRI) was calculated according to Feng et al. (16), with 
minor adjustments for the Eurotransplant population as described by Braat et 
al. (17) (considering all donors Caucasian and local). In addition, the following 
donor variables were collected and included in the analyses: gender, body mass 
index (BMI), causes of death, type of donor (DBD or DCD), and length of stay 
at the intensive care unit. Recipient variables collected and included were: age, 
gender, year of transplantation, BMI, indication for transplantation, MELD score, 
recipient status on the Eurotransplant waiting list (elective versus high urgency), 
time on the waiting list, length of stay at the intensive care unit and the need for 
retransplantation. With respect to the surgical variables, the following parameters 
were examined: graft implantation technique (conventional versus piggyback), 
CIT, warm ischemia time (WIT), type of bile duct anastomosis, and amount of total 
blood loss. 
Outcome Parameters
Primary non-function (PNF) was defined as non-life-sustaining function of the 
liver requiring retransplantation or leading to death within 7 days after OLT. 
Graft and patient survival were assessed at 90-days, 1-year, and 3-year after OLT. 
Graft survival was defined as the time period between OLT and patient death or 
retransplantation. Patient survival was defined as the time period between OLT 
and patient death. The period of 90 days after OLT was chosen because the most 
important impact of CIT on graft function should be evident within this time period 
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(7,16). Bile duct strictures were classified as either at the site of the anastomosis 
(anastomotic stricture; AS) or non-anastomotic strictures (NAS), as diagnosed 
by biliary imaging including endoscopic retrograde cholangiopancreatography, 
magnetic resonance imaging, or percutaneous transhepatic cholangiography. Based 
upon the first date of presentation, cases of NAS were subdivided into two groups: 
early NAS defined as presentation within 1 year and late NAS with presentation after 
1 year. Postoperative cholangitis was diagnosed on clinical symptoms (chills, fever) 
in combination with laboratory values indicating cholangitis. For posttransplant 
cholangitis antibiotics were given. Biliary leakage was always confirmed by biliary 
imaging. If necessary, biliary leakage was resolved by endoscopic treatment 
or surgical intervention. Occurrence of hepatic artery thrombosis (HAT) was 
diagnosed with Doppler ultrasonography (performed routinely on postoperative 
day 1, 4, and 7 or more often when clinically indicated) and was always confirmed 
by CT angiography or abdominal exploration. HCV recurrence was determined on 
the basis of liver histopathology as reported by an experienced local pathologist 
in combination with clinical, biochemical, and virological findings. Serum levels 
of aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were 
collected on postoperative days 1, 3, and 7 as indication for the degree of I/R injury. 
Statistical Analysis
Categorical variables were presented as numbers and percentages. Groups were 
compared using the Pearson χ2 test or Fisher’s exact test where appropriate. 
Continuous variables were expressed as median with interquartile range (IQR), 
and groups were compared using the Mann-Whitney U test. Patients and grafts 
survival was analyzed according to the Kaplan-Meier method, and differences 
between groups were investigated using the log-rank test. Statistical significance 
was indicated by p-values of less than 0.05. Statistical analyses were performed 




Recipient, donor, and surgical characteristics of the study group and their 
matched controls are presented in Table 1. As expected, there were no significant 
differences for the matching variables between the study group and the control 
2
Table 1 ▶
Data represent median with interquartile ranges (IQR) for continuous variables or numbers (percentages) for categorical variables.
Abbreviations used: BMI: body mass index, MELD: model of end-stage liver disease, OLT: orthotopic liver transplantation, INR: international 
normalized ratio, DBD: donation after brain death, DCD: donation after circulatory death, UW: University of Wisconsin, HTK: histidine-
tryptophane-ketoglutarate.
1 Data is presented as range.
2 Normal < 110 μmol/L, to convert the value for creatinine to mg/dL, divide by 88.4
3 Normal 0-17 μmol/L, to convert the value for bilirubin to mg/dL, divide by 17.1
4 Time from in situ flushing of the donor organ until the liver is removed from ice for implantation.
5 Time from removal of liver from ice until reperfusion via portal vein, hepatic artery or both.
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Table 1. Recipient, Donor and Surgical Characteristics in Patients Who Received a Donor Liver from an Elderly Donor (≥ 65 years) versus 
Control Patients Without an Elderly Donor Liver (donor age < 65 years)
Variable Study Group
Donor Age ≥ 65 years
(n = 68)
Control group


































MELD score 19 (15-27) 20 (14-25) 0.54
Serum creatinine before OLT (μmol/L)2 85 (67-114) 78 (64-105) 0.33
Serum total bilirubin before OLT (μmol/L)3 54 (24-96) 58 (32-134) 0.34
INR before OLT 1.3 (1.1-1.6) 1.4 (1.2-1.6) 0.89








Waiting time on list (days) 133 (46-342) 239 (57-419) 0.18
Donor variables
Donor Risk Index 2.2 (2.1-2.4) 1.6 (1.5-1.9) 0.001









BMI (kg/m2) 25.4 (24-28) 24.6 (22-26) 0.017





















































Cold ischemia time4 (hr:min) 7:25 (6:23 - 9:38) 8:09 (7:07-9:47) 0.027
Warm ischemia time5 (hr:min) 0:35 (0:25 - 0:42) 0:37 (0:29-0:48) 0.10
Blood loss (L) 3.6 (2.2– 6.0) 3.5 (2.1-6.7) 0.83
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group (transplantation center, type of liver graft, MELD score, and recipient age). 
The median CIT in the study group with elderly donors was 7 hours and 25 minutes 
(IQR 6:23 - 9:38 hr). The DRI was significantly higher in recipients of elderly donor 
liver grafts compared to their controls. However, the clinical importance of these 
differences in DRI score may not be relevant since elderly donors automatically 
achieve due to their advanced age more points for the DRI score compared to 
younger donors. Moreover, the cause of donor death differed among older donors 
and their controls. Cerebrovascular causes (e.g. cerebral stroke) of death were 
more frequently seen in the elderly donors. In addition, the donor BMI was 
significantly higher in the study group with elderly donors in comparison to their 
younger controls. For all other variables no significant differences were found 
between the two groups.
The Impact of Elderly Donor Age on Patient and Graft Survival
Ninety day, 1- and 3-year patient and graft survival rates after OLT are presented 
in Table 2. The median postoperative follow-up was 58 months (range 30-90 
months). Patient survival rates were not significantly different between recipients 
of an elderly donor liver (≥ 65 years) and recipients of a younger graft (< 65 years). 
In addition, no significant differences were found in 90-day, 1- and 3-year graft 
survival between the two groups. 
Postoperative Outcome and Biliary Complications
Postoperative outcome and complications are summarized in Table 3. The incidence 
of PNF in the group with elderly donors was not significantly different from that in 
the control group of younger aged donors (3% in the study group versus 4% in the 
control group, respectively). Furthermore, there were no significant differences 
in the number of retransplantations between the two groups (7% in the study 
group versus 8% in the control group, respectively). Serum markers of I/R injury, 
such as AST and ALT were also comparable between the two groups in the first 
postoperative week (Figure 1). 
2
Table 2. Comparison of Patient and Graft Survival Rates in Patients Who Received an Elderly Donor (≥ 65 years) Liver versus Control Patients 
Without an Elderly Donor Liver (< 65 years)
Variable Study Group
Donor Age ≥ 65 years
(n = 68)
Control group




  90-days 94% (99 – 90%) 90% (95 – 86%) 0.14
  1-year 90% (95 – 85%) 85% (90 – 80%) 0.53
  3-year 77% (87 – 68%) 77% (84 – 70%) 0.95
Graft survival 
  90-days 93% (96 – 89%) 87% (89 – 80%) 0.28
  1-year 84% (89 – 82%) 79% (83 – 74%) 0.37
  3-year 75% (85 – 65%) 74% (81 – 67%) 0.79
The value in the parentheses is the 95% confidence interval of the survival rate.
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The overall incidence of biliary complications was not significantly different 
between the two groups (Table 3). The incidence of early NAS (first presentation 
< 1 year after OLT) was 9% in patients receiving a donor liver ≥ 65 years versus 
11% in the control group (p = 0.68). The incidence of late NAS (≥ 1 year after OLT) 
was 4% in the study group versus 8% in the control group (p = 0.47). Additionally, 
no significant differences were observed in the incidence of the other biliary 
complications such as anastomotic strictures, biliary leakage, and posttransplant 
cholangitis. 
Next, we performed a separate analysis of potential risk factor for the development 
of any type of post-ischemic biliary complication including NAS, AS or biliary 
leakage. Variables included in this analysis were donor age, CIT, WIT, and type of 
biliary anastomosis (duct-to-duct versus Roux-en-Y hepaticojejunostomy). None 
of these variables appeared to be statistically significantly associated with the 
development of a post-ischemic biliary complication.   
Discussion 
The intention of this national multicenter study was to investigate outcome 
after OLT of elderly donor liver grafts (≥ 65 years). In particular, we focused on 
the incidence of biliary complications in recipients of an elderly donor liver. The 
present study indicates that the use of donors above 65 years may result in biliary 
complication rates that are comparable to younger donors (< 65 years). Similarly, 
patient and graft survival rates after OLT with elderly donor grafts were not 
different from their younger controls. 
Figure 1. Postoperative serum markers of ischemia/reperfusion injury at day 1, 3, and 7 postoperative. 
There were no significant differences between serum levels of aspartate aminotransferase (AST) (Panel 
A) and alanine aminotransferase (ALT) (Panel B) in recipients with an elderly donor liver (≥ 65 years) and 
recipients of a younger graft (< 65 years) at postoperative day 1, 3, and 7. Data represent median values with 
IQR (error bars). AST normal value < 48 U/l and ALT normal value < 42 U/l.
2
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Several donor risk analyses of US and European transplant registries have reported 
that advanced age is an independent predictor for worse postoperative outcome 
after OLT (16-21). Single center studies however, reported that elderly donor livers 
can be used for OLT with favorable patient/graft survival rates (22-29). The results 
of the current study are consistent with these single center reports. Nevertheless, 
our study is the first to assess outcome after OLT with elderly donor livers in a 
national multicenter cohort. Moreover, our study was performed in a matched 
case analysis including stratification per center. Therefore, the risk that poor 
clinical outcomes after OLT of elderly donor livers were compensated for good 
clinical outcomes achieved in another center may be minimized.  Furthermore, 
in our study several confounding factors were excluded due to the fact that 
recipients of an elderly donor liver and their control recipients were matched for 
MELD score, type of donation (DBD/DCD) and, recipient age. Next to single center 
reports with good postoperative outcome after OLT with elderly donor livers (22-
29), the incidence of other major donor related risk factors such as DCD and split 
liver donation are minimal in the current series. Likewise, it should be noticed 
that these elderly donor liver grafts were transplanted in relatively stable patients 
without high MELD scores and without major risk factors for postoperative graft 
failure (e.g. presence of HCV cirrhosis).   
A plausible explanation for excellent postoperative outcomes after OLT of elderly 
donor livers could be the short CIT obtained in the current series. The median CIT 
2
Table 3. Postoperative Outcome Parameters in Patients Who Received a Donor Liver from an Elderly Donor (≥ 65 years) versus Control 
Patients Without an Elderly Donor Liver (< 65 years)
Variable Study Group
Donor Age ≥ 65 years
(n = 68)
Control Group




Immediate function 66 (97%) 132 (96%) 0.62
Primary non-function 2 (3%) 6 (4%)
Late graft function
Need for retransplantation 5 (7%)  12 (8%) 0.12
Biliary complications
Early NAS (< 1 year) 6 (9%) 15 (11%) 0.67
Late NAS (≥ 1 year) 3 (4%) 11 (8%) 0.48
Anastomotic stricture 11 (16%) 25 (18%) 0.70
Biliary leakage 8 (12%) 9 (7%) 0.36
Postoperative cholangitis 14 (21%) 20 (14%) 0.45
Other complications
Hepatic artery thrombosis 1 (2%) 3 (2%) 0.66
HCV recurrence in patients with primary HCV 2 / 4 patients (50%) 7 / 14 patients (50%) 1.00
Median ICU stay (days) 3 (2-7) 2 (1-5) 0.93
Data represent median with interquartile ranges (IQR) for continuous variables or numbers (percentages) for categorical variables. 
Abbreviations used: NAS, non-anastomotic stricture; HCV, hepatitis C virus infection; ICU, intensive care unit.
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was 7:25 (hr:min) in the group recipients of an elderly donor liver graft. In the 
Netherlands, donor livers are nationally allocated and due to short travel distances 
and parallel surgical procedures, we are able to keep the CIT short (preferably < 
8 hrs). In general, there may be a threshold at which injury caused by ischemia 
and I/R injury becomes irreversible and influences substantially postoperative 
outcome. With respect to elderly donor livers, it is known that older aged livers are 
more prone to ischemia and I/R injury (5-7). When elderly donor livers are used 
for OLT, it is therefore necessary to keep the CIT as short as possible to withstand 
the harmful effects of ischemia and I/R injury. In our study, recipients of an elderly 
donor liver showed postoperative serum levels of the ischemic-injury markers, 
AST and ALT, similar to those of their younger controls. Furthermore, I/R injury 
related graft failure is mainly manifest within the first 90 days postoperative (7,16). 
In our series, no differences in 90-day graft survival rates were observed between 
the group recipients of an elderly donor liver and the recipients of a younger donor 
liver graft. 
In our study, we did not find an association between advanced donor age and biliary 
complications such as NAS, AS, biliary leakage and, posttransplant cholangitis. 
However, in other retrospective studies, a positive relationship between elderly 
donor livers and NAS has been reported (13,30,31). Recently, three independent 
clinical studies have demonstrated that major epithelial cell loss in the extrahepatic 
bile ducts can be seen in more than 80% the donor livers (DBD and DCD) after cold 
storage (32-34). The observation that only the minority develops NAS has led to 
the hypothesis that proliferation and regeneration of the bile duct wall, rather 
than ischemic injury alone, are important factors in the pathogenesis of NAS (35). 
Because of the poorer regeneration capacity due to the ageing process (2-4), we 
can assume that elderly donor livers are more susceptible for the development of 
NAS. Nevertheless, in the current study the incidence of the ischemia related type 
of NAS (NAS presentation within 1 year) was not higher in recipients of an elderly 
donor liver compared to younger controls. Therefore, we do not consider advanced 
donor age as a major risk factor for the development of NAS after OLT. 
By the use of a national protocol for allocation and OLT of elderly donor livers in 
the Netherlands, we are able to keep the CIT short. We believe this is currently 
the best strategy to deal with donor livers with advanced donor age. Other 
techniques to improve outcome after OLT of elderly donor livers could come from 
more sophisticated techniques such as machine preservation. It has been shown 
that a short period of oxygenated machine perfusion at the end of the period of 
static cold storage under hypothermic conditions (10°C), could lower the effects 
of I/R injury and improve functionality of the graft (36). In addition, with (sub)
normothermic machine perfusion (perfusion from 20 - 37°C), ex vivo assessment of 
liver viability prior to OLT could be examined (37). Although machine perfusion is 
a very promising method for improvement of graft quality during preservation of 
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ECD livers, this technique should be studied in clinical trials. We recently initiated 
such a trial to examine the benefits of hypothermic machine perfusion in DCD OLT.
In conclusion, this national multicenter study demonstrates that elderly donor 
livers can be transplanted with excellent postoperative outcomes, when a policy is 
adapted wherein the CIT is kept as short as possible and recipient and additional 
donor related risk factors are kept to a minimum. Moreover, this study does not 
confirm an association between biliary complications (especially NAS) and elderly 
donor livers. Therefore, by the use of strict logistics and eliminating recipient 
and additional donor related risk factors, elderly donors could be safely used for 
expanding the donor pool.  
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Abstract
Background: Livers with moderate (30-60%) macrovesicular steatosis have been 
associated with poor outcome after transplantation. Aim of this study was to 
examine outcome after transplantation of livers with moderate macrovesicular 
steatosis when the cold ischemia time (CIT) is kept very short. 
Methods: Postoperative outcome of 19 recipients with a moderate steatotic 
liver were compared with a matched control group of 95 recipients (1:5 ratio). 
We studied graft/patient survival rates, incidences of PNF, postoperative 
complications (classified according to the Clavien-Dindo classification), first week 
postoperative hepatic injury serum markers (AST/ALT), and liver function tests 
(PT time/bilirubin/lactate). In addition, we studied reversal of graft steatosis in 
follow-up biopsies. 
Results: Median CIT in livers with moderate steatosis and in controls was below 
8 hours in both groups. Although short and long-term patient/graft survival rates 
and results of liver function tests were similar, serum markers of hepatic injury 
and postoperative complications (especially grade IVa) were significantly higher 
in recipients of a moderate steatotic liver. Reversal of steatosis was seen in 9 of the 
11 (82%) recipients with follow-up liver biopsies.  
Conclusion: Despite the association with severe postoperative complications, 
moderate macrovesicular steatotic livers can be used successfully for 
transplantation if the CIT is kept very short. 
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Introduction
The success of orthotopic liver transplantation (OLT) has resulted in an expanding 
demand of liver grafts, which is not balanced by an increase in donation of livers. 
The annual report of the Eurotransplant International Foundation 2013 shows a 
growing difference between available livers, and the number of patients awaiting a 
new liver (1). To reduce the present imbalance between organ demand and supply, 
many centers have been using extended criteria donor (ECD) livers. ECD livers 
are livers associated with a higher postoperative risk of graft failure, compared to 
livers from optimal or reference donors (2,3). 
Hepatic steatosis has been identified as an important risk factor for graft failure 
after transplantation due to a higher susceptibility for ischemia/reperfusion 
(I/R) injury (4-6). Therefore, steatosis has been considered as one of the most 
important criteria to classify a donor liver as an ECD liver (7). Based on histology, 
steatosis can be divided into macrovesicular and microvesicular steatosis. 
Macrovesicular steatosis can be subcategorized as mild (> 10 - 30%), moderate 
(between 30 and 60%), or severe (> 60%), depending on the number of hepatocytes 
with fat accumulation (8). Macrovesicular steatosis is considered to be a more 
important risk factor for graft failure than microvesicular steatosis. Especially 
severe macrovesicular steatosis has been associated with a higher prevalence of 
primary non-function (PNF) and unfavorable patient and graft survival rates (9-
15). Because of these poor results, livers with a severe degree of macrovesicular 
steatosis are usually not accepted for transplantation. On the other hand, livers 
with moderate macrovesicular steatosis seem to be suitable for transplantation if 
no other risk factors for poor postoperative outcome are present (16-21). However, 
many centers will not accept moderately steatotic livers for transplantation 
because of the greater susceptibility to I/R injury and the perceived negative 
impact on postoperative outcome (22).
We hypothesized that donor livers with moderate macrovesicular steatosis may 
have similar outcomes as nonsteatotic livers, if the degree of I/R is minimized by 
keeping the cold ischemia (CIT) as short as possible. The aim of the present study is 
to examine the effect of moderate steatotic liver grafts on outcome after OLT when 
all possible efforts are taken to keep the CIT below 8 hours.
Postoperative outcome was assessed by determining patient and graft survival 
rates, as well as surgical complications according to the Clavien-Dindo classification 
(23), and by studying first week postoperative hepatic injury serum markers (AST/
ALT) together with liver function tests (prothrombin time [PT]/bilirubin/lactate). 
In addition, we have investigated the possible reversal of steatosis on follow-up 
liver biopsies after transplantation.
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Patients and Methods
Study Population
Between the first of January 2000 and 31st of December 2012, our center received 
2468 donor liver offers of which 657 liver grafts were accepted for transplantation. 
Seven percent of the unaccepted livers were turned down because of the 
combination of suspected severe graft steatosis in combination with other donor 
risk factors. After excluding pediatric transplants, retransplantations, and 
combined organ transplantations, 373 adult patients undergoing a first OLT 
formed the first basis of the current study. Follow-up was until the first of July 
2013, allowing a minimal follow-up period of half a year in all patients. 
Among the 373 patients, biopsies were taken from the donor liver at the time of 
transplantation in our center in 319 (86%) cases. One hundred and twenty-six 
patients received a liver with a certain degree of steatosis. These 126 patients were 
categorized according to the percentage of macrovesicular steatosis and included 
in one of the following subgroups; low (< 10%; n = 86), mild (10-30%; n = 21), and 
moderate (30-60%; n = 19) macrovesicular steatosis. During the study period, no 
grafts were transplanted with more than 60% macrovesicular steatosis. 
To examine the effect of moderate macrovesicular steatosis (30-60%) on outcome 
after transplantation, patients who received a graft with moderate macrovesicular 
steatosis were matched at random in a 1:5 ratio with control patients, who received 
a liver without any degree of steatosis in the same time period. The two groups 
were matched for type of donation (donation after circulatory death [DCD]) versus 
donation after brain death [DBD]), laboratory model for end-stage liver disease 
(MELD) score, CIT, recipient age, body mass index (BMI), and status on the waiting 
list of Eurotransplant (high urgent versus elective). The laboratory MELD score 
was calculated on the day of OLT, disregarding extra points for standard or non-
standard exceptions. According to national legislation, this type of retrospective 
analysis using anonymous data is allowed in the Netherlands and does not require 
informed consent from the individual patients.
Surgical Procedure and Logistics
Our institutional transplantation protocol contains guidelines to keep the CIT as 
short as possible. It is the institutional policy to start with the surgical procedure 
in the recipient as soon as we have discussed quality aspects of the graft with the 
surgeon performing the donor procedure, resulting in parallel procedures. In 
many cases the recipient operation has advanced that far, that the donor liver can 
be implanted immediately upon arrival after the back table procedure. We do not 
routinely request for a frozen section liver biopsy to quantify steatosis because 
of its inherent low sensitivity and specificity (24). Moreover, frozen section 
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analysis, ultrasound or computer tomography (CT) scanning for evaluation of 
liver steatosis is not common practice in the Eurotransplant countries. Therefore 
only the judgment of the donor surgeon and the clinical conditions with laboratory 
tests of the donor will help us in the decision process of accepting an organ. 
Furthermore, the cava-sparing piggyback technique is our preferred method for 
graft implantation, which results in a shorter anastomosis time in comparison to 
the classical implantation technique.
Histological Assessment of Steatosis
Liver biopsies were routinely performed at the bench in the recipient center. 
Biopsies were obtained with a 1.6-mm Menghini needle located deep parenchymal 
from the gallbladder fossa in the direction of Cantlie’s line to include enough 
portal triads for clear and representative pathology diagnosis. For examination of 
steatosis reversal, percutaneous liver biopsies were taken routinely after one week 
until 2005 and thereafter only when clinically indicated (e.g. suspicion of acute 
rejection or unexplained rise in serum liver enzymes). Biopsy specimens were fixed 
in formalin, embedded in paraffin, and subsequently stained with hematoxylin-
eosin, periodic acid Schiff ’s reagent (after diastase digestion), Masson’s trichrome, 
Gomori’s reticulin, Perls’ iron staining, and rhodanine for copper accumulation. 
All histological slides were evaluated by an experienced hepatopathologist 
(ASHG), who was unaware of the clinical assessment of steatosis. The semi-
quantitative assessment of steatosis was determined by estimating the percentage 
of hepatocytes containing lipid droplets (both micro- and macrosteatotic droplets) 
in 10 consecutive fields (magnification 25x), independently of lobular distribution. 
Macrovesicular steatosis was defined as fat vesicles larger than the cell nucleus, 
often displacing the nucleus. Microvesicular steatosis was defined as fat vesicles 
with similar size or smaller than the liver cell nucleus. The average size of a liver 
cell nucleus is about 5 µm. The amounts of micro- and macrovesicular steatosis 
were not taken together to achieve a higher degree of steatosis. Depending on the 
degree of macrovesicular steatosis, liver biopsies were graded in mild (10-30%), 
moderate (between 30 and 60%), or severe (> 60%) steatotic infiltration according 
to the Histological Scoring System for Nonalcoholic Fatty Liver Disease designed 
by the NASH Clinical Research Network (8). If follow-up biopsies were acquired, 
the same pathologist (ASHG) performed the histological assessment.     
Donor, Recipient Characteristics and Surgical Variables 
The donor risk index (DRI) was calculated according to Feng et al. (25), with minor 
adjustments as described by Braat et al. (26) (considering all donors Caucasian 
and local). In addition, other donor related risk factors were collected such as 
gender, BMI, type of donor (DBD versus DCD), first warm ischemia time in DCD 
donors, cause of donor death, graft type (full size versus partial grafts), stay at 
the intensive care (ICU), and type of organ perfusion fluid (histidine-tryptophane-
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ketoglutarate [HTK] versus University of Wisconsin [UW]). Other donor variables 
were collected using the Eurotransplant donor data files with results of the 
medical history, medication administered at the ICU, laboratory tests on the day 
of donation, and radiology/pathology data of the donor liver. Recipient variables 
collected and included were: age, gender, year of transplantation, BMI, indication 
for transplantation, laboratory MELD score, recipient status on the Eurotransplant 
waiting list (elective versus high urgency), and time on the waiting list.
Furthermore, the following surgical variables were examined; CIT, recipient warm 
ischemia time (WIT), type of venous and bile duct anastomosis, and total amount of 
blood loss. With respect to intraoperative transfusion requirements, the following 
variables were analyzed: the number of units of allogeneic red blood cells (RBC: 
1 U contained 250 mL), units of fresh frozen plasma (FFP: 1 U contained 225 mL), 
and units of platelets concentrates (1 U contained approximately 150 mL and was 
obtained from five donors). 
Liver graft I/R injury and function were assessed by laboratory parameters as 
serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
bilirubin, albumin, prothrombin time (PT), all collected postoperatively (day 1, 3, 
and 7). The serum level of lactate was assessed on the first day postoperative for 
the first 12 hours.  
Outcome Parameters
Postoperative outcome was studied by assessing primary non-function (PNF), 
patient and graft survival rates. PNF was defined as non-life-sustaining function 
of the liver requiring retransplantation or leading to death within 7 days after 
OLT. Graft and patient survival were assessed at 60 days, 1 year, and 3 year 
after transplantation. Graft survival was defined as the time period between 
transplantation and patient death or retransplantation. Patient survival was 
defined as the time period between transplantation and patient death. 
To evaluate surgical complications after OLT, the complications were graded 
according the Clavien-Dindo classification (23). In addition, bile duct strictures 
were recorded and classified as either at the site of the anastomosis (anastomotic 
strictures) or at any location in the donor biliary system (non-anastomotic 
strictures), as diagnosed by endoscopic retrograde cholangiography, magnetic 
resonance imaging, or percutaneous transhepatic cholangiography. 
Statistical Analysis
Categorical variables were presented as numbers and percentages. Groups were 
compared using the Pearson χ2 test or Fisher’s exact test where appropriate. 
Continuous variables were expressed as medians and interquartile ranges, and 
groups were compared using the Mann-Whitney U test. Patient and graft survival 
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rates were analyzed according to the Kaplan-Meier method, and differences 
between groups were investigated using the log-rank test. All statistical tests 
were performed two-tailed. Statistical significance was indicated by p-values of 
less than 0.05. Statistical analyses were performed using the statistical software 
package SPSS version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient Characteristics
Recipient and surgical characteristics of patients in the group with moderate 
steatosis and the nonsteatotic control group are presented in Table 1. There were 
no statistically significant differences between the two groups. As expected, there 
were also no significant differences in the matching variables in the moderate 
steatosis group and the nonsteatotic control group; type of donation, laboratory 
MELD score, recipient age, status on the waiting list (high urgency versus elective), 
CIT, and BMI. The CIT was below 8 hours in both groups; 7:29 hr:min and 7:41 
hr:min, respectively. In addition, no differences were found in the intraoperative 
transfusion requirements. The median postoperative follow-up was 81 months 
(range 8-152 months). The percentage missing variables was ≤ 6%. 
Donor Characteristics
A comparison of donor characteristics in the two groups are shown in Table 2. 
There were no differences in DRI or other donor related risk factors and donor 
characteristics between the two groups. As expected, assessment of hepatic 
steatosis before or during organ procurement (i.e. by ultrasound, CT scanning or 
frozen section analysis) was performed in only a minority of the donors. 
The Impact of Graft Steatosis on Patient and Graft Survival
When comparing the moderate macrovesicular steatosis group with the matched 
control group, we found no differences in the 60-day, 1-year or 3-year patient 
survival rates (Table 3). Similarly, the were no significant differences in 60-day, 
1-year, and 3-year graft survival rates between the two groups. 
Postoperative Outcome and Complications
Postoperative outcome and complications are provided in Table 4. The incidence 
of PNF was similar in the two groups. In the study group, the only patient with 
PNF was retransplanted, while 4 patients in the control group died because of PNF 
before retransplantation. A significant higher degree of surgical complications, 
especially grade IVa, were observed in the group of patients with a steatotic donor 
liver compared to patients without a steatotic donor liver. 
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MELD score (laboratory-MELD) 18 (15-27) 21 (14-25) 0.89
Serum creatinine before OLT (μmol/L)2 115 (66-353) 87 (69-127) 0.29
Serum total bilirubin before OLT (μmol/L)3 52 (33-99) 70 (31-195) 0.22
INR before OLT 1.3 (1.1-2.1) 1.4 (1.3-2.0) 0.62








Waiting time on list (days) 234 (32-589) 186 (38-336) 0.46
Surgical variables
CIT4 (hr:min) 7:29 (6:06-8:33) 7:41 (6:44-8:48) 0.49
WIT5 (hr:min) 0:43 (0:38-0:56) 0:45 (0:40-0:50) 0.88
















Blood loss (L) 3.0 (2.0-7.5) 2.5 (1.5-6.0) 0.51
RBC (units) (allogenic) 5 (0-9) 3 (0-8) 0.76
FFP (units) 0 (0-7) 3 (0-5) 0.74
Platelets (units) 0 (0-3) 3 (0-8) 0.88
Table 1 ▲ 
Data represent median with interquartile ranges (IQR) for continuous variables or numbers (percentages) for categorical variables.
Abbreviations used: BMI: body mass index, CIT: cold ischemia time, FFP: Fresh Frozen Plasma, INR: international normalized ratio, MELD: model 
of end-stage liver disease, OLT: orthotopic liver transplantation, RBC: red blood cell, WIT: warm ischemia time.  
1 Data presented as median and range.
2 Normal < 110 μmol/L, to convert the value for creatinine to mg/dL, divide by 88.4.
3 Normal 0-17 μmol/L, to convert the value for bilirubin to mg/dL, divide by 17.1.
4Time from in situ flushing of the donor organ until the liver is removed from ice for implantation.
5 Time from removal of liver from ice until reperfusion via portal vein, hepatic artery or both.
Table 2 ▶
Data represent median with interquartile ranges (IQR) for continuous variables or numbers (percentages) for categorical variables.
Abbreviations used: BMI: body mass index, CT: computer tomography, DCD: donation after circulatory death, DBD: donation after brain death, 
HTK: histidine-tryptophane-ketoglutarate, UW: University of Wisconsin, WBC: White Blood Count, WIT: warm ischemia time. 
1Normal value 7-13 mmol/l; 2Normal value 4-11 x 10^9/L; 3Normal value 150-400 x 10^9/L;
4Normal value 130-155 mmol/L; 5Normal value 25-150 μmol/L, to convert the value for creatinine to mg/dL divide by 88.4; 6Normal value 
1-12 mmol/L, to convert the value urea to mg/dl divide by 0.357; 7LDH: lactate dehydrogenase, normal value 50-300 U/L; 8AST: aspartate 
aminotransferase, normal value <48 U/L; 9ALT: alanine aminotransferase, normal value <42 U/L; 10Normal value < 35 U/L; 11Normal value 0-30 
μmol/L, to convert the value for bilirubin to mg/dL divide by 17.1; 12Normal value < 150 U/L; 13Normal value 25-40 g/L; 14Normal value < 10 mg/l; 
15Normal value 7.35-7.45. 
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BMI (kg/m2) 25 (25-26) 24 (22-26) 0.12








Donor Risk Index 1.6 (1.5-2.0) 1.6 (1.4-2.0) 0.83
First WIT DCD donor (min) 19 (13-23) 14 (12-19) 0.23


































Total hospital stay (days) 2 (1-4) 2 (1-4) 0.97
Total stay at the intensive care unit (days) 2 (1-2) 2 (1-3) 0.46
Total duration of mechanical ventilation (days) 2 (1-2) 2 (1-3) 0.46
Medical history donor
Hypertension 5 (26%) 22 (23%) 0.77
Diabetes mellitus 0 4 (5%) 0.49
Alcohol abuse 2 (11%) 9 (10%) 0.58
Smoking 7 (37%) 40 (42%) 0.44
Medication at the intensive care unit
Vassopressors or inotropes 16 (84%) 81 (87%) 0.49
Corticosteroids 4 (21%) 19 (20%) 0.58
Laboratory results
Hemoglobin (mmol/L)1 7.0 (6-8) 7.4 (6.3-9.0) 0.37
WBC (x 10^9/L)2 14 (9-17) 14 (10-18) 0.56
Platelet count (x 10^9/L)3 179 (121-247) 185 (148-285) 0.29
Sodium (mmol/l)4 143 (138-153) 146 (141-152) 0.36
Creatinine (μmol/L)5 79 (67-104) 71 (59-97) 0.47
Urea (mmol/L)6 5 (3.4-5.9) 5.2 (3.4-7.6) 0.77
LDH (U/L)7 258 (183-310) 300 (112-340) 0.10
AST (U/L)8 39 (20-71) 41 (25-69) 0.59
ALT (U/L)9 37 (20-63) 26 (17-50) 0.30
Gamma-GT (U/L)10 37 (28-47) 30 (18-63) 0.37
Total bilirubin (μmol/L)11 10 (8-17) 10 (7-16) 0.42
Alkaline phosphatase (U/L)12 61(43-69) 66 (51-88) 0.39
Albumin (g/L)13 27 (20-33) 29 (24-31) 0.37
C-reactive Protein14 110 (14-164) 70 (16-152) 0.75
pH in bloodgas15 7.43 (7.39-7.48) 7.40 (7.28-7.44) 0.11
Radiology and pathology results of donor
Ultrasound or CT abdomen 5 (26%) 31 (33%) 0.80
Frozen section analysis liver 0 1 (1%) 0.83
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Table 3. Comparison of Patient and Graft Survival Rates in Patients Who Received a Donor Liver with Moderate Macrovesicular Steatosis 







60-day 95% (100-89%) 94% (99-89%) 0.86
1-year 90% (92-82%) 90% (96-84%) 0.93
3-year 79% (87-71%) 74% (84-68%) 0.66
Graft survival
60-day 90% (100-80%) 92% (97-87%) 0.75
1-year 84% (94-73%) 85% (92-78%) 0.93
3-year 73% (83-63%) 73% (82-64%) 0.93
The values between brackets represent the 95% confidence interval of the survival rate. 
Table 4. Postoperative Outcome Parameters in Patients Who Received a Donor Liver with Moderate Macrovesicular Steatosis versus Controls 
without Steatosis





Primary non-function 1 (5%) 5 (5%) 0.67
Surgical complications1
  Grade II
  Grade IIIa
  Grade IIIb
  Grade IVa
  Grade IVb














Non-anastomotic biliary strictures 2 (11%) 13 (14%) 0.90
Anastomotic biliary strictures 4 (21%) 8 (8%) 0.11
Length of stay at the ICU (days) 7 (3-10) 3 (1-7) 0.006
Data represent median with interquartile ranges (IQR) for continuous variables or numbers (percentages) for categorical variables.
Abbreviation used: ICU: intensive care unit. 
1 Surgical complications were graded according the Clavien-Dindo classification (23). In both groups, complication grade I was not allocated due 
to the therapeutic regimen with standard antibiotic care after OLT. Grade II: Requiring pharmacological treatment with drugs other than such 
allowed for grade I complications; blood transfusions and total parenteral nutrition are also included. Grade III: Requiring surgical, endoscopic 
or radiological intervention. Grade IIIa: Intervention not under general anesthesia. Grade IIIb: Intervention under general anesthesia. Grade 
IV: Life-threatening complication (including CNS complications) requiring IC/ICU management. Grade IVa: Single organ dysfunction (including 
dialysis). Grade IVb: Multi organ dysfunction. Grade V: Death. 
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The majority of these grade IVa complications include single organ dysfunction 
such as respiratory insufficiency or renal insufficiency. Organ dysfunction was in 
most of the cases responsible for a significantly longer ICU stay. There were no 
significant differences in the incidences of biliary complications between the two 
groups. 
During the first week after transplantation, serum markers of hepatocellular 
injury, AST and ALT, were significantly higher in the group with a steatotic liver 
compared to their controls (Figure 1). 
41
Figure 1. Comparison of laboratory parameters after transplantation of livers with moderate macrove-
sicular steatosis versus livers without steatosis. Median serum levels of aspartate aminotransferase 
(AST), alanine aminotransferase (ALT) and the prothrombin time (PT) were significantly higher in the group 
of steatotic livers on day 1 and day 3 (*); AST day 1 (p=0.001), AST day 3 (p=0.048), ALT day 1 (p=0.001), ALT 
day 3 (p=0.007), PT time day 1 (p=0.003), and PT time day 3 (p=0.009). 
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To determine whether the length of the CIT influences the degree of hepatic injury 
as reflected by serum values of AST/ALT, we compared subgroups of steatotic livers 
with a CIT < 8 hours and ≥ 8 hours with nonsteatotic livers (Figure 2). Postoperative 
day 1 serum values of AST and ALT in the recipients with a moderate steatotic liver 
graft and CIT < 8 hours were almost comparable with the values in the control 
recipients of a nonsteatotic liver graft. However, recipients of a steatotic liver 
graft with a CIT ≥ 8 hours had significantly higher serum values of AST and ALT in 
comparison to recipients of a nonsteatotic liver. This is compatible with a greater 
susceptibility for I/R injury in steatotic livers in comparison to nonsteatotic livers. 
Laboratory markers of liver function such as serum bilirubin, albumin, and lactate, 
were not significantly different between the group recipients with moderate graft 
steatosis and their controls (Figure 1). The only significant difference in liver 
function was a longer PT on day 1 and 3 in the recipients with a moderate steatotic 
liver. But this difference had disappeared at day 7. Therefore, the almost similar 
results of liver function indicates that the hepatocellular function was not severely 
impaired in moderate steatotic livers and those moderate steatotic livers can be 
more seen as initial slow functional livers.
Reversal of Graft Steatosis 
Eleven of the 19 patients who received a donor liver with moderate macrovesicular 
steatosis had a liver biopsy within 2 months after transplantation. The median time 
period between transplantation and the postoperative liver biopsy was 12 days (IQR 
7 – 35 days). In 9 of the 11 cases (82%) the total amount of macrovesicular steatosis 
decreased from 60–30% to ≤ 10% (Figure 3). In one patient the posttransplant 
biopsy still displayed mild amounts of steatosis (10 - 30% macrovesicular steatosis) 
and in one patient the second biopsy (obtained at day 7 after OLT) demonstrated 
persistent moderate macrovesicular steatosis. 
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Figure 2. Comparison of median values of AST and ALT on postoperative day 1 in recipients of a liver 
graft with moderate steatosis and a cold ischemia time (CIT) <8 hours or ≥ 8 hours, versus recipients 
of a nonsteatotic liver graft. Errors bars represent the interquartile range. ALT and AST levels were 
significantly higher in recipients of a moderate steatotic liver with CIT ≥ 8 hours in comparison to recipients 
of a nonsteatotic liver graft (controls) (*); AST (p=0.016) and ALT day 1 (p=0.004), respectively.  
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Figure 3. Example of complete reversal of moderate macrovesicular steatosis in a liver graft within 
one month after transplantation. Panel A: Masson’s trichrome staining of donor liver biopsy at the 
time of transplantation. Panel B: Masson’s trichrome staining of follow-up biopsy at 30 days after liver 
transplantation; * reflects the central vein.
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Discussion
Moderately steatotic liver grafts are more prone to I/R injury and transplantation 
of these livers is associated with an increased risk of poor postoperative outcome 
compared to nonsteatotic donors (22). It is therefore the aim of the current study to 
assess the effect of moderate graft steatosis on patient outcome when the effects of 
I/R injury are minimized by using a strict policy to keep the CIT as short as possible. 
Our data demonstrated that the postoperative function of moderate steatotic livers 
is not impaired in comparison to nonsteatotic donor livers. We observed similar 
patient/graft survival rates and PNF incidences between recipients with a moderate 
steatotic liver and their nonsteatotic controls. Likewise, first week postoperative 
liver function parameters such as serum bilirubin, albumin, and lactate were not 
significantly different between the two groups. Nevertheless, our data showed that 
moderate steatotic livers are more sensitive for I/R injury (reflected by significant 
higher serum levels of transaminases) and recipients of these livers suffer from 
higher rates of severe complications. Especially, respiratory and renal insufficiency 
was more frequently seen in recipients with a moderate steatotic graft.   
Other groups have studied the impact of moderate or severe macrovesicular graft 
steatosis on outcome and this has resulted in conflicting data (9-21). Large registry 
studies revealed that moderate macrovesicular steatosis is an independent 
prognostic factor for poor postoperative outcomes (14,15). However, single 
center reports with a small number of recipients reported similar outcomes in 
postoperative graft function between moderate or severe steatotic livers and 
nonsteatotic liver grafts (16-21). The differences in postoperative outcome in these 
studies could depend on the presence or absence of other donor related risk factors 
for graft failure such as DCD, prolonged CIT, and advanced donor age, which are 
all reflected in the DRI score (25,26). In studies with favorable postoperative 
outcomes after transplantation of moderate steatotic livers, the frequency of 
additional donor risk factors might have been relatively low (16,18-21). In the 
current series, we observed a median DRI of 1.6 (IQR 1.5-2.0) in the group of 
moderate steatotic livers. This indicates that apart from steatosis, most livers have 
additional donor related risk factors. Moreover, in our center steatotic liver grafts 
are not preferentially allocated to low-risk recipients. The liver graft allocation 
system in the Netherlands is patient oriented (based on the MELD score) and not 
based on center allocation. Therefore, steatotic liver grafts are in general assigned 
to patients high on the national waiting list and not reserved for candidates in 
relatively good clinical condition. Our median laboratory MELD score is 18 (IQR 
15-27) and this value is comparable or even higher in comparison with the study 
of McCormack and coworkers who have also reported successful postoperative 
outcome after transplantation of moderate steatotic livers (median laboratory 
MELD score of 12 (range 6-25) (17). 
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Steatotic livers are more susceptible for the effects of cold ischemia during organ 
preservation and subsequent warm reperfusion (4). This I/R injury initiates 
a sequence of events that lead to cellular damage with early graft dysfunction 
as consequence (6). In most studies, the definition of early graft dysfunction 
included laboratory markers of both liver injury (i.e. serum transaminases) and 
function (i.e. PT and serum bilirubin) (9,10,13,18-21). In our opinion this may 
cause confusion, because high serum markers of I/R injury such as serum AST and 
ALT are not always accompanied by a poor liver function. By separating markers 
of hepatocellular injury and function, we confirmed the high susceptibility of 
steatotic grafts to I/R injury, yet we also demonstrated that most livers may function 
well and survival rates are similar between the groups of moderate steatosis and 
nonsteatotic livers. When accepting a donor liver with moderate steatosis one can 
expect postoperatively very high levels of serum transaminases in the recipient, 
however, this does not necessarily mean that graft function is poor.
A very interesting finding in our study is the reversal of steatosis in 82% of the 
donor livers with a follow-up biopsy. In these livers, the degree of fatty infiltration 
decreased from moderate to 10% or less. Others have made similar observations, 
although very few studies have performed long term follow-up examinations 
(10,17,20,27,28). Nevertheless, the mechanism of steatosis reversal remains 
unknown. Disappearance of steatosis in follow-up biopsies may not necessarily 
mean elimination of the fat content of hepatocytes. It could also reflect necrosis 
and subsequent disappearance of fatty hepatocytes that are very susceptible to I/R 
injury, early after transplantation. Sampling error may also play a role since the 
location of the biopsy taken during OLT is different from the side of the liver where 
the percutaneous biopsy is taken from.  
Macroscopic evaluation of steatosis by the surgeon during the donor procedure is 
subjective and susceptible for errors (29). Nevertheless, in our region liver grafts 
are not routinely investigated with liver frozen sections to evaluate the degree 
of steatosis because this method is not reliable (24). Also the use of ultrasound 
or CT scanning is not routinely performed during the donor work-up. Only 
medical history and laboratory parameters of the donor in combination with 
the macroscopic judgment of the liver by the donor surgeon, gives us in most 
cases information whether we have to accept the donor liver or not. Given these 
circumstances, in our study we declined 7% of the donor offers because of a 
suspicion of moderate and severe graft steatosis in combination with additional 
risk factors. We cannot assess whether this aspect has influenced our study results 
to some extent.  
A limitation of our study is that we are not able to show that moderate steatotic 
donor livers in combination with prolonged cold ischemia times (≥ 8 hr) are 
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related to poorer postoperative outcomes in comparison to moderate steatotic 
livers with short CIT (< 8 hr).  Nevertheless, we demonstrated that recipients of 
a steatotic liver graft and longer CIT (≥ 8 hr) have significantly higher values of 
AST/ALT than recipients of a nonsteatotic liver graft, the first day postoperative. 
However, recipients of a steatotic donor liver and short CIT (< 8 hr) have almost 
similar serum levels of AST and ALT compared with recipients of a nonsteatotic 
liver. This data is supportive for our hypothesis that short cold ischemia times (< 8 
hr) are necessary when moderate steatotic donor livers are used for OLT. 
By the use of very strict logistics we are able to keep the CIT below 8 hours. We 
believe this is currently the best strategy to deal with donor livers with significant 
steatosis. Better and more prolonged preservation of steatotic donor livers could 
come from more sophisticated techniques such as machine preservation. In this 
respect, machine preservation is a promising new method that could allow ex 
vivo assessment of liver viability and function prior to transplantation, especially 
when livers can be perfused while maintaining a physiological temperature during 
normothermic machine preservation (30).   
In conclusion, it is known that livers with moderate macrovesicular steatosis 
are more prone to I/R injury and related to higher incidences of graft failure. 
Nevertheless, when using a strict policy where the CIT is kept as short as possible, 
moderate macrovesicular steatotic livers can be used successfully for liver 
transplantation despite a higher degree of postoperative complications. The use of 
moderate steatotic livers with a strict protocol to keep the CIT as short as possible 
is a safe way to expand the donor pool.
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Abstract
Background: Assessment of fatty liver grafts during orthotopic liver 
transplantation is a challenge due to the lack of real-time analysis options. Diffuse 
reflectance spectroscopy (DRS) could be a new diagnostic tool to quickly assess the 
degree of steatosis. 
Methods: Eight hundred seventy-eight optical measurements were performed 
in vivo in 17 patients in liver tissue during surgery and ex vivo on liver resection 
specimens from 41 patients. The degree of liver steatosis per measurement location 
was quantified from the collected optical spectra and compared to the histology 
analysis, which was performed by three independent pathologists. 
Results: Twenty-two patients were diagnosed with less than 5% steatosis, fifteen 
patients had mild steatosis (5-33%) and four patients displayed moderate (33-
66%) steatosis in their liver biopsies. Severe steatosis (> 66%) was not identified. 
Intra-class correlation between the pathologists analysis was 0.949. A correlation 
of 0.854 was found between histological assessment and DRS analyses of liver 
steatosis ex vivo. For the same liver tissue, a correlation of 0.925 was demonstrated 
between in vivo and ex vivo DRS analysis for steatosis quantification. 
Conclusion: DRS can quantify steatosis in liver tissue both in vivo and ex vivo 
with good agreement compared to histopathological analysis. DRS analysis can be 
performed real-time and may therefore be useful for fast and objective assessment 
of liver steatosis during organ procurement procedures.
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Introduction
Liver steatosis is one of the most important risk factors for primary non-function 
or early graft failure after orthotopic liver transplantation (OLT). Non-alcoholic 
fatty liver disease (NAFLD) is the most common cause of chronic liver disease 
in the world and may ultimately lead to severe non-alcoholic steatohepatitis 
(NASH) or cirrhosis. Estimations of NAFLD prevalence vary between 20 and 30% 
in unselected populations from developed countries (1). Steatosis is generally 
characterized quantitatively and qualitatively. Steatosis is traditionally quantified 
as none (< 5%), mild (5% to 33%), moderate (33% to 66%), or severe (> 66%) 
dependent on the percentage of hepatocytes containing fat vacuoles (2-6). Within 
the degree of fat accumulation in the hepatocytes, the histological evaluation of 
steatosis can be qualified in two major patterns: microvesicular and macrovesicular 
steatosis. Microvesicular steatosis solely, has been shown to have no negative 
impact on outcome (7-9). Yet, several studies have shown that moderate and severe 
macrovesicular steatosis of liver grafts is associated with impaired graft function 
after transplantation (10-13).
Assessment of fatty liver grafts during OLT is still a challenge for the transplant 
team. Surgical evaluation of fat accumulation by visual inspection and palpation 
during organ procurement has low predictive values and remains subjective (14). 
In addition, conventional imaging technologies also have their limitations in 
steatosis analysis and quantification. Ultrasound (US) is widely used in clinical 
practice to detect fatty infiltration by assessing the echogenicity in the liver. On 
the other hand, US has some disadvantages; this technique is not quantitative, 
prone to inter-observer variance and its sensitivity is reduced in morbidly obese 
patients (15,16). Other imaging techniques, such as computer tomography (CT), 
magnetic resonance imaging (MRI), and magnetic resonance spectroscopy (MRS) 
are able to visualize intrahepatic fat very accurately. The limitations of all three 
techniques are the inability to differentiate between micro- and macrovesicular 
steatosis and the relatively time-consuming and logistic efforts involved in these 
methods during a donation procedure (16,17). New techniques like electrical 
bioimpedance have recently been used to assess hepatic steatosis with high 
reliability (3). However, only results have been displayed in an animal set-up. 
Invasive histological evaluation still remains the gold standard for assessment of 
steatosis in liver tissue (18). Nevertheless, discrepancy in histological analysis has 
been described due to variability in interpreting the histological assessment per 
biopsy and the inter-observer variation among expert pathologists (19). 
Over the last decade, diffuse reflectance spectroscopy (DRS) has been suggested 
to be a potential diagnostic tool for objective and quick assessment of tissue 
lipid concentration (20-22). During DRS, tissue is illuminated by a selected light 
spectrum. By subsequent analysis of absorption and scattering characteristics, 
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an “optical fingerprint” is obtained which represents specific biochemical and 
morphological information of the tissue examined. DRS is consequently able 
to determine the amount of fat in the tissue that is illuminated. The goal of the 
present study is to investigate whether DRS allows to quantify steatosis in human 
liver tissue in an in vivo as well as in an ex vivo clinical setting.  
Materials and methods
Clinical Study Design  
The study was conducted at The Netherlands Cancer Institute - Antoni van 
Leeuwenhoek hospital (NKI-AVL) between October 2009 and December 2012, 
under approval of the protocol and ethics review board. Optical measurements 
were performed both in vivo and ex vivo. 
For in vivo measurements, 17 patients were included that were scheduled for partial 
liver resection mainly because of metastatic disease. Written informed consent 
was obtained from all patients. Before liver resection was performed, a 15 Gauge 
optical needle (Figure 1a, Invivo, Schwerin, Germany) was inserted into normal 
liver tissue within the planned resection area (Figure 1B and 1C) just below the liver 
surface. Ultrasound guidance (Hitachi Aloka, ProSound SSD-4000) was used to 
confirm the location of the tip of the needle to be in normal liver tissue and at least 
2 cm from the liver tumor. A total of 242 optical measurements were performed at 
49 different measurement locations. After the optical measurements, a twist coil 
marker (OTM 3.0SA, BIP GmbH, Türkenfeld, Germany) was inserted to mark the 
exact measurement location. 
Ex vivo optical measurements were performed in normal liver tissue from 41 
patients after partial liver resection. These patients included the 17 patients from 
the previously mentioned in vivo analysis combined with 24 additional patients 
that underwent only ex vivo measurements of resected liver tissue. Immediately 
after liver resection, DRS measurements were performed within benign liver 
tissue at least 2 cm from the metastatic sites. Several measurement locations 
were determined within each tissue specimen and on average 5 consecutive 
DRS measurements were performed at each measurement location. Thereafter 
a biopsy was directly taken from each specific measurement location for further 
histopathological analysis. A total of 636 DRS measurements at 127 different 
measurement locations were collected (Figure 1D).  
Optical Spectroscopy Instrumentation 
Recently, Nachabé et al. described the instrumentation and calibration procedure 
of our DRS system (20,23-25). The DRS system consists of a console comprising 
a Tungsten/Halogen broadband light source and two spectrometers. The two 
spectrometers resolve light in the visible wavelength range between 400 nm and 
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Figure 1. Overview of the optical spectroscopy system and optical measurements. Panel A: Optical 
needle with close-up of the tip. Panel B: Schematic display of an in vivo measurement performed before liver 
resection; L - benign liver tissue; RM - planned resection margin; T - tumor; GB - gallbladder; ON - optical 
needle. Panel C and D: In vivo and ex vivo measurement in “normal” liver tissue.
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1100 nm (Andor Technology, DU420A-BRDD) and in the near infrared wavelength 
range from 800 up to 1700 nm (Andor Technology, DU492A-1.7), respectively. An 
optical probe that contained four optical fibers was attached to the DRS system for 
optical measurements (26). One fiber was connected to the light source and two 
fibers were connected to the spectrometers to capture the diffusely scattered light 
from the tissue in this study. The remaining fiber was not used. The average tissue 
volume that is illuminated with the probe is roughly 5 mm3. The acquisition time 
of each spectrum was on average 0.2 seconds. 
Histopathological Analysis   
In the resected liver tissue, a pathologist located the twist markers indicating the 
in vivo measurements and excised the surrounding liver tissue for tissue analysis. 
These biopsies as well as the biopsies retrieved from the ex vivo measurements were 
first fixed in formalin, subsequently paraffin embedded and processed for standard 
hematoxylin and eosin (H&E) staining. Three experienced pathologists, who were 
blinded for the outcome of the DRS results, individually examined the histological 
slides and visually determined the amount of steatosis within the benign liver 
tissue. A semi-quantitative assessment of steatosis was determined by estimating 
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the percentage of hepatocytes containing lipid droplets (both microvesicular and 
macrovesicular steatosis droplets) in 10 consecutive fields (magnification 25x). 
Macrovesicular steatosis was defined as fat vesicles larger than the cell nucleus, 
often displacing the nucleus. Microvesicular steatosis was defined as fat vesicles 
with similar size or smaller than the liver cell nucleus. The pathologic degree of 
steatosis was estimated with increments of 5%. If both steatosis subtypes were 
evidently present with similar percentages, the steatosis was defined as a ‘mixed 
type’. The mean of steatosis quantifications for each tissue specimen determined 
by the three pathologists was used for comparison with the DRS analysis. Each 
tissue specimen was subsequently divided into one of four preselected steatosis 
groups; none 0 to 5% steatosis, mild 5 to 33% steatosis, moderate 33 to 66% 
steatosis and severe > 66% steatosis. Finally, the liver tissue was also categorized as 
macrovesicular, microvesicular or mixed steatosis type. 
Spectral Data Analysis 
The light delivered to the tissue by the illumination fiber is subject to optical 
absorption and scattering before being collected by the detection fiber of the optical 
probe. Optical absorption is determined by the concentration of chromophores 
in the probed tissue. Each chromophore has its own intrinsic optical absorption 
characteristic, which is a function of wavelength. Fat and water are the dominant 
chromophores in the wavelength range between 1100 and 1600 nm (25). Oxygenated 
and deoxygenated hemoglobin and bile are the dominant chromophores in the 
wavelength range between 500-900  nm (20). The total absorption of the tissue 
as a function of wavelength can be written as the summation of the absorption of 
each chromophore multiplied by their concentrations in the tissue.  
Optical scattering in tissue is dependent on the cellular structure of the target 
tissue and is sensitive to size and density of cellular and subcellular structures. 
Optical scattering can be described by the reduced scattering coefficient at a 
certain wavelength. To interpret the acquired DRS spectra, a widely accepted 
analytic model, introduced by Farrell et al. (27), was used to estimate the various 
DRS absorption and scattering coefficients. The acquired spectra were fitted and 
analyzed over the wavelength range from 500 to 1600 nm. Spectral characteristics 
analysis was performed with a Matlab software package (MathWorks Inc., Natick, 
MA, USA). Median values for fat, water, oxygenated and deoxygenated hemoglobin, 
bile, and the scattering parameters were calculated from the obtained spectra of 
each optical measurement. 
Statistical Analysis
The lipid fraction scored by the pathologist was considered to be a two dimensional 
analysis of the same three dimensional volume of liver tissue analyzed with the 
DRS. To be able to compare the pathological analysis to the DRS analysis, the 
pathological lipid fractions were recalculated using the principle postulated 
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by Weibel et al. (28) and the following formula  ( ) 2/33
4
areavolume LL π
= . Larea is the lipid 
fraction from the histological slide of the liver tissue scored by the pathologist and 
Lvolume is the histological volume lipid fraction assuming a homogeneous volume 
distribution of lipid spheres. 
Inter-observer variability between pathologists was determined using a one-way 
single score intraclass correlation (ICC). We used a Spearman’s rank correlation 
test for the correlation between both the DRS ex vivo measurements and the 
pathologists’ quantification of steatosis as well as for the correlation between 
in vivo and ex vivo measurements within the same 17 patients. Analyses were 
performed using SPSS software (version 16.0, Chicago, IL, USA). 
Results
A total of 41 patients (24 male and 17 female) were included in this study. The 
average age of all patients was 64 years (range 38-83 years). Patient characteristics 
as well as the histological characterization of the liver tissues are displayed in 
Table 1. 
Table 1. Patient and Histological Characteristics
Characteristics Number (percentage)
Included patients Total 41
Male 24  (58.5%)
Female 17  (41.5%)
Indications for resection Colorectal metastases 38 (92.8%)
Mesothelioma 1   (2.4%)
Mamma carcinoma metastases 1   (2.4%)
Hepatocellular carcinoma 1   (2.4%)
Neoadjuvant chemotherapy Yes 22 (53.7%)*
No 19 (46.3%)
Histological steatosis quantification None (0 - 5%) 22 (53.7%)
Mild (6 - 33%) 15 (36.6%)
Moderate (33 - 66%) 4  (9.7%)
Severe (> 66%) 0    
Histological steatosis characterization No steatosis 10 (24.4%)
Microvesicular steatosis 2    (4.9%)
Macrovesicular steatosis 14 (34.1%)
Mixed steatosis 15 (36.6%)
*Chemotherapy regime for colorectal metastases consisted of a combination of Capecitabine and Oxalipatin. Seven patients also were treated 
with Bevacizumab. Mesothelioma was pretreated with Cisplatin and Pemetrexel and mamma carcinoma metastases were pretreated with 
Capecitabine and Lapatinib.
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Figure 2. Examples of different types of steatosis (hematoxylin and eosin staining). Panel A and B: Typical 
example of the diffuse pattern of steatosis in liver tissue in one patient specimen. Panel C: Lipid droplets 
generally accumulate in the zone around the central veins in each liver lobule. Panel D: Normal liver with 
mixed pattern of both macro- and microvesicular steatosis. Panel E: High magnification of microvesicular 
steatosis. Panel F: High magnification of macrovesicular steatosis. Magnifications are added in the bottom 
right corner of each photograph.
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Histological Characteristics
To be able to assign specific DRS patterns to differences in liver tissue composition, 
detailed histopathological examinations were performed for the tissue areas 
measured. Examples of the steatosis patterns encountered are displayed in 
Figure 2. The generally observed pattern of steatosis was a diffuse and relatively 
homogenously spread of clusters of lipid droplets as depicted in Figure 2A and 2B. 
Within a liver lobule the lipid droplets particularly accumulate near the central 
vein (Figure 2C). Histological analysis determined 22 patients in the group with 
less than 5% steatosis (represented as the group ‘none’). Twelve of these 22 patients 
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had between 1 and 5% steatosis, the other 10 patients had 0% steatosis. Fifteen 
patients had ‘mild’ steatosis (5 to 33%), four had ‘moderate’ steatosis (33 to 66%), 
and no patients were diagnosed with ‘severe’ steatosis (> 66%). Differentiation of 
the steatosis type was performed on the 19 patients diagnosed with ≥ 5% steatosis. 
Most of these patients (n = 12) displayed a mixed pattern of both microvesicular and 
macrovesicular steatosis (Figure 2D). Macrovesicular steatosis, with lipid droplets 
up to 80 µm, was observed in 6 of these 19 cases. The steatosis percentages of these 
patients ranged from 6 to 47%. Microvesicular steatosis was only observed in 1 
patient. High magnification illustrations of both steatosis subtypes are respectively 
displayed in Figures 2E and 2F. Three independent pathologists determined the 
quantification of steatosis for each individual patient. The calculated intraclass 
correlation (ICC) between the pathologists was 0.949, indicating a good agreement 
with each other. 
DRS Steatosis Analysis
On average, 15 DRS measurements were performed within each liver specimen 
ex vivo. Examples of the optical spectra from one patient of each defined group 
and their corresponding histopathological slides are displayed in Figure 3 (next 
page). The spectrum in the vicinity of 1200  nm is dominated by the absorption 
of light by lipid cells. A more prominent inverse sharp peak in the light spectrum 
at this wavelength corresponded to a higher fat concentration in the tissue and 
consequently a higher steatosis score was observed. Figure 4 shows box plots 
of the calculated concentrations of fat, water and bile as well as the scattering 
coefficient from all tissue measurements for each defined steatosis group. The 
amount of fat, as determined by DRS, clearly increasd with a higher grade of 
steatosis on histopathology. In addition, with an increasing steatosis score a 
significant decrease in water and bile concentration was observed together with 
an increase in scattering at 800 nm. The results of the average concentration of 
steatosis determined by both DRS and histology for each measured liver tissue 
specimen are displayed in Figure 5. A high level of agreement is presented with a 
correlation of 0.854 when comparing the results of both quantification methods 
for each measured tissue specimen. The comparison of the DRS analysis for each 
of the 17 patients for which steatosis was determined both in vivo and ex vivo is 
depicted in Figure 6. The correlation of 0.925 indicates a little difference in the 
quantification of liver steatosis by the optical needle before and after resection.
Discussion 
Liver steatosis may significantly affect the function and survival rate of donor 
livers after transplantation. This renders identification of moderate and severe 
macrovesicular steatotic donor livers. Invasive histological evaluation remains 
the gold standard for the assessment of steatosis in liver tissue (18). However, 
limitations in the histological assessment have necessitated the search for novel 
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No steatosis
Steatosis pathology: 0%       Steatosis DRS: 0%
5x
Mild steatosis
Steatosis pathology: 27%       Steatosis DRS: 30%
5x
Moderate steatosis
Steatosis pathology: 47%       Steatosis DRS: 57%
5x
Figure 3. Examples of steatosis of the liver of increasing severity and the corresponding light spectra 
of the tissue generated with DRS. The estimated steatosis percentages for each tissue sample by three 
specialized pathologists and the corresponding DRS spectra are displayed. Specific wavelengths from which 
the fat volume concentration was calculated are indicated between the dashed lines. Magnifications are 
added in the bottom right corner of each photograph.
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Figure 4. Box plots of different tissue components compared in different degrees of steatosis: none, 
mild, and moderate steatosis. Panel A: Fat. Panel B: Water. Panel C: Bile. Panel D: With an increasing degree 
of steatosis, an increase in scattering was observed at 800 nm.
Figure 5: Comparison of steatosis analysis 
by DRS versus pathological evaluation in 41 
patients. Between pathological and DRS analysis 
a Spearman’s rank correlation of 0.854 was 
calculated.
Figure 6. Measurements with the DRS were 
performed in liver tissue of 17 patients in vivo 
as well as ex vivo. Between in vivo and ex vivo 
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tools capable of accurately quantification of fat in liver tissue (19). DRS has the 
ability to determine the lipid fraction within a tissue specimen with high accuracy 
(21,23,24,29). Our group recently compared the accuracy of DRS quantification of 
liver steatosis in murine livers with analysis by magnetic resonance spectroscopy, 
magic angle spinning - nuclear magnetic resonance, high-performance thin-layer 
chromatography, and histopathology. A good agreement of the estimated lipid 
fractions was demonstrated between DRS, the various imaging techniques and 
histopathological analysis (22). The next step towards the introduction of DRS 
into daily clinical practice of liver surgery, such as liver transplantation, is to first 
explore the accuracy quantifying liver steatosis in human liver tissue in vivo.
In this present study we have analyzed liver tissue in comparable conditions to 
those during liver transplantation: in a controlled situation in the operating 
theater during abdominal surgery immediately before and after liver tissue 
resection. Our results confirmed that DRS shows good agreement (correlation of 
0.854) in fat quantification of liver tissue in comparison with the mean histological 
quantification of three independent expert pathologists. We subsequently 
demonstrated that DRS could quantify liver steatosis in vivo and ex vivo with 
comparable accuracy. The results of this preliminary study demonstrate that DRS 
can have the potential to improve real-time quantification of steatosis during 
organ donation procedures.  
The main advantages of DRS compared to other available imaging techniques as 
well as to histopathology, are that the quantification of steatosis can be performed 
in real-time. In contrast, histological analysis requires specific staining at the 
pathology department and will generally take at least 30 minutes before reliable 
conclusions can be drawn. Similarly, CT, MRI, and MRS, are also relative time-
consuming procedures during the donation procedure. In contrast, analysis of the 
degree of steatosis with the DRS can be performed much faster, especially during 
donation procedures, where every second counts. 
It is known that liver steatosis is heterogeneous distributed throughout the 
liver parenchyma. However, during organ procurement, a needle biopsy is 
performed one or two times (30). Compared to these biopsies, with the DRS it is 
easier to perform multiple measurements. Therefore, we postulate that with the 
DRS a better estimation of the steatosis content of the whole liver can be made 
compared to histological analysis. In the current study, in liver specimens of the 
same patients, there was little variation of the steatosis concentration determined 
with DRS between different locations. The individual standard variation of the fat 
fraction varied from 1 and 13.0% steatosis. However, it should be noticed that for 
the most optimal result with the DRS, we have to validate the number of necessary 
measurements. 
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The main disadvantage regarding DRS in this study is that it concerns an invasive 
technique. During the invasive measurements in vivo, we did not observe any 
bleeding complications of the examined liver tissue. Microscopic analysis of 
the examined tissue specimen did not reveal obvious tissue damage of local 
bleeding. Moreover, an improved version of our optical needle has recently been 
developed for clinical applications, 20 G (= 0.8 mm) instead of 15 G (31). Biopsy 
needles generally used during invasive hepatic procedures nowadays range up 
to 14 G (or 1.6 mm). These arguments render our current DRS system as a similar 
invasive technique when comparing it to the generally performed core biopsy for 
histopathology analysis. 
Interestingly, when comparing pathological assessment with DRS, higher 
percentages of steatosis were detected with the DRS system (Figure 5). Percent 
differences up to 20% were observed between the analysis methods. An 
explanation for this discrepancy could be the staining method that we used to 
visualize steatosis. The staining method was a standard H&E staining. Levene et 
al. (32) demonstrated that this staining method could cause an underestimation 
of the quantification of steatosis by expert pathologists when the lipid droplets 
are mainly microvesicular, as shown by an alternative staining method with Oil 
Red-O on frozen liver samples. However, Oil Red-O staining is not routinely used in 
clinical practice. In addition, the good ICC between the three pathologists is notable 
when compared to a previous study (19). We believe that this high correlation is 
due to the fact that more than half (n = 22) of the included patients were assigned 
to the ‘none’ steatosis group. This results in a relatively low variation in steatosis 
concentration over the entire cohort. 
Within the steatosis groups as defined by histology, important differences were 
displayed in concentrations of water and bile (Figure 4). Both tissue parameters 
significantly decreased with an increase of lipid deposit in the hepatic tissue. 
The decrease in water concentration together with an increase in the degree of 
steatosis is in line with observations made by Marsman et al. (33). In a subsequent 
study, the same group confirmed these results, hypothesizing that the decrease 
in water is a result of exudation (34). In addition, the low concentrations of bile 
in steatotic liver tissue could be caused by a decreased hepatic uptake of serum 
bilirubin, as shown by McCormack et al. (35).  
It has been shown that inferior graft function after transplantation is associated 
with macrovesicular steatosis. On the other hand, solely microvesicular steatosis 
has not this association (10-13). Therefore, it is necessary to determine the steatosis 
subtype during organ procurement. In our study, the incidence of livers with 
microvesicular steatosis was low. Although the predominance of macrovesicular 
and mixed steatosis in our patient cohort is comparable to previously published 
papers (3,35,36), it was in our experiment not possible to distinguish between 
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micro- and macrovesicular steatosis. Due to this limitation, we could not draw 
any conclusions towards a possible applicability of DRS distinguishing micro- and 
macrovesicular steatosis. 
The results of this study provide a proof-of-principal that the DRS has the potential 
to enhance liver steatosis quantification. However, several questions remain to 
be answered before DRS can be translated into clinical practice. First, in future 
studies we must first reconfirm our results with specific evaluation of safety. 
Moreover, another future direction is to determine whether DRS can qualify both 
steatosis subtypes. We hypothesize that discrimination of microvesicular from 
macrovesicular steatosis could be made based on differences in the scattering of 
light. Optical scattering depends on the size and distribution of cellular particles 
compared to the wavelength of light (23). Notable differences in the scattering of 
light at 800 nm between the defined steatosis groups were apparent as displayed in 
Figure 4. Graaff and coworkers (37) demonstrated that the wavelength dependence 
of the scattering parameters depends on the size of the scattering particles. Since 
microvesicular and macrovesicular steatosis droplets significantly differ in size, 
careful analysis of the wavelength dependence of the scattering parameters 
might allow discrimination between the two subtypes of steatosis. In addition, 
we further aim to assess relevant transplantation related questions e.g. if the DRS 
is able to quantify steatosis after perfusion and cold storage. Finally, before DRS 
can be implemented into clinical practice, important focus must be put towards 
development of practical DRS hardware with minimization of user costs.
In conclusion, we have demonstrated that DRS can quantify steatosis in liver tissue 
both in vivo and ex vivo with good agreement in comparison to histopathology 
analysis. DRS analyses of liver steatosis can be performed within seconds and could 
therefore be used for a rapid clinical assessment of liver tissue during donation 
and prior to transplantation. Future studies need to be carried out to in order to 
establish whether DRS can distinguish between different subtypes of steatosis and 
to examine how the DRS can be implemented in the field of organ procurement 
and transplantation. 
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Diff use Refl ectance Spectroscopy Accurately 
Quantifi es Various Degrees of Liver Steatosis 
in Murine Models of Fatt y Liver Disease




Background: A real-time objective evaluation for the extent of liver steatosis 
during liver transplantation is currently not available. Diffuse Reflectance 
Spectroscopy (DRS) rapidly and accurately assesses the extent of steatosis in 
human livers with mild steatosis. However, it is yet unknown whether DRS 
accurately quantifies moderate/severe steatosis and is able to distinguish between 
micro- and macrovesicular steatosis.
Methods: C57BL/6JolaHsd mice were fed wit a choline-deficient L-amino acid-
defined diet (CD-AA) or a choline-sufficient L-amino acid-defined control diet (CS-
AA) for 3, 8, and 20 weeks. In addition B6.V-Lepob/OlaHsd (ob/ob) mice and their 
lean controls were studied. A total of 104 DRS measurements were performed in 
liver tissue ex vivo. The degree of steatosis was quantified from the DRS data and 
compared with histopathological analysis. 
Results: When assessed by histology, livers of mice fed with a CD-AA and CS-
AA diet displayed macrovesicular steatosis (range 0-74%), ob/ob mice revealed 
only microvesicular steatosis (range 75-80%), and their lean controls showed no 
steatosis. The quantification of steatosis by DRS correlated well with pathology 
(correlation of 0.76 in CD-AA/CS-AA fed mice and a correlation of 0.75 in ob/
ob mice). DRS spectra did not distinguish between micro- and macrovesicular 
steatosis. In samples from CD-AA/CS-AA fed mice, the DRS was able to distinguish 
between mild and moderate/severe steatosis with a sensitivity and specificity of 
86% and 81%, respectively. 
Conclusion: DRS can quantify steatosis with good agreement to histopathological 
analysis. DRS may be useful for real-time objective evaluation of liver steatosis 
during liver transplantation, especially to differentiate between mild and 
moderate/severe steatosis. 




A widely adopted strategy to increase the number of liver donors is the use of 
extended criteria donor (ECD) livers (1). One of the most prevalent conditions to 
classify a graft as ECD liver is hepatic steatosis. According to histopathological 
evaluation, steatosis can be categorized in a qualitative and quantitative manner. 
Qualitatively, steatosis is subdivided into two different histological patterns: 
micro- and macrovesicular steatosis. Quantitatively, steatosis is classified 
according to the percentage of hepatocytes affected by fat vacuoles; mild (less 
than 30%), moderate (between 30 and 60%), or severe (above 60%) (2-4). How 
steatosis affects graft survival depends on the type and degree. Donor livers with 
microvesicular steatosis (in all degrees) and with mild macrovesicular steatosis 
are suitable for transplantation. On the other hand, livers with moderate and 
severe macrovesicular steatosis are in most cases considered as a contraindication 
for transplantation due to their relation with poor postoperative outcome (2-4).
Given the rising incidence of obesity, the general expectation is that more steatotic 
livers will become available for liver transplantation. However, evaluation of the 
degree and type of steatosis is still a challenge for the surgical team during organ 
procurement procedures. Currently, assessment of hepatic steatosis requires 
a liver biopsy. However, processing and examination of the biopsy is a logistic 
challenge during off-hours, when most organ procurement procedures take place. 
Moreover, tools for a quick and accurate assessment of the type and degree of 
steatosis are not yet available (4). 
Recently, diffuse reflectance spectroscopy (DRS) has demonstrated its possibilities 
to measure lipid concentration in tissue minimal invasively, accurately, and 
in real-time (5-9). In a recent study performed by our group, DRS was able to 
quantify only mild degrees of steatosis (10). However, from a clinical perspective, 
it is also necessary to determine if the DRS is able to discriminate between mild 
and moderate/severe macrovesicular steatosis. In addition, the ability of the DRS 
to discriminate between micro- and macrovesicular steatosis is yet unknown. 
The aim of the current study is therefore to investigate if DRS could quantify 
moderate and severe steatosis and if DRS could differentiate between micro- and 
macrovesicular steatosis. Because (discarded) human donor livers with mild 
and moderate steatosis are not available in large quantities, we used two well-
established mouse models (choline-deficient diet and leptin deficiency; ob/ob) of 
hepatic steatosis.   
 
 
Binnenwerk_Andrie_Final.indd   71 12/20/15   11:01 AM
72
Macrovesicular steatosis (mild and moderate)
         and hepatocellular ballooning 
Study Groups Histology
    3
weeks
    8
weeks
    20
weeks











Macrovesicular steatosis (moderate and severe)
          and hepatocellular ballooning
Macrovesicular steatosis (severe)
    and hepatocellular ballooning
Microvesicular steatosis 
                (severe)
Macrovesicular steatosis (minimal) 
and/or hepatocellular ballooning
No steatosis
Macrovesicular steatosis (mild and moderate) 
               and hepatocellular ballooning
Figure 1: Overview of the experimental groups and type and grade of hepatic fat content. To induce 
hepatic steatosis, mice received the choline-deficient L-amino acid-defined (CD-AA) diet for 3, 8, and 20 
weeks. The control mice were fed with choline-sufficient L-amino acid defined (CS-AA) chow diet for the 
same time periods. The ob/ob (leptin deficient) mice and their lean controls received the standard chow 




C57BL/6JolaHsd mice (5-6 weeks old) and B6.V-Lepob/OlaHsd (ob/ob) mice (9-10 
weeks old) were purchased from Harlan Laboratories (Boxmeer, the Netherlands). 
Animals were caged in animal rooms with an alternating 12-hour light/dark period 
and had free access to food and water for the duration of the experiment. All 
procedures were approved by and performed in compliance with the Institutional 
Animal Care and Use Committee of the University of Groningen (IACUC-RuG). 
Experimental Design
To induce different stages of hepatic steatosis, the C57BL/6JolaHsd mice received a 
choline-deficient L-amino acid-defined (CD-AA) chow diet (no. 518753, Dyets Inc., 
PA, USA) for 3, 8, and 20 weeks. The control mice were fed with a choline-sufficient 
L-amino acid defined (CS-AA) chow diet (no. 518754, Dyets Inc., PA, USA) for the 
same time periods. The ob/ob mice and their lean controls received a standard chow 
diet (reference no. 2181 AB Diets, Woerden, the Netherlands) for 4 weeks (Figure 1). 
Each group comprised of 5-7 mice, for a total of 52 mice. 
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Figure 2: Overview of the DRS system and optical measurement. Panel A: Set-up of the DRS system with 
the optical needle. The diameter of the needle is 0.91 mm (20 Gauge) with a fiber distance of 0.8 mm. Panel 
B: Ex vivo measurement in mouse liver tissue with DRS needle.
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After 3, 4, 8 or 20 weeks of feeding, mice were anesthetized using a mixture of 
isoflurane/O2, subjected to a hepatectomy, and sacrificed. After the hepatectomy, 
the liver was stored on a petri dish for immediate measurement with the DRS (Figure 
2). Per mouse liver, two liver lobes (left median and right upper) were used for ex 
vivo measurements with the optical needle of the DRS system. The optical needle 
was inserted once in each liver lobe. Per lobe, 5 consecutive DRS measurements 
were performed, which were averaged. Thereafter, a biopsy was taken from the 
specific measurement location for further histopathological analysis. 
Optical Spectroscopy Instrumentation and Analysis
Recently, the instrumentation and calibration procedure of the DRS system was 
described by Nachabé et al. (6). In brief, the DRS system consists of a console 
comprising a broadband light source and one spectrometer (Figure 2). The 
spectrometer resolve light in the near infrared wavelength range from 1000 up 
to 1600 nm. Within the optical needle one fiber was connected to the light source 
and one fiber was connected to the spectrometer to capture the diffusely scattered 
light from the tissue. The diameter of the needle is 20 Gauge (0.91 mm) with a 
fiber distance of 0.8 mm. The average tissue volume that is illuminated with the 
needle is roughly 1 mm3. The acquisition time of each spectrum was on average 0.2 
seconds.  
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Analysis of the spectral data has been described previously (10). In brief, each 
cellular component such as lipid, hemoglobin or collagen (component of fibrosis) 
has its own intrinsic optical characteristic (spectrum), which consists of a 
combination of absorption and scattering coefficients in a specific wavelength 
range. From our earlier experiments, the spectra of lipid, hemoglobin and collagen 
are identified. Fat and collagen are the dominant chromophores in the wavelength 
range between 1100 and 1600 nm, while (oxygenated and deoxygenated) 
hemoglobin have the dominant chromophores in the wavelength range of 500-
900 nm (11). Moreover, the absorption coefficients of lipid compared to collagen 
are different (11). Dependent of the spectra and combination of absorption and 
scattering coefficients, the DRS is able to estimate the hepatic lipid (fat) content. 
In addition, scattering in the wavelength range 1000-1600 nm is dominated by 
Mie scattering. The reduced scattering coefficient μs’(λ) is modeled by μs’(λ) = α λ-b 
where λ is the wavelength and b the Mie-slope (11). Furthermore, it is known that 
contact pressure of the needle affects the absorption, scattering and intensity of 
the spectra (12-15), we performed measurements very thoroughly in order to apply 
similar contact pressure on each liver specimen. Spectral characteristics analysis 
(fitting of the data) was performed with a Matlab software package (MathWorks 
Inc., Natick, MA, USA). 
Histological Analysis
Biopsy specimens from the optical measurement locations were first fixed in for-
malin, then paraffin embedded and subjected to standard hematoxylin and eosin 
(H&E) staining. For assessment of macrovesicular steatosis, the sections were dig-
itally scanned using a digital whole slide scanner (Aperio ScanScope GS, Aperio 
Technologies, Vista, CA, USA) at a magnification of 40 (100.000 pixels/inch). Per 
section, eight digital images were saved as TIFF files. Next, a computer-based im-
age-processing algorithm was developed in ImageJ (National Institutes of Health, 
Bethesda, MD, USA) for morphometric calculations of the macrovesicular lipid 
droplet area, as described previously (7). The lipid droplets were identified by their 
shape and diameter. Non-hepatocyte areas such as sinusoids, vessels and artifacts 
(tissue cracks) were excluded. Macrovesicular steatosis was enumerated for each 
picture as the percentage of surface consisting of lipid droplets per total surface 
area. The morphometric calculations with ImageJ were not applicable for microve-
sicular steatosis and hepatocellular ballooning. Assessment of microvesicular ste-
atosis and hepatocellular ballooning was therefore performed visually with light 
microscopy. Microvesicular steatosis was defined as innumerable tiny lipid vesicles 
that were diffusely distributed and causes a foamy appearance of the cytoplasm. 
In hepatocellular ballooning, no cytoplasmic fat vacuoles are present; hepatocytes 
are swollen due to lipid accumulation in nonvesiculated areas (16). Scoring of mi-
crovesicular steatosis and ballooning was performed in a blind fashion by two in-
dependent observers (ACW and FB) according to the established scoring method 
of Kleiner et al. (17). The lipid fraction scored by pathological evaluation was con-
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sidered to be a two dimensional analysis of the same three dimensional volume 
of liver tissue analyzed with DRS. To adjust the pathological scored lipid fraction 
to a volume lipid fraction, the pathological lipid fractions were recalculated using 
the principle postulated by Weibel et al. (18). Moreover, it should be noticed that 
between histological scoring and DRS analysis an intrinsic difference of 5% is ob-
tained due to that lean mice livers without steatosis also contain some intracellular 
lipids (19). In order to score DRS analysis as positive, the determined fat fraction 
should be above the threshold value of 5%.     
Statistical Analysis  
Spearman’s rank correlation test was used to examine the correlation between the 
DRS ex vivo measurements and the histological quantification of steatosis. Linear 
regression (r2) was used to assess correlations between DRS measurements and 
histological quantification of steatosis. The statistical differences between the 
scattering parameters were determined using a non-parametric Kruskal-Wallis 
test (20). P-levels smaller than 0.05 were considered as statistically significant. 
Analyses were performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software Inc., La Jolla, CA, USA).
Results
Histological Assessment
Histological evaluation of the liver biopsies of mice in the CD-AA diet group showed 
macrovesicular steatosis in the range from 17 to 73%. The degree of macrovesicular 
steatosis increased with the duration of the diet. In addition, ballooned hepatocytes 
were observed in the CD-AA diet group with an increased number together with an 
increasing duration of the diet. Mice fed with CS-AA diet for 3 weeks displayed no 
steatosis in their biopsies. However, 8 and 20 weeks of CS-AA diet also resulted in 
the development of macrovesicular steatosis and/or hepatocellular ballooning but 
these degrees were lower than the CD-AA diet group. The ob/ob mice developed 
exclusively microvesicular steatosis, which was severe (range 75-80%) in all 
animals. Evaluation of the liver biopsies of their lean controls showed no evidence 
of hepatic fat infiltration (Figure 1). 
Figure 3 shows examples of the different types of hepatic fat infiltration. The 
large fat droplets of macrovesicular steatosis were predominately present in 
clusters around the central vein. In particular, macrovesicular steatosis was not 
evenly distributed throughout the liver. The patterns of microvesicular steatosis 
as well as hepatocellular ballooning were more heterogeneous distributed in the 
liver parenchyma. In addition, Figure 4 illustrates an example of liver biopsy with 
macrovesicular steatosis, ballooning, inflammation, and periportal/perivenular 
fibrosis, which were mainly observed in the late stages of the CS-AA and CD-AA 
diet. 






Figure 3: Overview of normal hepatic mouse tissue and different types of hepatic fat filtration. Panel A and B: 
Normal hepatic mouse tissue, panel B is a magnification of panel A. Panel C and D: Macrovesicular steatosis, panel D is 
a magnification of panel C. Panel E and F: Microvesicular steatosis, panel F is a magnification of panel E. Panel G and H: 
Hepatocellular ballooning, panel H is a magnification of panel G. Black arrows point to the central vein. All sections are 
H&E stained. Scale bars in the panels A, C, E, and G indicate 500 μm. Scale bars in the panels B, D, F, and H indicate 50 μm.
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Figure 4: Masson trichrome staining of mouse liver in the CD-AA diet group. Clusters of inflammatory 
cells are visualized in the dashed white circle. White arrows show fibrosis (periportal and perivenular). Scale 
bar indicates 100 μm.
5
Evaluation of Steatosis with DRS
In total, 104 DRS measurements were performed in 104 hepatic tissue specimens 
from 52 livers. Examples of optical spectra of macrovesicular, microvesicular 
steatosis, and hepatocellular ballooning are presented in Figure 5A. Lipid cells in 
fatty liver tissue have an absorption peak around 1200 nm (11). In all the three 
fat spectra, an inverse peak was observed in the vicinity of 1200 nm. However, 
discrimination between the three different spectra was not possible due to similar 
absorption and scattering characteristics of these types of fat around 1200 nm (see 
also Figure 6, where boxplots of scattering parameters are presented). Therefore, 
the DRS system was not able to differentiate between types of fat; only the total 
hepatic fat fraction could be measured. Figure 5B shows examples of hepatic fat 
fraction of increasing severity and the corresponding light spectra of the tissue 
generated with the DRS. Depending on the percentage of hepatic fat fraction; a 
deeper inverse peak in the vicinity of 1200 nm is related to a higher degree of 
hepatic fat infiltration. Additionally, in Figure 6 boxplots are displayed showing 
the reduced scattering coefficient at 1600 nm and the corresponding Mie-slope “b”. 
Due to the substantial spread of scattering parameters, both scattering parameters 
were not significantly different between macrovesicular, microvesicular, and 
hepatocellular ballooning, indicating that it was not possible to differentiate 
between the three types of hepatic fat based on this limited data set.  
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A B
Figure 5: Examples of spectra measured with the DRS in different types of hepatic fat infiltration and various 
degrees of steatosis. Panel A: The dashed lines correspond to the wavelength section (around 1200 nm) for which the 
spectra are altered by the presence of lipid. Panel B: Examples of spectra of normal hepatic mouse tissue and fatty mice 
livers with an increasing severity of macrovesicular steatosis. A more prominent inverse peak in the light spectrum in 
the vicinity of 1200 nm is related to a higher fat concentration in the measured tissue. A.u. represents arbitrary units.
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Figure 6: Boxplots of the reduced scattering coefficient at 1600 nm and the corresponding Mie-slope 
“b” for micro- and macrovesicular steatosis, and hepatocellular ballooning. Panel A: Boxplots of the 
reduced scattering coefficient at 1600 nm. Panel B: Boxplots representing the Mie-slope “b”. For both 
scattering parameters, no significant differences were found between micro- and macrovesicular steatosis, 
and hepatocellular ballooning.
5
Figure 7 and 8 shows the correlation coefficients between the pathological 
evaluation of macrovesicular and microvesicular steatosis and DRS analysis. 
Because the mouse models differ in patterns of steatosis (macrovesicular versus 
microvesicular), we were able to calculate the Spearman’s rank correlation 
coefficients between the two different patterns of steatosis and the total fat 
fraction analyzed by the DRS. For macrovesicular steatosis the Spearman’s rank 
correlation coefficient was 0.761 and for microvesicular steatosis 0.747. In addition, 
the overall sensitivity of DRS to identify macrovesicular and microvesicular 
steatosis was 100% (Table 1 and 2). Moreover, the positive predictive value was 
80% for macrovesicular steatosis and 72% for microvesicular steatosis. Therefore, 
a high level of agreement was observed between pathological evaluation and DRS 
analysis in assessment of the hepatic fat content. On the other hand, the specificity 
of DRS to exclude macro- and microvesicular steatosis was 48% for macrovesicular 
and 29% for microvesicular steatosis, respectively (Table 1 and 2). However, it 
should be noticed that in the majority of false positive cases (95%), hepatocellular 
ballooning was observed in histological analysis. Therefore, the DRS was still 
measuring fat, despite no macrovesicular or microvesicular steatosis was observed 
in these cases. 
As separate analysis, we assessed in the CS-AA and CD-AA diet group whether 
the DRS is able to differentiate between mild macrovesicular steatosis and either 
moderate/severe macrovesicular steatosis (Figure 7 and Table 3). Therefore, we 
changed the cut-off values for sensitivity and specificity calculations to 30% of 
macrovesicular steatosis measured by pathological analysis and to 30% of hepatic 
fat fraction assessed by the DRS. Interestingly, above 30% of macrovesicular 
steatosis, the DRS predicts hepatic fat fraction with a sensitivity of 86% and 
specificity of 81%.  
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Figure 7: Comparison of pathological evaluation of macrovesicular steatosis and DRS analysis. 
Comparison between pathological assessment and DRS analyses provides a Spearman’s rank correlation 
coefficient of 0.761. The solid line represents the linear regression line (r2) between pathological evaluation 
and DRS analysis. The dashed lines illustrate the quadrants for the sensitivity and specificity calculations 
above 30% of macrovesicular steatosis between pathological evaluation and DRS analysis.
Figure 8: Comparison of pathological analyses of microvesicular steatosis and DRS analysis. Comparison 
between pathological assessment and DRS analyses provides a Spearman’s rank correlation of 0.747. The 
solid line represents the linear regression line (r2) between pathological evaluation and DRS analysis.
5
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Table 1. Accuracy Calculations of DRS Analysis with respect to Macrovesicular Steatosis in the CD-AA and CS-AA Diet Groups.
  Result pathology positive for 
macrovesicular steatosis
Result pathology negative for 
macrovesicular steatosis
Positive result DRS analyses 57 14 71




Positive predictive value 80%
Negative predictive value 100%
The DRS analyses are positive for steatosis when the determined fat fraction value is larger than 5%.
   
Abbreviations used: DRS, diffuse reflectance spectroscopy. 
Table 2. Accuracy Calculations of DRS Analysis with respect to Microvesicular Steatosis in the Ob/ob and Control Mice.
  Result pathology positive for 
microvesicular steatosis
Result pathology negative for 
microvesicular steatosis
Positive result DRS analyses 13 5 18




Positive predictive value 72%
Negative predictive value 100%
The DRS analyses are positive for steatosis when the determined fat fraction value is larger than 5%.
Abbreviations used: DRS, diffuse reflectance spectroscopy. 
Table 3. Accuracy Calculations of DRS Analysis in the CD-AA and CS-AA Diet Groups when Cut-off Values are Changed to 30% of 
Macrovesicular Steatosis Measured by Pathological Evaluation and 30% of Hepatic Fat Fraction Assessed by the DRS.  
  Result pathology positive for 
moderate/severe macrovesicular 
steatosis
Result pathology negative for 
moderate/severe macrovesicular 
steatosis
Positive result DRS analyses 36 8 44




Positive predictive value 82%
Negative predictive value 85%
The DRS analyses are positive for steatosis when the determined fat fraction value is larger than 5%.
Abbreviations used: DRS, diffuse reflectance spectroscopy. 
5




This study demonstrates that DRS quantifies steatosis with high accuracy in two 
mouse models of hepatic steatosis. Using the DRS for assessment of the total 
hepatic fat content showed a good correlation with histological evaluation of the 
total hepatic fat content. In addition, the DRS is able to discriminate between mild 
and moderate/severe macrovesicular steatosis with a high sensitivity (86%) and 
specificity (81%). Although DRS can qualify steatosis in liver tissue, the DRS was 
not able to discriminate between micro- and macrovesicular steatosis.  
During the clinical donation procedure, it is necessary to distinguish between 
mild (0-30%) and moderate/severe macrovesicular (> 30%) graft steatosis. As 
already described, transplantation of moderate/severe macrovesicular steatotic 
donor livers is related to poor postoperative outcome, while transplantation 
with mild macrovesicular steatotic livers is not associated with inferior outcome 
(2-4). Our study showed that DRS is able to differentiate between isolated mild 
macrovesicular steatosis and moderate and/or severe macrovesicular steatosis 
with high sensitivity and specificity. So far, there are no tools for accurate steatosis 
measurements available that can be performed in real-time (4). In comparison to 
the currently best measuring methods for steatosis; computer tomography (CT), 
magnetic resonance imaging (MRI), and magnetic resonance spectroscopy (MRS) 
(21-24), DRS analysis is easier and less time-consuming, which is beneficial in 
the short time period of donation. Moreover, it is known that surgeon’s accuracy 
in predicting steatosis is low, especially when macrovesicular steatosis is above 
30% (25,26). As a consequence, DRS has the potential to assist the surgical team 
with estimating the hepatic fat content during the transplantation procedure. 
Therefore, further research should be focused on development of the DRS system 
in a hand-held optical instrument. 
In the current study, DRS analysis was not able to differentiate between micro- and 
macrovesicular steatosis, and hepatocellular ballooning. Although we hypothesized 
that the DRS could discriminate between the three types of hepatic fat, we did 
not find significant differences in the scattering parameters between the three 
groups. Therefore, the inability to distinguish between hepatic fat content may 
have consequences when the DRS is applied in clinical situations. First, micro- and 
macrovesicular steatosis are occasionally simultaneously present in donor livers 
(26,27). However, in most cases where micro- and macrovesicular steatosis are 
simultaneously present, the amount of microvesicular steatosis is quite minimal 
compared to the amount of macrovesicular steatosis (26,27). We expect therefore 
that the overestimation of the degree of hepatic fat infiltration will be negligible 
when livers with micro- and macrovesicular steatosis are measured with the 
DRS. Secondly, it could also happen that only microvesicular steatosis is present 
in donor livers. Hence, there is a risk for a false positive result when a liver with 
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only microvesicular steatosis is measured with the DRS. However, the presence of 
only microvesicular steatosis is uncommon in potential donor livers (26,27). Solely 
microvesicular steatosis is frequently observed in subtypes of acute liver failure 
such as the syndrome of Reye and acute fatty liver of pregnancy, due to toxin- or 
drug-induced impairment of the mitochondrial β-oxidation (28). Consequently, 
it is unlikely livers with only microvesicular steatosis would be considered for 
transplantation and consequently would be measured with the DRS.  
Another aspect of hepatic fat infiltration is hepatocellular ballooning. In 
our experiment some mice livers displayed severe degrees of hepatocellular 
ballooning. Hepatocellular ballooning is an important histological feature of 
nonalcoholic steatohepatitis (NASH) (16). Patients with NASH show in most cases 
elevated serum levels of transaminases and/or alkaline phosphatase (29). These 
elevated levels of transaminases and/or alkaline phosphatase will be noted when 
the potential donor is screened at the intensive care. Moreover, NASH is related 
to the development of fibrosis. Fibrotic livers are mostly enlarged and stiff. These 
characteristics will be observed during assessment of the liver during the donation 
procedure. Therefore, it is likely that livers of most of these donors with NASH 
are declined early in the donation procedure. As a result, the risk that livers with 
severe hepatocellular ballooning are measured with the DRS will be minimal.    
A limitation of the current study is that we have used mouse livers instead of human 
donor livers. However, with respect to C57BL6 mice on a choline-deficient diet, 
it has been shown that these mice are representative for human features of fatty 
liver disease, in particular for macro- and microvesicular steatosis (30). Another 
limitation regarding the DRS is its invasiveness. However, in our earlier clinical 
study where we have performed in 17 patients’ 49 in vivo DRS measurements, no 
bleeding complications were observed (10). In addition, the diameter of the optical 
DRS needle is smaller (0.8 mm) compared to a general biopsy needle used for liver 
biopsies during surgery (1.6 mm). Therefore, we expect that the bleeding risk in 
liver tissue after DRS measurements will be negligible.
In conclusion, the current study demonstrates that DRS can quantify steatosis with 
good agreement compared to histopathological analysis. In particular, its feature 
to differentiate accurately and real-time between isolated mild and moderate/
severe macrovesicular steatosis may have clinical relevance. Consequently, 
further research should be focused on the development of the DRS in a hand-held 
device. The DRS system in a hand-held device can assists the surgical team in a 
more accurate assessment of the hepatic fat content during organ procurement 
procedures. 
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Abstract
Background: The use of extended criteria donor (ECD) grafts may reduce waiting 
list mortality in orthotopic liver transplantation (OLT). ECD livers, however, are 
associated with increased risk of graft failure and recipient morbidity. Aim of this 
study was to determine whether ECD liver grafts are associated with increased 
blood loss and transfusion requirements after graft reperfusion. 
Methods: A consecutive series of 318 primary adult liver transplant recipients 
was analyzed. Recipient, donor, and intraoperative transfusion requirements 
were available in a prospectively collected database. Donor risk index (DRI) 
was calculated retrospectively. An ECD graft was defined as DRI ≥ 1.7. Graft and 
patient survival were calculated according to the Kaplan-Meier method. Uni- and 
multivariate analyses were performed to determine risk factors for postreperfusion 
red blood cell (RBC) transfusion.
Results: ECD livers were used in 36% of recipients. Graft survival rate at 1 and 
5 years was 83% and 71%, respectively. Patient survival rate at 1 and 5 years was 
88% and 80%, respectively. Completely blood transfusion-free transplants were 
performed in 27% of patients. After uni- and multivariate analysis the following 
variables were found to be independently associated with postreperfusion RBC 
transfusion requirements: DRI ≥ 1.7, female recipient, recipient age, and no 
aprotinin administration. 
Conclusion: The use of ECD grafts, defined as a DRI ≥ 1.7, is associated with 
significantly increased intraoperative RBC transfusion requirements after graft 
reperfusion. This information can help surgeons and anesthesiologist to be 
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Introduction
Orthotopic liver transplantation (OLT) is a successful treatment for patients with 
end-stage liver failure caused by acute liver failure, chronic liver diseases or 
several metabolic disorders (1-3). Although more OLTs were performed in the last 
decade, the imbalance between available donor livers and candidates for OLT is 
still growing with an increased mortality rate on the waiting list as consequence 
(4). Expanding the donor pool by accepting extended criteria donor (ECD) grafts is 
a way to reduce waitlist mortality (5,6). Several studies have shown that selective 
use of ECD livers can result in acceptable survival rates after transplantation 
(5-9). Nevertheless, ECD livers are clearly associated with higher postoperative 
morbidity such as higher incidence of primary non-function (PNF) and initial 
poor function (IPF) (10-13). One study describes a cumulative effect of ECD criteria 
on the severity of preservation and ischemia/reperfusion (I/R) injury after liver 
transplantation (14). Furthermore, I/R injury may lead to an increased release of 
fibrinolytic proteins from the donor liver, potentially causing bleeding problems 
after graft reperfusion (15,16). We hypothesized that ECD liver grafts in general are 
associated with increased intraoperative bleeding complications after reperfusion 
of the graft. The aim of the current study was to determine the impact of ECD 
criteria of liver grafts on intraoperative blood transfusion requirements during 
OLT, especially after graft reperfusion.
Methods
Study Population
Between the first of January 2000, and the 31st of December 2010, 572 patients 
underwent an OLT at the University Medical Center of Groningen. After excluding 
pediatric recipients (age < 18 yr; n = 171), retransplantations (n = 79), and combined 
organ transplantations (n = 8), 318 adult patients undergoing a first transplant 
were identified and these patients were included in the current study. Follow-
up was complete until the 31st of December 2011. Characteristics of the patients, 
including donor and recipient variables, as well data on blood loss and transfusion 
requirements in the three separate stages of the OLT procedure (pre-anhepatic, 
anhepatic and postreperfusion) were obtained from a prospectively maintained 
computer database. When necessary, the original patient notes were reviewed for 
missing information. The maximum percentage of missing data per variable was 
9.7%. Medical ethical committee approval to perform this retrospective study was 
waived. All data were analyzed anonymously; no written informed consent was 
necessary for this type of research. 
89
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Surgical Technique and Anesthetic Management
Surgical techniques, anesthetic management and blood transfusion policy in our 
center were extensively described previously (17). Before 2007, aprotinin was 
administered in all patients, except patients with known thrombophilia, who 
showed hypercoagulability on thromboelastography at induction of anesthesia. 
Obviously, when aprotinin was taken of the market in 2007 we stopped using this 
antifibrinolytic drug. As has been described previously, the transfusion policy in 
our center is characterized by a restrictive use of blood products, maintaining 
hematocrit levels between 0.25 and 0.30 (2,17,18).
Data Collected for Statistical Analysis
ECD variables determined to be meaningful predictors of blood loss and transfusion 
requirements in the postreperfusion stage (stage 3) were selected after review of 
the literature and clinical experience. The following ECD variables were included: 
moderate graft macrovesicular steatosis (30-60%), type of donor (donation after 
brain death [DBD] versus donation after circulatory death [DCD]), cause of donor 
brain death (trauma versus cerebrovascular accident and other), graft type (full 
size versus partial grafts), donor intensive care unit (ICU) stay ≥ 7 days, donor 
age ≥ 60 years, and body mass index (BMI ≥ 28). The DRI (donor risk index) was 
calculated according to Feng et al. with minor adjustments (we considered all 
donors Caucasian and local) (19). To identify an ECD graft, we used a DRI cut-off 
point of 1.7, as was done in a recent study by Maluf et al. (20). In addition, the 
following recipient and procedure related variables were included in the analyses: 
age, gender, BMI, surgical technique (conventional versus piggyback), use of 
aprotinin, cold ischemia time (CIT) ≥ 10 hours, warm ischemia time (WIT) ≥ 40 
minutes, and type of preservation fluid (HTK versus UW). The MELD score was 
based on laboratory tests alone, disregarding extra points for standard or non-
standard exceptions. With respect to intraoperative transfusion requirements, the 
following variables were analyzed in the three separate stages of the operation; the 
number of units of allogeneic red blood cells (RBC; 1 U contained approximately 
250 mL), units of fresh frozen plasma (FFP; 1 U contained approximately 300 mL), 
and units of platelets concentrates (PLT; 1 U contained approximately 150 mL and 
was obtained from five donors). In addition to this, we analyzed the differences 
between transfusion in stages 1&2 versus stage 3 (postreperfusion stage).
Selection of Statistical Models
Aim of this study was to analyze the effect of ECD variables on postreperfusion 
RBC transfusion. Therefore, patients were stratified according to a relatively high 
RBC transfusion rate in the postreperfusion stage, compared to the prereperfusion 
stages, representing patients who were relatively stable until implantation of the 
graft. We decided to compare the group of patients who required at least twice the 
amount of RBC transfused in the postreperfusion stage (stage 3) compared to the 
prereperfusion stages (stage 1&2), with a minimal amount of 1 RBC unit in stage 
3 to the patients that did not fulfil these criteria. The reason to choose a double 
90
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amount instead of the same amount is to compensate for blood loss in stage 1&2 
that is corrected with RBC transfusion in stage 3. 
Secondary endpoints were impact of ECD variables, reflected by a DRI ≥ 1.7, on 
the incidence of primary non-function (PNF), initial poor function (IPF), and the 
need for relaparotomy. Graft and patient survival were assessed at 1 and 5 years 
after transplantation. Graft survival was defined as the time interval between 
transplantation and patient death or retransplantation. Patient survival was 
defined as the time interval between transplantation and patient death. PNF was 
defined as non-life-sustaining function of the liver, requiring a retransplantation 
or leading to death within 7 days after OLT. IPF was defined as serum AST > 2000 
U/L on any day between postoperative day 2–7 and a prothrombin time (PT) > 16 
seconds.
Statistical Analysis
To examine the impact of ECD variables on intraoperative blood loss after graft 
reperfusion (stage 3), transfusion requirements were correlated with donor, 
recipient, and procedure related factors using uni- and multivariate analysis. 
Missing data were treated according to list wise deletion approach. Continuous 
variables were expressed as median and interquartile range (IQR). Categorical 
variables were expressed as number and percentage. Comparisons of categorical 
variables between the two study groups were performed with the use of Fisher’s 
exact test or Pearson chi-square test. For comparison of continuous variables we 
used the Mann-Whitney U test. All statistical tests were performed two-tailed. 
All variables tested in the univariate analysis with a p-value < 0.10 were included 
in a multivariate logistic regression analysis. A two-sided p-value < 0.05 was 
considered to indicate statistical significance. Patient and graft survival rates 
were analyzed according to the Kaplan-Meier method. Statistical analyses were 




More than half of the recipients were male (58%), the median age was 53 years 
(Table 1). Median postoperative follow up was 6.3 years (range 3 months – 12 years). 
Patients who received a liver graft with a DRI ≥ 1.7 compared to DRI < 1.7, were 
older (55 versus 51, p-value 0.005), and were more often female (50% versus 36%, 
p-value 0.044) (Table 1). Four patients died during the transplantation procedure. 
PNF was seen in 14 patients (4%), of whom 11 patients were retransplanted within 
one week, and 3 patients died before retransplantation. The incidence of IPF was 
9.4% and a relaparotomy during the admission for OLT was necessary in 82 (26%) 
patients. There was no significant difference in the incidence of PNF, IPF and 
relaparotomy (Table 1). Patient survival rates at 1- and 5-year were 88% and 80%, 
respectively. One- and 5-year graft survival rates were 83% and 71%, respectively. 
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Table 1. Recipient, Surgical, and Donor Variables







Age (years) 53 (43-58) 51 (40-58) 55 (46-59) 0.005
BMI (kg/m2) 25 (23-28) 25 (22-27) 25 (23-28) 0.88
MELD score (lab-MELD) 15 (10-23) 15 (10-23) 14 (9-22) 0.33
Serum creatinine before OLT (μmol/L) a 89 (73-127) 87 (73-131) 91 (71-127) 0.99
Serum total bilirubin before OLT (μmol/L) b 51 (26-117) 52 (29-132) 46 (24-107) 0.27
INR before OLT 1.3 (1.2-1.7) 1.3 (1.2-1.7) 1.3 (1.2-1.7) 0.77















































Donor variables (n = 318)
Age (years) 49 (40-57) 44 (34-53) 60 (48-64) <0.001
BMI (kg/m2) 25 (22-26) 24 (22-26) 25 (23-26) 0.14
Length of stay at the intensive care unit (days) 1 (1-3) 1 (1-4) 1 (1-2) 0.46


















































23 (7%)     
175 (55%)
101 (32%)




























WIT (min)e 46 (40-53) 46 (40-54) 45 (39-50) 0.10
Estimated blood loss (L) stage 1&2 1.4 (0.7-3.0) 1.3 (0.6-3.0) 1.4 (0.7-2.9) 0.94
Estimated blood loss (L) stage 3 1.1 (0.6-2.5) 1.0 (0.6-2.2) 1.5 (0.6-3.0) 0.06
Estimated total blood loss (L) 3.0 (1.7-6.0) 2.5 (1.5-5.4) 3.1 (2.0-6.5) 0.06
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Table 1. Recipient, Surgical, and Donor Variables

















RBC transfusion stage 1&2 (U) 0 (0-4.0) 0 (0-4.0) 0 (0-4.0) 0.70
RBC transfusion stage 3 (U) 0 (0-3.0) 1.0 (0-7.0) 2.0 (0-4.0) 0.001
Total RBC transfusion (U) 3.0(0-8.0) 3.0 (0-7.0) 3 (0-9.0) 0.035
FFP transfusion stage 1&2 (U) 0 (0-2.0) 0 (0-2.0) 0 (0-2.0) 0.50
FFP transfusion stage 3 (U) 0 (0-2.0) 0 (0-1.0) 0 (0-3.2) 0.011
Total FFP transfusion (U) 0 (0-4.6) 0 (0-0) 0 (0-0) 0.14
PLT transfusion stage 1&2 (U) 0 (0-0) 0 (0-0) 0 (0-0) 0.64
PLT transfusion stage 3 (U) 0 (0-0) 0 (0-0) 0 (0-0) 0.11




















































Data represent median with interquartile ranges (IQR) for continuous variables or numbers (percentages) for categorical variables.
Abbreviations used: BMI: body mass index, OLT: orthotopic liver transplantation, MELD: model of end-stage liver disease, INR: international 
normalized ratio, HTK: histidine-tryptophane-ketoglutarate, UW: University of Wisconsin, DCD: donation after circulatory death, DBD: donation 
after brain death, RBC: red blood cells, FFP: fresh frozen plasma, PLT: platelets, PNF: primary non-function, IPF: initial poor function, L: liters, 
U: units.
a) Normal < 110 μmol/L, to convert the value for creatinine to mg/dL, divide by 88.4.
b) Normal 0-17 μmol/L, to convert the value for bilirubin to mg/dL, divide by 17.1.
c) Donor Risk Index according to Feng et al. (Am J Transpl 2006; 6: 783). Because no data was available on region and race, all donors were 
considered as local and Caucasian.
d) Time from in situ flushing of the donor organ until the liver is removed from ice for implantation.
e) Time from removal of liver from ice until reperfusion via portal vein, hepatic artery or both.
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Table 2. Univariate Analysis for Relatively High Postreperfusion RBC Transfusion




Continue Variables  
Donor
DRI 0.029 1.5 (1.3-1.8) 1.7 (1.4-2.0)
Age (yrs) 0.19 48 (39-57) 48 (41-60)
ICU LOS (days) 0.40 1.0 (1.0-3.5) 1.0 (1.0-3.0)
BMI 0.83 24.2 (22.5-26.2) 24.2 (22.1-26.3)
Length (cm) 0.84 175 (168-180) 175 (168-180)
Weight (kg) 0.85 75 (65-85) 75 (65-85)
Recipient
CIT (hrs) 0.94 7:44 (6:53-9:17) 7:46 (6:44-9:34)
WIT (hrs) 0.60 45 (39-54) 47 (40-50)
Age (yrs) 0.10 52 (41-58) 54 (46-60)
BMI 0.40 24.8 (22.4-27.7) 25.8 (22.8-27.5)
Length (cm) 0.06 176 (168-182) 172 (166-188)
Weight (kg) 0.66 77 (67-85) 75 (65-86)









Age  < 60 yrs 
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ICU LOS < 7 days 






























CIT < 10 hrs





WIT < 40 min





Age  < 60 yrs

















Aprotinine   No





Piggyback   No
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Donor Characteristics
Median donor age was 49 years (Table 1). Of all grafts, 36% had a DRI ≥ 1.7. In 4 
patients the DRI could not be calculated because of missing variables (1.3%). DCD 
(donation after circulatory death) grafts were used in 17% of patients. Moderate 
macrovesicular steatosis (30-60%) was present in 19 (6%) grafts. Reduced size or 
split grafts were used in 17 (5%) patients. In the group with a DRI ≥ 1.7 more often 
HTK was used (32% versus 16%, p-value < 0.001), which is probably explained by 
the fact that in the early years HTK was used in DCD grafts.
Blood Loss and Transfusion of Blood Products
Median blood loss in pre and postreperfusion was 1.4 and 1.1 L respectively (Table 
1). The median postreperfusion blood loss did not differ significantly when we 
compared the group with a DRI < 1.7 with the group ≥ 1.7, but in patients with a 
DRI ≥ 1.7 significantly more patients had blood loss over 1.5 L postreperfusion 
(50% versus 36 of patients, p-value 0.019, Table 1). In 95 (30%) of all transplant 
procedures there was no need for RBC transfusion. In 86 (27%) of all transplants 
there was no need for any blood product transfusion (red blood cell (RBC), fresh 
frozen plasma (FFP), or platelets (PLT). In our model, 29% of patients required at 
least twice the amount of RBCs in stage 3 (post-reperfusion) compared to stages 
1&2 combined, or in case of no RBC requirements in stages 1&2 had at least 1 unit 
of RBC in stage 3 (Table 2).
Uni- and Multivariate Analysis of Variables Associated with RBC Transfusion
Variables associated with an increased requirement of RBC transfusion after graft 
reperfusion are summarized in Table 2. In our model (outcome parameter defined 
as RBC in stage 3 = at least 2 x RBC stage 1&2, minimal 1 RBC unit in stage 3) the 
following variables were associated with increased RBC transfusion requirements: 
DRI, graft type, age recipient ≥ 60 years, female recipient, and no aprotinin use. 
Variables with a p-value < 0.10 were entered into a multivariate logistic regression 
model. Multivariate analysis for increased RBC transfusion requirements in the 
postreperfusion stage (stage 3) revealed the following independent variables: DRI, 




Data represent median with interquartile ranges (IQR) for continuous variables or numbers (percentages) for categorical variables.
Abbreviations used: DRI: donor risk index, ICU LOS: intensive care unit length of stay, BMI: body mass index, CIT: cold ischemia time, WIT: warm 
ischemia time, MELD: model of end-stage liver disease, COD: cause of death, DBD: donation after brain death, DCD: donation after circulatory 
death, HTK: histidine-tryptophane-ketoglutarate, UW: University of Wisconsin, RBC: red blood cells.  
1 High RBC transfusion in the postreperfusion stage was defined as higher RBC in stage 3 = at least 2 x RBC stage 1&2, minimal 1 RBC unit in 
stage 3.
Table 3. Multivariate Analyses for Relatively High Postreperfusion RBC Transfusion in Liver Transplantation
Variable Odds Ratio 95% CI p-value
DRI (≥ 1.7) 1.777 1.048-3.013 0.033
Recipient age ≥ 60 years 1.852 1.001-3.425 0.049
Recipient gender (F) 1.846 1.095-3.114 0.022
No aprotinin used 1.845 1.055-3.230 0.032
Outcome parameter is increased RBC requirement in stage 3, defined as at least 2 x RBC stage 1&2, minimal 1 RBC unit in stage 3.
Abbreviations used: DRI: donor risk index, CI: confidence interval, F: female.
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Discussion
In an era of increasing organ shortage, accepting ECD grafts seems a necessary 
way to reduce waiting list mortality in liver transplantation. In general, ECD grafts 
are considered to be organs with a greater risk of initial poor function or non-
function and therefore they are associated with an increased risk of postoperative 
recipient morbidity and mortality (21,22). The results of this study indicate that 
the quality of the donor liver as reflected by the DRI has also an impact on RBC 
transfusion requirements after graft reperfusion. 
The effect of graft quality on posttransplant outcome has been analyzed extensively 
(10-13,20,23-25). So far, not much emphasis has been put on the intraoperative 
effects of the use of ECD grafts. In one study the short and long term outcomes 
after transplantation of steatotic liver grafts was studied (26). Investigators of 
this study found that the intraoperative RBC and FFP transfusion requirements 
were significantly higher after transplantation of liver grafts with > 35% steatosis 
(n = 22), compared to grafts with < 5% steatosis (n = 222). They also concluded 
that recipients of steatotic grafts required increased resource use, including 
increased length of stay in the ICU and overall length of stay. In our study, we did 
not find a relation between the grading of steatosis and intraoperative transfusion 
requirements. This may be explained by the relative low number of grafts with 
moderate (30-60%) macrovesicular steatosis (only 6 % of our cohort). 
It is evident that donor factors have no influence on blood loss and transfusion 
requirements during the recipient hepatectomy phase. Previous studies have 
shown that various recipient factors are associated with intraoperative blood loss 
and transfusion requirements in liver transplantation (27,28). Apparently, when 
considering the procedure as whole, recipient factors overshadow the influence of 
donor factors on transfusion requirements. Probably a difficult hepatectomy with 
major blood loss due to portal hypertension will affect blood loss and transfusion 
requirements during the postreperfusion stage. But the other way around, after 
an uncomplicated, bloodless hepatectomy, we hypothesized that quality of the 
liver graft is a risk factor for postreperfusion blood loss and thus transfusion 
requirements. To detect the group of patients that were relatively stable until 
implantation of the graft, but suffered from increased blood loss after graft 
reperfusion, we selected the patients who had a relatively high RBC transfusion 
rate in the postreperfusion stage, compared to the prereperfusion stages. To this 
end we used a model with doubling of the RBC requirements in postreperfusion 
stage, compared to prereperfusion stages. This model showed that, in addition to 
recipient factors and the use of aprotinin, the DRI was independently associated 
with the need for RBC transfusions in the postreperfusion stage.
There is no clear definition of the features of an ECD liver, but in general high donor 
age, high grade of steatosis, DCD grafts, partial grafts, or cerebrovascular cause of 
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death are considered as ECD criteria (22,29). Donor risk scores, such as the DRI, 
have been developed to quantify the risk associated with donor variables (23). To 
identify an ECD graft, we used the same DRI cut-off point of 1.7, as was done in a 
recent study by Maluf et al. (20). Since we considered all donors in this study of 
the Caucasian race and local, our calculated DRI may have been underestimated in 
some cases. 
Potential mechanisms for increased blood loss after graft reperfusion may be 
related to a higher degree of (I/R) injury in ECD grafts. Briceno et al. stated that 
poorer condition of the donor, irrespective of the variable, seemed to be directly 
associated with poorer graft function (14). A poor graft function may lead to a 
disturbed hemostatic balance and potentially lead to bleeding problems (30). 
Briceno et al. correlated accumulation of ECD factors with I/R injury. Risk factors 
for severe I/R injury were moderate to severe fatty infiltration, prolonged ICU 
hospitalisation, CIT, high dosage of inotropic drugs in the donor, and older donors 
(14). 
In addition, I/R injury is associated with endothelial cell damage caused by 
high release of toxic reactive oxygen species generated upon reintroduction 
of O2 to ischemic tissues (31). A key characteristic of I/R injury is the release of 
proteolytic enzymes, including phagocyte proteases and endothelial cell derived 
thrombomodulin leading to coagulopathy and hyperfibrinolysis (32,33). Two other 
studies suggest that increased I/R injury is accompanied by an increased release of 
fibrinolytic proteins (i.e. tissue-type plasminogen activator) from the donor graft, 
which may contribute to excessive blood loss in the last phase of the operation 
(15,16). In the current study, however, we identified DRI and no administration 
of the antifibrinolytic drug aprotinin as variables that were both independently 
associated with increased blood loss after reperfusion. This finding indicates that 
excessive blood loss after reperfusion cannot simply be ascribed to the release of 
tissue-type plasminogen activator alone. Other mechanism must play a role as 
well. Nevertheless, focus of further research should lie in organ optimisation and 
reduction of preservation and I/R injury. 
This study has some limitations. Due to its retrospective design, it is possible that 
we were not able to address all the risk factors for blood loss or transfusion, for 
instance the presence of portal hypertension or previous abdominal surgery in 
this cohort of patients, but we think we have eliminated this factors as much as 
possible by using a model that focuses on excessive postreperfusion blood loss, 
compared to blood loss during hepatectomy. 
In conclusion, the use of liver grafts with a DRI ≥ 1.7 is associated with significantly 
increased intraoperative RBC transfusion requirements after graft perfusion. 
This information can help surgeons and anesthesiologist to be more prepared 
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Abstract
Purpose of Review: The incidence, pathogenesis and management of the most 
common biliary complications are summarized with an emphasis on non-
anastomotic biliary strictures (NAS) and potential strategies to prevent NAS after 
orthotopic liver transplantation (OLT).
Recent findings: NAS have variable presentations in time and localization, 
suggesting various underlying pathogeneses. Early-onset NAS (presentation 
within 1 year) has shown to be largely related to ischemia-induced injury, whereas 
late-onset NAS (> 1 year after OLT) has more immune-mediated causes. Cytotoxic 
hydrophobic bile salts and impaired biliary bicarbonate (HCO3-) secretion may 
also play a role in the occurrence of NAS. Recently, insufficient biliary epithelial 
regeneration capacity after transplantation has also been suggested to be 
important in the pathogenesis of NAS. A potential strategy to prevent NAS can 
come from machine perfusion instead of classical static cold storage (SCS). While 
machine perfusion has been shown to be a better preservation method for the liver 
parenchyma, efficacy in preventing ischemic injury of the biliary epithelium is 
largely unknown.
Summary: The potential advantages of machine perfusion are very promising 
as it may provide better protection of the vulnerable bile ducts against ischemia/
reperfusion injury. Clinical trials will be needed to demonstrate the impact of 
machine perfusion in reducing the incidence of biliary complications, especially 
NAS, after OLT. 
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Introduction
Despite an increase in the number of donor livers obtained from donation after 
circulatory death (DCD) in some European countries and the US in recent years, 
donation after brain death (DBD) remains to be the major source of organs for 
orthotopic liver transplantation (OLT) in most western countries. In general, patient 
and graft survival rates after DBD liver transplantation are higher compared to DCD 
liver transplantation, mainly because of an increased rate of biliary complications 
after DCD liver transplantation (1,2). However, biliary complications are also the 
most frequent and troublesome complication after DBD OLTs.
Biliary complications occur in 10-40% of the patients after OLT and have 
an important impact on graft survival, hospital readmissions, the need for 
reinterventions and the overall costs of care (3-5). Among the variety of 
biliary complications occurring after OLT, bile leakage and bile duct strictures 
(anastomotic and non-anastomotic) are the most common. Relative minor (and 
infrequent) biliary complications, such as sphincter of Oddi dysfunction, external 
compression by peribiliary cysts, neuroma or lymphoma’s, have also been reported 
(6,7). An overview of the various types of biliary complications, their incidence 
and management is provided in Table 1. 
7
Abbreviations used: PTC: percutaneous transhepatic cholangiography.
Table 1. Biliary Complications after Liver Transplantation
Complication Incidence Management
Bile duct strictures
- Anastomotic   
  
- Non-anastomotic  
  
     9-12% 
1-30%
- Endoscopic/Percutaneous dilatation or stenting
- Roux-en-Y hepatico-jejunostomy 
- Endoscopic dilatation/stenting
- PTC drainage/ dilatation
- Surgical resection of extrahepatic bile duct + Roux-en-Y hepatico-jejunostomy 
Bile Leakage 2-21% - Conservative therapy
- PTC drainage
- Endoscopic stenting/sphincterotomy 
- Nasobiliary drainage
- Hepatico-jejunostomy
Bacterial cholangitis 10% - Antibiotic therapy
- Treat strictures if present
Common bile duct filling defects
- Stones/Casts/Sludge
6% - Endoscopic removal
Sphincter of Oddi dysfunction 0-7% - Endoscopic sphincterotomy/stenting
External compression of biliary tract






- Surgical excision of cystic duct remnant
- Treat underlying lymphoma + endoscopic stenting
- Amputation neuroma
Kinking of redundant bile duct Rare - Surgical resection and re-anastomosing
- Endoscopic stenting
- Roux-en-Y hepatico-jejunostomy 
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In this review the most common biliary complications will be discussed with an 
emphasis on the pathogenesis of non-anastomotic biliary strictures (NAS) and 
on the potential preventive role of oxygenated machine perfusion, as a potential 
strategy to reduce the incidence of NAS after OLT. In this review we have used the 
term NAS for biliary strictures that can be found in the intra- or extrahepatic bile 
ducts of the donor liver in the presence of a patent (open) hepatic artery. The terms 
ischemic-type biliary lesions (ITBL) and ischemic cholangiopathy are also used in 
the literature for this type of injury. 
Bile leakage
Bile leakage has been reported in 2-21% of the patients after OLT. It can be 
categorized as early and late events and may be anastomotic or non-anastomotic 
in site, i.e. occurring at the T-tube tract exit site or the cut surface of the graft 
in case of living donor or partial liver graft transplantation (5,6). Bile leakage can 
later result in biloma due to extravasation of bile into the hepatic parenchyma or 
the abdominal cavity. Depending on the size of the leakage and the patient being 
asymptomatic or symptomatic, bile leaks can be managed conservatively, non-
surgically or surgically (8,9). 
Bile duct strictures (anastomotic and non-anastomotic)
Bile duct strictures can be categorized into anastomotic strictures (AS) and non-
anastomotic strictures (NAS). A combined presentation of both AS and NAS is not 
uncommon. Solitary strictures at the site of biliary anastomosis have been reported 
in 9-12% of patients after OLT (4,10,11), with the majority occurring within the first 
12 months after OLT (4,5,10,11). Major predictive risk factors for development of 
AS include donor age, prior anastomotic bile leak, duct to duct anastomosis, and 
sex mismatch with a female donor/male recipient (4,5). Local ischemia caused by 
surgical techniques is believed to be the main underlying mechanism, leading to 
fibrotic scarring of anastomosis. To minimize the risk of local ischemia at the end 
of donor choledochal duct, the bile duct should remain surrounded by sufficient 
amount of tissue (3). Uncomplicated anastomotic strictures can generally be 
successfully treated with endoscopic or percutaneous dilatation/stenting (12,13). 
Resection of the stenotic anastomosis and construction of a Roux-en-Y hepatico-
jejunostomy is indicated if non-surgical treatment fails (4,14). Recurrent AS, 
which occurs in approximately 20% of the cases, can still be treated effectively 
with dilatation/stenting (15).
In contrast to anastomotic strictures, NAS may occur at any location of the biliary 
tree (extrahepatic as well as intrahepatic), but is usually limited to the large bile 
ducts in a multifocal pattern. The reported incidence of NAS in patients receiving a 
DBD liver graft varies between 1 and 20% (10,16,17). Non-surgical treatments for NAS 
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are endoscopic dilatation/stenting, percutaneous transhepatic cholangiography 
with  drainage and/or dilatation. In case of extrahepatic NAS, surgical resection of 
the diseased part and construction with a hepatico-jejunostomy can be successful 
(4,6). In up to 50% of the patients with NAS, retransplantation may be the only 
treatment option (4). Therefore, NAS is the most troublesome complication and 
is associated with high rates of morbidity, mortality and overall costs of care (18). 
In the current shortage of available donor livers for OLT, a better understanding 
of pathogenesis and better strategies to prevent NAS after transplantation are 
needed.
Variable presentations of NAS
Presentations of NAS vary extensively in anatomical localization and severity as 
well as in time of occurrence. Fifty percent of the cases of NAS present within 
the first year after OLT, constituting early-onset versus late-onset (> 1 year after 
OLT) NAS (19). Early-onset NAS have shown to mostly occur around the hepatic 
bifurcation and common bile duct. In contrast to early-onset NAS, late-onset NAS 
is more frequently identified in the periphery of the liver, affecting small bile ducts 
in a more diffuse pattern (19). It seems that early-onset and late-onset NAS not 
only develop at different anatomical locations but that they are also associated 
with different risk factors. Retrospective studies have suggested that early-onset 
NAS is prominently associated with ischemia related injury whereas late-onset 
NAS have been more frequently associated immunological factors (19,20). 
Variable pathogenesis of NAS
NAS is thought to have a multifactorial etiology, which can be grouped based on 
three relevant types of biliary injury; ischemia-related injury; immune-mediated 
injury; and cytotoxic injury caused by hydrophobic bile salts (3,21).  
Ischemia-Related Injury
Prolonged ischemia time (> 13 hours) during static cold storage has been identified 
as a main risk factor for the development of NAS (16,22). However, to reduce the 
detrimental impact of cold ischemia, the period of static cold storage has nowadays 
become shorter with an average of 8-10 hours (19). Oxygenation of biliary epithelial 
cells (cholangiocytes) is fully dependent on the hepatic artery, in contrast to the 
hepatocytes, which are oxygenated via both the hepatic artery and the portal 
vein. Hepatic artery thrombosis and stenosis may result in the development 
of massive bile duct necrosis after OLT (23). Moreover, injury of the peribiliary 
microvasculature has also been shown to have an important role in the occurrence 
of NAS after OLT (24). Thus, adequate flush out of the graft and the peribiliary 
vasculature with preservation fluid is crucial for effective preservation of the 
microvasculature and subsequently the bile duct. Some studies have suggested 
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that liver preservation with high-viscosity preservation fluids may lead to higher 
rates of biliary strictures, because of an insufficient flush out and preservation of 
the peribiliary microvasculature (25). However, it seems that perfusion with low-
viscosity preservation fluid such as HTK solution is also not sufficient enough for 
an effective perfusion of the peribiliary microvasculature (26). Additional arterial 
back-table pressure perfusion may therefore be necessary for ample perfusion of 
the peribiliary microvasculature (27).
Another well-known risk factor for development of NAS is warm ischemia during 
organ procurement, especially during the period between cardiac arrest and cold 
perfusion in case of a DCD procedure. The incidence of NAS after OLT of livers 
from DCD donors is as high as 30%, which is much higher than the incidence of 
NAS after DBD OLT (1-20%) (17,28,29). The method of graft reperfusion during 
implantation has also been shown to have an impact on the occurrence of NAS. 
Retrograde reperfusion via the inferior vena cava while constructing the portal 
vein anastomosis has been associated with an increased risk of developing 
NAS, probably because of the relative warm ischemia of the bile ducts during 
implantation (30). Some investigators have advocated arterial reperfusion instead 
of portal vein reperfusion or simultaneous reperfusion via the portal vein and 
hepatic artery instead of sequential reperfusion; however, there is no strong 
evidence supporting any of these strategies. Initial reperfusion via the portal vein 
is mostly preferred because of its technical simplicity (31). 
Immune-Mediated Injury
Many studies have suggested a role for immunological factors in development of 
NAS. For example, transplantation of ABO incompatible donor livers has shown 
to be associated with higher incidence of NAS (32). The reason for this immune-
mediated biliary injury is thought to be the result of the existence of blood 
type antigens on the biliary epithelium of the donor bile ducts. As a result, ABO 
antibodies target these biliary epithelium cells (32,33). Moreover, pre-existing 
autoimmune diseases such as primary sclerosing cholangitis (PSC) are associated 
with a higher incidence of NAS (34). In addition, it has also been reported that a 
loss-of-function mutation in the chemokine receptor CCR5 (CCR5-Δ32) is related 
to the development of NAS (35,36). The CCR5 mutation has been associated with 
impaired attraction of regulatory T cells to the site of injury. Regulatory T cells 
reduce inflammation and suppress activation of potential harmful, self-reactive 
lymphocytes. The strong association between the CCR5 mutation and NAS could be 
explained by an increased inflammatory response of the host towards the biliary 
epithelium of the liver graft (35,36). The risk of developing NAS is even higher in 
patients transplanted for PSC who also have a CCR5-Δ32 mutation (36).
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Cytotoxic Hydrophobic Bile Salts
In contrast to hydrophilic bile salts, which are cytoprotective, hydrophobic bile 
salts may cause injury to hepatocytes and cholangiocytes due to their detergent 
properties. The role of hydrophobic bile salts in the occurrence of NAS after 
transplantation can be explained by a couple of mechanisms; 1) insufficient 
flush out of bile from the bile ducts during organ procurement; 2) altered bile 
composition after OLT, leading to a relatively high biliary bile salt to phospholipid 
ratio; 3) intracellular accumulation of hydrophobic bile salts due to a disturbed 
cholehepatic shunt after OLT; and 4) an impaired biliary HCO3- secretion after 
OLT. Studies have shown that early after transplantation, the composition of 
bile changes to a higher concentration of hydrophobic bile salts compared to 
phospholipds (37). This higher bile salt to phospholipid ratio may be explained 
by a different expression and function of the bile salt export pump (BSEP) and 
multidrug resistance protein 3 (MDR3) transporters (37). Disturbed protective 
micelle formation by a lower concentration of phospholipids allows injury of the 
cholangiocytes by hydrophobic bile salts, resulting in an increased incidence of 
NAS (38).
In addition to the elevated bile salt to phospholipid ratio, reuptake of bile acids 
by cholangiocytes as part of the cholehepatic shunt may be disturbed after OLT, 
causing accumulation of toxic bile salts inside cholangiocytes. This phenomenon 
has been explained by misbalance in function and/or expression of transporter 
responsible for reuptake of bile salts by cholangiocytes from the apical side (apical 
sodium-dependent bile acid transporter or ASBT) and the basolateral transporters 
responsible for secretion of bile salts into the peribiliary vascular plexus (organic 
solute and steroid transporters OSTα and OSTβ). This could lead to cellular 
accumulation of the hydrophobic bile salts and subsequently the development of 
intracellular injury (3). 
Experimental studies have shown that biliary HCO3- secretion prevents bile salt-
induced cholangiocyte injury. By alkalizing the bile close to the apical membrane 
of the cholangiocytes, most of the hydrophobic bile salts become deprotonated and 
neutralized. Neutralizing of the hydrophobic bile salts protects the cholangiocytes 
against penetration of toxic bile salts (39,40). The main transporters in biliary 
bicarbonate secretion are the cholangiocyte Cl-/HCO3- exchanger AE2 and 
transporter cystic fibrosis transmembrane conductance regulator (CFTR), which 
are all adenosine triphosphate (ATP) dependent. Not only ATP levels but also the 
expression of these transporters is disturbed due to ischemia, which may lead to 
a diminished function of the biliary “HCO3- umbrella” after transplantation (41).
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Lack of regeneration: a new concept of pathogenesis of 
NAS
Recent retrospective studies on histological examinations of biopsies taken from 
the distal end of extrahepatic bile duct at the time of OLT have shown signs of 
severe injury characterized by biliary epithelial loss, mural stroma necrosis, and 
injury of the peribiliary vasculature (24,42). Despite the universal biliary epithelial 
injury of large bile ducts of donor livers (about 90%), only a minority of recipients 
develop NAS after OLT. This has brought up a new concept of pathogenesis of NAS 
based on insufficient regeneration and repair capacity of the biliary epithelium 
after OLT (43). More studies will be needed to investigate better the true relevance 
of this new finding and examine whether stimulation of the regenerative capacity 
of the biliary epithelium may result in a reduction of NAS.
Oxygenated machine perfusion: a strategy to reduce NAS?
As described before, NAS is associated with high rates of morbidity, mortality, 
and subsequently higher overall costs of care after OLT. It is therefore necessary 
to develop new strategies to reduce the occurrence of NAS. The potential strategies 
can be defined as reduction of biliary epithelial cell injury by; 1) reduction of 
ischemia induced injury; 2) reduction of cold induced injury; 3) enhancement of 
endogenous protective mechanisms (e.g. stimulation of the “HCO3- umbrella”) and 
4) stimulation of regenerative strategies.
Recently, machine perfusion (MP) showed to be a more powerful preservation 
method than the current method static cold storage (SCS) (44). During MP, 
livers are perfused with an oxygenated (45) or non-oxygenated perfusion fluid 
(46), at either low temperature or normal body temperature. A relatively simple 
technique to “revitalize” grafts after the period of cold ischemia is end-ischemic 
hypothermic oxygenated machine perfusion (perfusion at 10-12° C) (47). A couple 
of studies have demonstrated that oxygenated machine perfusion can help 
organ recovery by improving cellular energy homeostasis. The restoration of 
mitochondrial function by oxygenated MP will result in increased intracellular 
concentration of ATP concentration and a reduction of the oxygen debt. This 
has been associated with less formation of reactive oxygen species after graft 
reperfusion and subsequent less cellular injury (47-49). Subnormothermic 
oxygenated machine perfusion (20° C) has also shown to have a beneficial role in 
recovery of the liver graft after transplantation (50). In all the above techniques 
the metabolism of the liver is limited due to low temperatures. Normothermic 
machine perfusion, on the other hand, allows the organ to have a full metabolism 
in a near physiological environment. In a recent study, the technical feasibility 
of normothermic machine perfusion was demonstrated in discarded human 
livers. In this study, a commercially available device (Liver Assist, Organ Assist, 
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Groningen, the Netherlands), was used for machine perfusion of the liver, using 
continuous portal perfusion and pulsatile arterial perfusion (45). Normothermic 
machine perfusion provides the opportunity to assess viability and function 
of liver grafts before OLT. So far, studies only have demonstrated that machine 
perfusion results in a better preservation of the liver parenchyma compared 
to SCS preservation. Although these results are very promising, it has yet to be 
established whether machine perfusion is also a superior preservation method 
for the vulnerable biliary epithelium compared to SCS. We postulate that during 
machine perfusion the status of the  biliary epithelium could be investigated by 
measuring biomarkers of bile duct injury in perfusate and/or bile. For example, 
detection of gamma-glutamyl transferase (gamma-GT) and lactate dehydrogenase 
(LDH) in bile samples during machine perfusion can be  correlated with the degree 
of biliary epithelial injury. In addition, a recent study reported that cholangiocyte 
microRNA’s can be used as a specific marker to predict the development of NAS 
after OLT. MicroRNA’s are stable and can be easily detected in perfusate, bile or 
tissue during machine perfusion prior to OLT (51).
Moreover, machine perfusion also provides an opportunity to improve organ 
viability. During machine perfusion, organs can be treated with therapeutic agents, 
such as hydrophilic bile salts (i.e. ursodeoxycholic acid and nor-ursodeoxycholic 
acid) to substitute hydrophobic bile salts and increase the “HCO3- umbrella” 
function (Figure 1, next page) (39,40). The benefits of such strategies, however, 
have to be proven in future studies.
Summary
Biliary complications remain to be a burden in liver transplantation. Biliary leakage 
and stricture formation are the most frequent types of biliary complications. 
While bile leakage and AS can usually be managed successfully with non-surgical 
or surgical approaches, NAS are frequently therapy resistant and leave long-term 
sequels. NAS have variable presentations in time and localization, suggesting 
different underlying mechanisms and pathogeneses. Early-onset NAS has shown 
to be more ischemia-related in contrast to late-onset NAS. Late-onset NAS is more 
frequently immune-mediated. Cytotoxic hydrophobic bile salts play a critical role 
in biliary epithelial injury and occurrence of NAS. An adequate flush out of the 
liver, peribiliary microvasculature, and the bile ducts during organ procurement 
could reduce biliary epithelial injury to some extent. However, bile duct injury 
during subsequent cold ischemic storage of a liver graft may still be substantial and 
may contribute to a high incidence of biliary complications after OLT, especially in 
case of an extended criteria (pre-injured) liver graft. Two recent histopathology 
studies of bile duct biopsies taken from human DBD donor livers at the time of OLT 
have shown almost universal loss and injury of the biliary epithelial lining of the 
extrahepatic bile duct (up to 90% of all grafts). The degree of injury was strongly 
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associated with the occurrence of NAS aft er OLT. Th ese studies have suggested that 
lack of complete and timely regeneration of the biliary epithelium rather than the 
amount of initial bile duct wall injury may be an important underlying cause of NAS. 
Machine perfusion has received increasing attention during the last years as an 
attractive alternative method of graft  preservation prior to OLT. Although the most 
optimal method of machine perfusion still needs to be determined (temperature, 
duration, timing, etc.), most studies have shown an improved preservation of the 
liver parenchyma with this technique. Much less is known about the potentially 
benefi cial eff ects of machine perfusion on the bile ducts of a donor liver. However, 
the capacities of machine perfusion are very promising (i.e. viability testing by 
biomarkers or administering therapeutic agents) and may provide a new tool to 
protect the vulnerable bile ducts against preservation-induced injury. Th erefore, 
further studies regarding the role of machine perfusion in its ability to reduce bile 
duct injury are awaited with great interest.
Figure 1. Schematic overview of the mechanisms of biliary injury during and aft er liver transplantation. 
Machine perfusion is an att ractive alternative method of organ preservation that could contribute to bett er 
preservation of the biliary tree and may subsequently result in a reduction of preservation induced biliary 
complications. 
Abbreviations used: BS: bile salts, BS/PS ratio: bile salt to phospholipid ratio, MDR3: multidrug resistance 
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Key points
Biliary complications remain to be the major problem after liver transplantation.
Non-anastomotic biliary strictures are the most challenging complication after 
liver transplantation  due to variability in pathogenesis and resistance to therapy.
The main mechanisms described for pathogenesis of NAS include ischemia/
reperfusion injury, immune-mediated injury, cytotoxic hydrophobic bile salts, and 
impaired biliary bicarbonate secretion.
Insufficient regeneration capacity of biliary epithelium has recently been proposed 
as a new perspective to view the pathogenesis of NAS.
Machine perfusion has been proposed as a potential preservation strategy to 
reduce ischemia/reperfusion injury in donor livers; however, clinical trials are 
needed to demonstrate whether machine perfusion can reduce the incidence of 
NAS after liver transplantation.
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Abstract
Background: Injury to the peribiliary glands (PBGs) during static cold storage 
is associated with an increased risk for non-anastomotic biliary strictures (NAS) 
formation after liver transplantation. However, it is unknown if the PBGs are also 
injured in severe stages of NAS. The aim of this study was therefore to perform 
a systematic histological analysis of large bile ducts of the first liver allograft in 
patients with severe NAS. 
Methods: Large bile ducts of patients with severe NAS (n = 19) were compared 
with those of patients without NAS (n = 5) or any concomitant biliary pathology 
(control patients). Sections were obtained during retransplantation for end-stage 
NAS or for non-biliary causes, respectively. Sections were scored using a systematic 
histological grading system. Patients with primary sclerosing cholangitis were 
excluded from the analysis. 
Results: The degree of injury to the biliary epithelium or the PBGs, and the degree 
of inflammation were significantly higher in large bile duct sections of patients 
retransplanted for NAS compared to control patients. In addition, thrombosis 
and injury to the peribiliary vascular plexus were only minimally present in both 
groups. 
Conclusion: Our study indicates that injury to the peribiliary glands and biliary 
epithelium but not injury to the peribiliary vascular plexus is strongly associated 
with end-stage NAS. Our data suggest that ongoing injuries to the PBGs with a 
consequently insufficient regeneration of the biliary epithelium are important 
factors in the pathogenesis of NAS.
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Introduction
Non-anastomotic biliary strictures (NAS) are a common and often troublesome 
complication after liver transplantation. In severe stages of NAS, patients 
have fibrotic and necrotic bile ducts and may suffer from progressive jaundice, 
episodes of bacterial cholangitis and ultimately biliary cirrhosis. Unfortunately, 
retransplantation is currently the only curative treatment for patients with severe 
stages of NAS (1,2).
NAS comprises a heterogeneous group of bile duct strictures and equally 
variable presentations. A large variation is observed in the time interval between 
transplantation and the first presentation of NAS. Early NAS (presenting within 1 
year) is related to ischemia, such as a longer cold and warm ischemia time, whereas 
late NAS (presenting after 1 year) is related to immune-mediated mechanisms 
like blood group incompatibility and loss-of-function mutation in the chemokine 
receptor CCR5 (3,4). 
The perspective on the pathogenesis of NAS, especially for the ischemia-related 
NAS, has recently been changed. Three recent independent clinical studies have 
demonstrated that major epithelial cell loss in the extrahepatic bile ducts is 
observed in more than 90% of donor livers after static cold storage (SCS) (5-7). 
Nevertheless, only a minority of recipients of these livers develops NAS after 
transplantation. This observation has therefore led to the hypothesis that defective 
proliferation and regeneration of the biliary epithelium, rather than ischemic 
injury, are important factors in the pathogenesis of NAS (8). 
Compelling evidence has shown that the peribiliary glands (PBGs) function 
as a local reservoir for biliary stem cells (9-13). The PBGs are situated around 
the extrahepatic and intrahepatic larger bile ducts and drain directly into the 
ductal lumen (14). After injury, proliferating cells can migrate from the PBGs and 
differentiate to renew the biliary epithelium (15).
Recently, our group reported that injury to the PBGs after static cold storage was 
associated with the development of NAS after transplantation (7). We suggested 
that insufficient regeneration due to loss of PBGs during static cold storage is an 
important factor in the pathogenesis of NAS after transplantation. To support 
these earlier findings, we expect that in severe stages of NAS, the epithelial cells 
of the PBG remain severely injured. However, knowledge about the status of the 
PBGs and other aspects of the biliary wall in severe stages of NAS is limited. This 
study was therefore designed to perform a systematic histological analysis of bile 
ducts and PBGs of patients with severe stages of NAS. Bile ducts obtained during 
retransplantation of patients for end-stage NAS were compared with bile ducts 
obtained from patients retransplanted for non-biliary causes. Patients with 
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underlying primary sclerosing cholangitis (PSC) were excluded from the analysis 
because of the higher risk of NAS and/or biliary injury in these patients. 
Materials and methods
Study Population 
Between January 1990 and April 2015, a total of 1299 liver transplantations were 
performed at the University Medical Center Groningen (UMCG). In this cohort, 205 
patients underwent a retransplantation with a full-size graft. After exclusion of 
patients who were younger than 18 years at the time of their first transplantation, 
we identified 116 adult patients eligible for this study. Of these 116 patients, 28 
patients were excluded because of PSC, leaving 88 patients for further inclusion. 
The remaining group was subdivided based on the indication for retransplantation. 
Sixty-two patients were retransplanted for one of the following reasons: primary 
non-function (PNF), hepatic artery thrombosis (HAT), chronic rejection, and 
biliary leakage. These patients were excluded because next to their main reason for 
graft failure these patients also had a substantial risk for biliary pathology. Of the 
remaining 26 patients, 21 patients were retransplanted for severe NAS and five for 
other reasons (recurrent HBV or HCV cirrhosis (n = 4) and portal vein thrombosis 
(n = 1)). These causes of graft failure are all associated with a minimal risk for the 
development of concomitant biliary pathology, which made these patients suitable 
controls for the current study. Patients with severe NAS were further subdivided 
based on the time of occurrence of the disease: early NAS presenting within 1 
year (n = 19), and late NAS occurring after 1 year (n = 2). Patients with late NAS 
were excluded because late NAS is more related to immune-mediated mechanisms 
rather than ischemia-related factors, leading to the inclusion of 19 patients with 
early NAS for this study (Figure 1). 
Donor, recipient, and surgical characteristics were obtained from a prospectively 
maintained database. Missing information was obtained from the original patient 
files, when necessary. This retrospective analysis using fully anonymized data was 
performed according to the current guidelines of the Dutch legislation (Code Goed 
Gebruik, Federation of Medical Scientific Societies in the Netherlands, https://
www.federa.org/code-goed-gebruik).
Donor, Recipient Characteristics and Surgical Variables 
The European donor risk index (ET-DRI) was calculated according to Braat et 
al. (16). In addition, the following donor variables were collected and included 
in the analyses: gender, body mass index (BMI), causes of death, type of donor 
(donation after brain death [DBD] or donation after circulatory death [DCD]), first 
warm ischemia time in DCD donors, graft type (full size versus partial grafts), and 
type of organ perfusion fluid (histidine-tryptophane-ketoglutarate [HTK] versus 
University of Wisconsin [UW]). Recipient variables collected and included were: 
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age, gender, BMI, indication for transplantation, laboratory model for end-stage 
liver disease (MELD) score (calculated on the day of transplantation, disregarding 
extra points for standard or non-standard exceptions), and recipient status on the 
Eurotransplant waiting list (elective versus high urgency). With respect to the 
surgical variables, the following parameters were examined: graft implantation 
technique (conventional versus piggyback), cold ischemia time (CIT), warm 
ischemia time (WIT), type of bile duct anastomosis (duct-to-duct or Roux-en-Y 
hepatico-jejunostomy), and amount of total blood loss. 
Figure 1: Flowchart of patients who developed severe non-anastomotic biliary strictures (NAS) or 
another cause of graft failure after their first liver transplantation in a period of 25 years. Nineteen 
patients with severe NAS (NAS presentation within the first year postoperative) and 5 patients 
retransplanted for another cause without concomitant biliary injury were included in this study. 
Abbreviations used: OLT: orthotopic liver transplantation, ReOLT: re-orthotopic liver transplantation, PNF: 
primary non-function, HAT: hepatic artery thrombosis, NAS: non-anastomotic biliary strictures.
8
Binnenwerk_Andrie_Final.indd   125 12/20/15   11:01 AM
126
Definition of Non-Anastomotic Biliary  Strictures
NAS were defined as strictures, dilatations, or irregularities of the intra- or 
extrahepatic bile ducts of the liver graft in the absence of hepatic artery thrombosis 
(17). Isolated strictures at the bile duct anastomosis (anastomotic strictures) were 
excluded. The diagnosis of NAS was based on adequate imaging study of the biliary 
tree, as diagnosed by endoscopic retrograde cholangiography, magnetic resonance 
imaging, or percutaneous transhepatic cholangiography. In most patients, imaging 
of the biliary tree was indicated based on clinical symptoms (i.e. fever, chills, 
jaundice) in combination with laboratory values indicating biliary pathology. The 
time of first presentation of NAS was recorded for all patients. 
Histological Assessment of Large Bile Ducts in Resected Primary Transplants 
Large bile ducts in resected primary transplants were fixed with 10% formaldehyde 
and embedded with paraffin. Paraffin-embedded slides were stained with 
hematoxylin and eosin (H&E) staining, Periodic acid-Schiff-diastase (PAS diastase) 
staining, and Masson’s trichrome staining.
Bile duct injury of the larger bile ducts was semi-quantified using a histological 
systematic scoring system for H&E staining described by Hansen et al. (5) and Op 
den Dries et al. (7) with minor adjustments; each variable was assessed as being 
either present or absent (Table 1). With respect to injury to the PBGs, it was defined 
as detachment of the cells from the basement membrane and/or disappearance of 
epithelial cells from the glands. All bile duct sections were examined in a blinded 
fashion by two experienced liver pathologists (MCH and ASHG).
Statistical Analysis
Continuous data were presented as median and interquartile range (IQR). The 
Mann-Whitney U test was used to compare groups. Categorical data were expressed 
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Table 1.  Scoring System for Histological Grading of Bile Duct Injury*
Bile Duct Wall Component Injury Score
Absent Present
Biliary epithelium No loss of the epithelial lining Presence of Epithelial loss 
Mural stroma No injury in stroma cells Presence of Necrotic stroma cells 
Peribiliary vascular plexus No vascular lesions Presence of Vascular injury 
Thrombosis No trombi Occurrence of thrombi
Intramural bleeding No bleeding in bile duct wall Presence of bleeding in bile duct wall 
PBG (periluminal & deep) No injury in PBG Presence of injury in PBG 
Inflammation No leucocyte infiltration At least 10 leukocytes / HPF
*) According to Hansen et al. (5) and to Op den Dries et al. (7) with minor adjustments. Each variable was assessed as being either present 
or absent.
Abbreviations used: PBG, peribiliary gland; HPF, high power field.  
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as numbers and percentage and groups were compared using Pearson chi-square 
test or Fischer’s exact test where appropriate. The level of significance was set at 
a p-value < 0.05. Analyses were performed using SPSS software version 22.0 for 
Windows (SPSS Inc., Chicago, IL, USA).
Results
Recipient, Donor, and Surgical Characteristics of Primary Liver Transplantation
Recipient, donor, and surgical characteristics of the primary liver transplantation 
in the group of patients retransplanted for severe NAS and the group of patients 
retransplanted for another reason are presented in Table 2 (next page). No 
statistical differences were observed in the recipient, donor, and surgical 
variables between the groups. In particular, the median laboratory MELD score 
was comparable between the group of patients retransplanted for severe NAS and 
the group of patients retransplanted for another reason (MELD score of 21 versus 
19, respectively). Moreover, the median ET-DRI score was also comparable (2.0 
versus 1.8, respectively) between both groups. Although there was no statistically 
significantly difference in the distribution of donor type (DBD versus DCD) between 
groups, it should be noticed that proportion of DCD donor livers used for the 
primary liver transplantation was higher in the group of patients retransplanted 
for severe NAS in comparison with the group of patients retransplanted for 
another reason. In addition, in both groups the majority of biliary reconstructions 
were performed with the duct-to-duct anastomosis technique, 95% in the group 
of patients retransplanted for severe NAS and 100% in the group of patients 
retransplanted for another reason. Furthermore, the median graft survival was 
not statistically different between the group of patients retransplanted for severe 
NAS (1190 days, IQR 14-2171 days) and in the group of patients retransplanted for 
another reason (361 days, IQR 138-2271 days) (p=0.68).  
Histological Grading of Large Bile Duct Injury in the First Liver Allograft
The results of the histological grading of large bile duct injury in the first allograft 
in patients retransplanted for severe NAS and for another reason are provided 
in Table 3. Figure 2 illustrates a large bile duct biopsy from a patient with severe 
NAS. In the group of patients retransplanted for severe NAS, a significantly 
increased proportion of patients had biliary epithelial injury compared to the 
group of patient retransplanted for another reason (p=0.037). In the majority of 
cases, mural stroma necrosis was absent in both groups. Similarly, vascular injury 
to the peribiliary vascular plexus, vascular thrombosis, and bleeding were also 
minimally observed in the group of patients retransplanted for severe NAS and 
retransplanted for another reason. See Figure 3 for an example of normal mural 
stroma without injury to the peribiliary plexus, vascular thrombosis, and bleeding. 
With respect to injury to epithelial cells of the PBGs, a significantly increased 
proportion of patients with severe NAS displayed injury to the PBGs compared to 
8
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Table 2. Demographics and Surgical Variables of the Primary Liver Transplantation in Patients Retransplanted for Severe Non-Anastomotic 
Biliary Strictures (NAS) versus Patients Retransplanted for Another Reason
Variable Patients Retransplanted 
for NAS




(n = 5 )
p-value
Recipient variables









BMI (kg/m2) 26 (23-27) 26 (24-27) 0.59
Indication for primary transplantation
- Postnecrotic cirrhosis
- Primairy biliary cirrhosis
- Metabolic disease













(Laboratory) MELD score 21 (15-24) 19 (15-23) 0.61
Serum creatinine before OLT (μmol/L)1 83 (57-122) 90 (69-116) 0.84
Serum total bilirubin before OLT (μmol/L)2 103 (40-384) 61 (44-293) 0.89
INR before LT 1.81 (1.3-2.3) 1.5 (1.2-1.6) 0.29








Days on the waiting list 140 (14-336) 286 (143-381) 0.25
Donor variables
Eurotransplant Donor Risk Index 2.0 (1.6-2.4) 1.8 (1.5-2.1) 0.58









BMI (kg/m2) 25 (23-26) 23 (21-25) 0.60








Time between withdrawal of life support and 
circulatory arrest (min)3
22 (17-34) - NA
Time between circulatory arrest and cold flush in 
situ (min)3
15 (12-21) - NA




































     5 (100%)
     0
0.60
Cold ischemia time4 (hr:min) 8:42 (7:00 – 10:26) 10:10 (6:57-13:55) 0.45
Warm ischemia time5 (hr:min) 0:50 (0:37 – 1:02) 0:49 (0:45-0:55) 0.86
Blood loss (liter) 4.5 (2.5– 14) 3.0 (1.5-4.5) 0.29
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Table 3. Comparison of Histological Grading of Bile Duct Injury in First Liver Allografts in Patients Retransplanted for Severe Non-
Anastomotic Biliary Strictures (NAS) or Retransplanted for Another Reason
Bile Duct Wall Component
Injury Score



























































Abbreviations used: PBG, peribiliary gland.
1 In one patient no peribiliary glands were present in the large bile duct specimen in the group of patients retransplanted for early NAS. 
◀ Table 2
Data represent median with interquartile ranges (IQR) for continuous variables or numbers (percentages) for categorical variables.
Abbreviations used: BMI: body mass index, MELD: model for end-stage liver disease, INR: international normalized ratio, DBD: donation after 
brain death, DCD: donation after circulatory death, UW: University of Wisconsin, HTK: histidine-tryptophane-ketoglutarate. OLT: orthotopic 
liver transplantation, NA: not applicable.
1 Normal < 110 μmol/L, to convert the value for creatinine to mg/dL, divide by 88.4.
2 Normal 0-17 μmol/L, to convert the value for bilirubin to mg/dL, divide by 17.1.
3 The total of both time periods can be defined as the total donor warm ischemia time during DCD donation.
4 Time from in situ flushing of the donor organ until the liver is removed from ice for implantation.
5 Time from removal of liver from ice until reperfusion via portal vein, hepatic artery or both.
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Figure 2: Histological overview (H&E staining) of a bile duct from a patient with severe  non-anastomotic 
biliary strictures (NAS). The biliary epithelial layer is absent due to massive necrosis and inflammation 
(curly bracket). The cells in the periluminal PBGs were detached from their basement membrane or even 
absent (dashed circle). The bile duct lumen is marked with an asterisk. In the bile duct lumen cellular debris 
and bile residues are observed. Scale bar indicates 300 μm.
Figure 3: PAS diastase staining of a bile duct wall injured by severe non-anastomotic biliary strictures 
(NAS). The biliary epithelial layer is absent (curly bracket). No mural stroma necrosis is observed (white 
arrow points to a vital stroma cell). Additionally, no injury to the peribiliary vascular plexus or thrombosis is 
observed in this case (black arrows). Scale bar indicates 100 μm.
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Figure 4: Masson’s trichrome staining of peribiliary glands of a bile duct from a patient with severe 
non-anastomotic biliary strictures (NAS). Panel A: Detachment of epithelial cells from the basement 
membrane. Panel B: Disappearance of epithelial cells from the glands. Scale bar indicate 50 μm. 
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the proportion of control patients (p=0.016) (Figure 4). Similarly, a significantly 
higher percentage of inflammation was observed in biopsies of the first allograft 
in patients retransplanted for severe NAS compared to patients retransplanted for 
another reason (p=0.005). 
Discussion    
This study demonstrates that in the histological sections of the larger bile ducts 
of patients retransplanted for severe NAS, significantly more biliary epithelial 
detachment and loss of epithelium cells was present in comparison to (control) 
patients retransplanted for reasons without concomitant biliary injury. In 
addition, in the larger bile ducts of patients retransplanted for severe NAS, a 
higher degree of PBG injury and inflammation was observed compared to control 
patients. Interestingly, we did not find an association between vascular injury and/
or the presence of microthrombi in the peribiliary vascular plexus and end-stage 
NAS. 
The relation between either formation of microthrombi in the peribiliary 
vascular plexus and/or peribiliary vascular injury in bile ducts during SCS and 
the occurrence of NAS or ischemic cholangiopathy has been described previously 
(5,7,18-21). Injury to the peribiliary vascular plexus and/or thrombosis may cause 
interruption of blood supply to bile ducts and subsequent (local) ischemia. After 
a certain time period, the effects of ischemia are not reversible and cellular 
injury occurs. Cellular injury may take the form of bile duct necrosis or fibrosis 
depending on the severity of vascular occlusion (22). In our study, we did not 
observe injury to the peribiliary vascular plexus and/or thrombosis in the larger 
bile duct of patients retransplanted for severe NAS. Hence, our data do not support 
the concept of ongoing injury to the peribiliary vascular plexus as a contributive 
factor for the further progression of severe NAS after transplantation. 
With respect to proliferation and regeneration of the biliary epithelium, the 
PBGs have been identified as reservoir from which biliary epithelial cells of the 
larger bile ducts can regenerate (9-15). Our group recently demonstrated that 
in donor bile ducts, injury to the PBGs during transplantation is associated with 
the occurrence of NAS (7). The current study illustrates that in the end-stages 
of NAS, the PBGs are injured as well. As a result, our data support our earlier 
findings that the injury to the PBGs during organ preservation is related to NAS 
formation. Data from both studies suggest that PBG injury developed during organ 
preservation is an ongoing process, resulting in insufficient capacity of the PBGs 
to replenish new cholangiocytes of the damaged bile ducts. It is therefore likely 
that between transplantation and NAS formation the defective regeneration of the 
lining epithelium of the larger bile ducts results in inappropriate luminal lining 
of the bile ducts. As a consequence, the bile duct wall is inadequately protected 
against the toxic effects of bile salts. Bile salts are toxic due to their properties 
to solubilize membrane-bound lipids. Inside the cell, bile salts are harmful for 
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mitochondria and are able to trigger necrosis or apoptosis (23). Normally, biliary 
epithelial cells form a protective barrier against the toxic effects of bile salts (24). 
Next to their barrier function, the cholangiocytes actively secrete bicarbonate to 
neutralize the effects of the toxic bile salts (25,26). In addition, it has been shown 
that bile is even more toxic during NAS formation (17). Normally, the effects of the 
toxic bile salts are counteracted by phospholipids and mixed micelles formation. 
However, NAS formation is associated with a higher bile salt phospholipid ratio 
(17). Given the knowledge that the protective cholangiocyte layer is almost absent 
in cases of severe NAS, we hypothesize that the combination of the absence of a 
cholangiocyte protective layer and increased effect of toxic bile acids, are both 
important factors for inflammation of the bile duct wall and further progression 
of NAS after transplantation. 
A limitation of our study is the relative small number of control patients. However, 
patients retransplanted with a minimal risk for the development of biliary 
pathology are available in limited numbers in our cohort over 25 years. Due to 
optimal care after transplantation for hepatitis B or C cirrhosis, retransplantation 
for recurrent hepatitis related graft cirrhosis is not common in our center.
Further studies regarding the capacity of PBGs in regeneration of the biliary 
epithelium after SCS would be worthwhile. Recently, a proof-of-principle study 
in two patients with advanced cirrhosis has shown the beneficial effects of 
stem cell therapy with human fetal biliary tree stem/progenitor cells (hBTSCs) 
harvested from the PBGs (27). These hBTSCs are able to differentiate into mature 
cholangiocytes, hepatocytes and pancreatic β-cells (10,28,29). After 6 months 
follow-up, both patients had a reduction of approximately 4 points in their MELD 
score, suggesting a better hepatic function in these patients (27). In addition, 
studies with ex vivo normothermic machine perfusion of the donor livers after SCS 
have demonstrated its potential role to serve as a vehicle for the delivery of stem 
cells (30-32). Therefore, it is plausible that the combination of stem cell therapy 
and normothermic machine perfusion has potential in revitalizing injured bile 
ducts before transplantation.  
In conclusion, our study demonstrates that injury to the peribiliary glands and 
biliary epithelium but not injury to the vascular plexus is strongly associated 
with end-stage NAS. In addition, our data suggest that ongoing injuries to the 
PBGs with a consequently insufficient regeneration of the biliary epithelium are 
important factors in the pathogenesis of NAS. Furthermore, we postulate that 
the combination of the loss of the protective cholangiocyte layer and effects of 
the toxic bile salts are important factors for the further progression of NAS. The 
pivotal role of PBG as a source for cholangiocyte replenishment following injury 
has been substantiated by stem cell therapy with PBG derived progenitors cells. 
Therefore, stem cell therapy together with normothermic machine perfusion may 
have potential to reduce biliary injury during organ preservation. 
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Oxygenated Hypothermic Machine Perfusion aft er 
Static Cold Storage Improves Hepatobiliary Function 
of Extended Criteria Donor Livers




Background: The mechanism through which oxygenated hypothermic machine 
perfusion (HMP) improves viability of human extended criteria donor (ECD) livers 
is not well known. Aim of this study was to examine the benefits of oxygenated 
HMP after static cold storage (SCS). 
Methods: Eighteen ECD livers that were declined for transplantation underwent 
ex situ viability testing using normothermic (37°C) machine perfusion (NMP) 
after traditional SCS (0-4°C) for 7-9 hours. In the intervention group (n = 6), livers 
underwent 2 hours of oxygenated HMP (at 12°C) after SCS and before NMP. Twelve 
control livers underwent NMP without oxygenated HMP after SCS. 
Results: During HMP, hepatic ATP content increased >15-fold and levels remained 
significantly higher during the first 4 hours of NMP in the HMP group, compared 
to controls. Cumulative bile production, as well as biliary secretion of bilirubin 
and bicarbonate, was significantly higher after HMP, compared to controls. In 
addition, the levels of lactate and glucose were less elevated after HMP compared 
to SCS preservation alone. In contrast, there were no differences in levels of 
hepatobiliary injury markers such as AST, ALT, LDH, and gamma-GT after 6 
hours of NMP. Hepatic histology at baseline and after 6 hours of NMP revealed no 
differences in the amount of ischemic necrosis between both groups. 
Conclusion: Two hours of oxygenated HMP after traditional SCS restores hepatic 
ATP levels and improves hepatobiliary function, but does not reduce (pre-existing) 
hepatobiliary injury in ECD livers.




One of the greatest challenges in liver transplantation is the shortage of suitable 
donor livers. Today, many patients are waiting in vain for a liver transplant, 
which is often the only successful treatment of their liver failure (1). One way 
to minimize the shortage of liver donor grafts for transplantation is the use of 
extended criteria donor (ECD) livers. However, ECD livers are in general associated 
with a higher postoperative risk of early graft failure, compared to livers from 
optimal or reference donors (2). Because of this, many ECD livers are declined for 
transplantation and an important question is how these livers can be functionally 
improved and made suitable for transplantation.  
During the last decade, machine perfusion (MP) has been receiving increasing 
attention as a promising method to reduce preservation injury, compared to the 
traditional method of static cold storage (SCS) (3-5). A short period of MP after SCS 
(end-ischemic MP) has been suggested to reduce the risk of early graft dysfunction 
after transplantation (6). In particular ECD livers, which have a higher risk of early 
graft failure due to the pre-existing hepatocellular injury and dysfunction, could 
potentially benefit from end-ischemic MP during organ preservation (6). 
End-ischemic MP can be performed at different temperatures. Hypothermic ma-
chine perfusion (HMP; perfusion at 4-12 °C), has recently made a first step into 
clinical practice. Guarrera et al. (7,8) and Dutkowski et al. (9) have described suc-
cessful application of end-ischemic MP of ECD livers in human liver transplan-
tation. In these studies, livers that first underwent end-ischemic HMP displayed 
better graft function compared to matched control livers that did not undergo 
end-ischemic HMP. In addition, the incidence of ischemic cholangiopathy, also 
known as non-anastomotic biliary strictures (NAS), was lower in the group with 
end-ischemic HMP treatment (8,9). Although these results are very promising, 
knowledge about the mechanisms through which end-ischemic HMP may improve 
liver and biliary function of human ECD liver grafts is limited. The aim of the cur-
rent study was therefore to assess whether end-ischemic dual (combined arterial 
and portal) oxygenated hypothermic machine perfusion (HMP) improves hepato-
biliary function and reduces preservation injury of human ECD livers, compared 
to traditional SCS preservation alone. In the current study, hepatobiliary viability 
after traditional SCS preservation or after SCS followed by 2 hours of HMP was 
assessed during ex situ normothermic machine perfusion (NMP) for 6 hours.





Between August 2012 and August 2014 eighteen consecutive full size human donor 
livers were included in this study. All livers were declined for transplantation 
within the Eurotransplant region. The two main reasons for declining were: 1) the 
combination of donation after circulatory death (DCD) with advanced donor age; 
and 2) the combination of DCD or donation after brain death (DBD) and a high 
body mass index (suspicion of graft steatosis). Informed consent for research 
was obtained from the donor families. The study protocol was approved by the 
medical ethical committee of the University Medical Center Groningen (METc 
2012.068) and the competent authority for organ donation in the Netherlands, 
the Dutch Transplantation Foundation (NTS). The Eurotransplant donor risk 
index (ET-DRI) was calculated for all livers using the method described by Braat 
et al. (10). During the study period, the first 12 ECD livers were included in the 
SCS only group, which consisted of NMP viability assessment after traditional SCS 
preservation. Subsequently, 6 other ECD livers were included in the HMP group. 
These liver grafts were exposed to 2 hours of HMP after the period of traditional 
SCS preservation. After HMP these livers underwent 6 hours of NMP for viability 
assessment (Figure 1 and 2). 
Procurement and Preparation of Donor Liver Grafts
All donor livers were procured by one of the regional multi-organ procurement 
teams in the Netherlands using the standard technique of in situ cooling and 
flush out with preservation fluid (University of Wisconsin [UW] or histidine–
tryptophan–ketoglutarate solution [HTK]) at 0-4 degrees Celsius. In case of DBD, 
25,000 units of heparin were administered intravenously before cross clamping of 
the supratruncal aorta. In DCD cases, the surgical procedure was not started until 
after 5 minutes “no touch” period following declaration of circulatory death. During 
Figure 1: Schematic overview of the study groups to examine the effects of end-ischemic oxygenated 
hypothermic machine perfusion (HMP) after static cold storage (SCS). The group that underwent end-
ischemic HMP contained 6 livers. The SCS only group contained 12 livers. In both groups ex situ normothermic 
machine perfusion (NMP) was used for viability testing for 6 hours.




Figure 2:  Photos of the liver during machine perfusion (MP) experiments.  Panel A: In a bowl with melting 
ice and preservation solution, the liver is prepared for oxygenated hypothermic machine perfusion (HMP) or 
normothermic machine perfusion (NMP). Panel B: Liver perfused with HMP. Panel C: Liver perfused for 30 
minutes with NMP. Panel D: Liver perfused for 6 hours with NMP. During MP, the organ chamber is covered 
with a transparent lid to prevent heat loss and to maintain a moist environment.
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the flush out procedure, the same dose of heparin (25,000 units of heparin) was 
added to the first bag of preservation solution. All livers were packed in ice-cold 
preservation solution (UW or HTK), stored on ice, and transported to our center. 
Upon arrival in our center, an experienced transplant surgeon performed the 
back table preparation. The portal vein, the supratruncal aorta, and the bile duct 
were cannulated and the graft was prepared for oxygenated machine perfusion as 
described previously (11-13). 
Machine Perfusion
HMP and NMP were performed using a machine perfusion device that includes 
two perfusion circuits, each comprising a rotary perfusion pump, a membrane 
oxygenator with integrated heat exchanger and pressure sensor for perfusion of the 
portal vein and hepatic artery, respectively (Liver Assist, Organ Assist, Groningen, 
the Netherlands). Flow through the hepatic artery was pulsatile, whereas flow 
through the portal vein was continuous. The system was both pressure and 
temperature controlled. During HMP, portal pressure was set at 4 mmHg, mean 
arterial pressure at 25 mmHg, and temperature of the perfusion fluid was set at 
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10-12°C, as described previously (11-13). The solution was oxygenated with 100% 
oxygen (1 L/min) resulting in a pO2 between 50-80 kPa (375-600 mmHg). During 
NMP (37°C), the portal pressure was 11 mmHg and mean arterial pressure was 70 
mmHg. In contrast to HMP, we oxygenated during NMP with a carbogen mixture 
of 95% O2 and 5% CO2 (2 L/min), resulting in a pO2 between 50-80kPa (375-600 
mmHg). During HMP, livers were perfused with 3 L of Belzer-UW Machine 
Perfusion solution (Bridge-to-Life, Ltd. Northbrook, IL, USA). After 2 hours of HMP 
the liver graft was disconnected from the perfusion device, placed in a bowl with 
cold (0-4°C) UW cold storage solution (Bridge-to-Life, Ltd. Northbrook, IL, USA), 
in order to change the perfusion fluid and prime the perfusion device for NMP. 
Before NMP, the liver was flushed with 1 L cold NaCl 0.9% solution, followed by 
500 mL warm NaCl 0.9% solution. Livers were perfused normothermically (37 oC) 
for 6 hours with a perfusion solution based on heparinized human plasma and red 
blood cells enriched with nutrients, trace elements and antibiotics, as described 
previously (11-13). Before NMP and every 30 minutes during NMP samples from 
the perfusion fluid were taken for analysis of the blood gas parameters (pO2, 
pCO2, sO2, HCO3-, and pH) using an ABL800 FLEX analyzer (Radiometer, Brønhøj, 
Denmark). If needed, small amounts of sodium bicarbonate (8.4% solution) 
were added to maintain a pH within the physiological range (7.35-7.45), as been 
described previously (11-13).  
Assessment of Hepatobiliary Function and Injury
During NMP, flow through the portal vein and hepatic artery as well as perfusion 
fluid temperature was recorded every 10 minutes. Vascular resistance of both 
vessels was expressed as mmHg/mL/min/kg liver. 
Before and every 30 minutes during NMP, samples were taken from the perfusion 
fluid. Of each sample, one part was used for analysis for biochemical parameters 
(glucose and lactate) using an ABL800 FLEX analyzer (Radiometer, Brønhøj, 
Denmark). Another part of the perfusion fluid sample was centrifuged (2700g 
for 5 min at 4°C) and the supernatant was collected and stored at -80°C for 
determination of aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), lactate dehydrogenase (LDH), and gamma-glutamyl transferase (gamma-
GT), using standard biochemical methods. 
Bile production was measured gravimetrically at 30-minute intervals by weighing 
Eppendorf tubes in which bile was collected from the biliary drain. The cumulative 
bile production was expressed as mL bile/kg liver. The density of bile was defined 
as 1 mg/mL. Based on the (cumulative) bile production during NMP, livers were 
classified as good or poor functioning using a modification of the method described 
by Sutton et al. (12). While Sutton et al. (12) expressed bile production as gram/hr, we 
expressed bile production as mL/hr/kg liver tissue. Livers were classified as good 
functioning if they met the following criteria: bile production of more than 2 mL/
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hr/kg during 1.5 – 2.5 hours of NMP, and cumulative bile production of more than 
5 mL/hr/kg after 2.5 hours of NMP. Biliary concentration of bicarbonate and pH 
were measured as markers of biliary epithelial cell (cholangiocyte) function (14). 
For this purpose, bile samples were collected under mineral oil and were analyzed 
immediately using an ABL800 FLEX analyzer (Radiometer, Brønhøj, Denmark). 
Biliary concentration of gamma-GT and LDH were measured as markers of biliary 
epithelial cell injury and biliary bilirubin concentration was measured as marker 
of hepatocellular secretory function (15), using standard biochemical methods. 
Hepatic oxygen consumption was calculated every 30 minutes during NMP based 
on the difference between the arterial and venous oxygen content of the perfusion 
fluid, as described previously (12). In brief, samples were taken from the perfusion 
fluid before and after the liver. Prehepatic samples were taken from a side port 
before the perfusion cannula and posthepatic samples were taken directly from 
the suprahepatic vena cava.  
Hepatic concentration of adenosine triphosphate (ATP) was used as an indicator 
of the energy status of grafts during HMP and NMP. For this purpose, liver tissue 
biopsies were immediately frozen in liquid nitrogen and were processed later for 
ATP measurement, as described previously (12).
Histological Evaluation
Biopsies were taken from the liver parenchyma at the end of SCS and after 6 hours 
of NMP. Samples were fixed in 10% formalin and paraffin embedded for further 
preparation for hematoxylin and eosin (H&E) staining. Histological assessment 
was performed by an expert liver pathologist (ASHG), who was not aware of 
the assigned study groups. To assess preservation injury, the degree of ischemic 
necrosis was semi-quantified based on the percentage of necrotic hepatocytes and 
categorized as: low (< 10%), mild (10 – 30%), moderate (30– 60%) or severe (> 60%). 
Statistical Analysis
Continuous variables were presented as median with range or interquartile 
range (IQR). Categorical variables were presented as number and percentage. 
Continuous variables were compared between groups using the Mann-Whitney U 
test. Categorical variables were compared with the Pearson chi-square or Fischer’s 
exact test where appropriate. The level of significance was set at a p-value of < 
0.05. All statistical analyses were performed using SPSS software version 22.0 for 
Windows (SPSS, Inc., Chicago, IL, USA).
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Table 1. Comparison of Donor Characteristics of Livers that Underwent Static Cold Storage Preservation (SCS) Alone and Livers that 
Underwent Oxygenated Hypothermic Machine Perfusion (HMP) after SCS
Variables SCS only SCS + HMP p-value
(n = 12) (n = 6)
Age (years) 61 (52-64) 64 (57-70) 0.21
Gender 0.49
- Male 8 (67%) 3 (50%)
- Female 4 (33%) 3 (50%)
Length (m) 1.77 (1.67-1.80) 1.75 (1.68-1.79) 0.75
Weight (kg) 88 (76-100) 73 (65-90) 0.08
Body mass index (kg/m2) 27.3 (24.5-36.0) 24.6 (22.6-27.3) 0.10
Type of donor liver 0.18
- DCD 9 (75%) 6 (100%)
- DBD 3 (25%) 0
Cause of death 0.29
- Cardiovascular 2 (16%) 3 (50%)
- Post-anoxia 5 (42%) 2 (33%)
- Trauma 5 (42%) 1 (17%)
Reasons livers were declined for transplantation 0.29
- DCD + age > 60 years 5 (42%) 5 (84%)
- DCD + high BMI 5 (42%) 1 (17%)
- DCD + high transaminases 2 (16%) 0
Latest laboratory value gamma-GT (U/L) 83 (34-130) 30 (19-106) 0.30
Type of preservation solution 0.18
- UW solution 9 (75%) 6 (100%)
- HTK solution 3 (25%) 0
Time between withdrawal of life support treatment and 
circulatory arrest (min)1
20 (4-46) 14 (13-36) 0.61
Time between circulatory arrest and cold flush in situ (min)1 18 (12-22) 15 (13-23) 0.96
Cold ischemia time (hr: min)2 9:04 (7:01-11:14) 7:18 (6:10-8:32) 0.15
Total preservation time (hr:min)3 9:04 (7:01-11:14) 11:37 (10:01-12:25) 0.10
Eurotransplant - Donor risk index 2.79 (2.24-3.21) 3.11 (2.77-3.39) 0.38
Weight of liver (kg) 2.11 (1.81-2.30) 1.83 (1.15-2.23) 0.29
Data represent median with interquartile ranges for continuous variables or numbers (percentages) for categorical variables.
Abbreviations used: HMP: hypothermic machine perfusion, DCD: donation after circulatory death, DBD: donation after brain death, SCS: static 
cold storage, UW: University of Wisconsin, HTK: histidine- tryptophan-ketoglutarate, BMI: body mass index, gamma-GT: gamma-glutamyl 
transferase.
1The total of both time periods can be defined as the total donor warm ischemia time during DCD donation. 
2Time period between cold flush out of the liver in the donor and start of machine perfusion (either HMP or NMP).  




A comparison of donor characteristics of livers that received 2 hours of HMP 
after SCS and livers that did not undergo HMP after SCS (SCS only) is provided in 
Table 1. There were no significant differences among the donor variables such as 
donor age, type of donor graft, donor warm ischemia time (in case of DCD), type 
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Figure 3: Vascular resistance patterns in the portal vein and the hepatic artery during 6 hours of nor-
mothermic machine perfusion (NMP). Panel A and panel B: During NMP, the vascular resistance in the 
portal vein and hepatic artery were lower in livers that first underwent oxygenated hypothermic machine 
perfusion (HMP) versus livers that underwent static cold storage (SCS) only; however these differences 
were not statistically significant. Data are represented as medians with IQR. The error bar of SCS only group 
illustrates the range from the median (50th percentile) till the 75 percentile; the error bar of the HMP group 




of preservation solution, and the ET-DRI. The median ET-DRI was 3.11 in the HMP 
group and 2.79 in the SCS only group, illustrating the poor baseline quality of these 
donor livers. Moreover, the total preservation time (including 2 hours of HMP) 
was not significantly different between livers that underwent HMP (11:37 hr:min, 
IQR 10:01 – 12:25 hr:min) and livers that only underwent SCS preservation (9:04 
hr:min, IQR 7:01 – 11:44 hr:min) prior to viability assessment using NMP. 
Vascular Resistance
Changes in vascular resistance of the portal vein and hepatic artery during NMP are 
presented in Figure 3A and B. Although the vascular resistance was lower in livers 
that first underwent HMP, compared to only SCS preservation, this difference did 
not reach statistical significance.   
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▶ Figure 4: Cumulative bile production and biliary composition during 6 hours of normothermic 
machine perfusion (NMP). Panel A: Two hours of oxygenated hypothermic machine perfusion (HMP) 
resulted in significantly higher bile production (mL/kg liver) during 6 hours of NMP, compared to SCS only 
(*p<0.05). The error bar of HMP group illustrates the range between the 50th and 75th percentile; the error 
bar of the SCS only group represents the range between the 25th and 50th percentile. Panel B: The cumulative 
secretion of total bilirubin (total μmol) in the last 30 minutes of NMP was significantly lower in the group 
with only SCS preservation, compared to livers that first underwent HMP (*p<0.05). The Y-axis is on a 
logarithmic scale (log 10). Panel C: The cumulative secretion of bicarbonate (HCO3-) (total μmol) in the last 
30 minutes of NMP was significantly higher in the group with HMP, compared to livers that underwent only 
SCS preservation (*p<0.05). Panel D: Comparison of biliary pH between the group with HMP and only SCS 
preservation, measured at the end of 6 hours NMP. In Panel B, C, and D data are represented as medians 
with IQR. In the group with HMP, one liver was excluded from the bile analysis because of hemobilia.
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Evaluation of Hepatobiliary Function
Bile production was used as marker of hepatocellular function and viability (12,16). 
During 6 hours of NMP, bile production was significantly higher in donor livers 
that first underwent HMP, compared to livers that underwent SCS alone (Figure 
4A). Moreover, based on the (cumulative) bile production during NMP, all livers in 
the HMP group met the criteria for good functioning livers, whereas only 42% of 
the livers that underwent SCS alone met these criteria (Table 2). In both groups, 
there was no association between the ET-DRI and bile production during NMP.   
The cumulative total biliary bilirubin concentration in the last 30 minutes of NMP 
was significantly higher in the group that underwent HMP, compared to livers 
that underwent only SCS preservation (Figure 4B). This finding is compatible with 
a better hepatocellular secretory function of livers in the HMP group. Similarly, 
HMP significantly improved the cumulative biliary bicarbonate secretion in the 
last 30 minutes of NMP, compared to only SCS preservation (Figure 4C). Moreover, 
median biliary pH after 6 hours of NMP was higher in the HMP group compared 
to livers that underwent SCS preservation only, but this difference did not reach 
statistical significance (Figure 4D).  
Concentrations of glucose and lactate in the perfusion fluid during HMP and NMP 
are presented in Figure 5. During HMP, a small increase in the levels of glucose 
and lactate was observed. During subsequent NMP, glucose and lactate levels were 
significantly higher in the SCS group compared to HMP preserved livers. With 
respect to glucose levels, these levels normalized in the HMP group (median 11.6 
mmol/L), whereas glucose levels in the SCS group remained elevated after 6 hours 
of NMP (median 27.5 mmol/L) (p = 0.009) (Figure 5A). In addition, in the SCS only 
group a significantly increase in the concentration of lactate was noticed in the 
first hour of NMP (median peak value of 10.1 mmol/L), which was not observed 
in the HMP group (median 2.3 mmol/L) (p = 0.002) (Figure 5B). Moreover, to 
maintain a physiological pH, significantly more sodium bicarbonate solution had 
to be administered to the perfusion fluid during NMP in the group of livers that 
underwent SCS only, compared to livers that first underwent 2 hours of HMP 
(Table 3). 
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Table 2. Bile Production During Ex Situ Viability Testing Using Normothermic Machine Perfusion of Livers that Underwent Static Cold Storage 
(SCS) Preservation Alone or SCS Followed by Oxygenated Hypothermic Machine Perfusion (HMP)
Group Liver (number) Eurotransplant 
donor risk index 
(ET-DRI)
Bile output between 
1.5 and 2.5 hrs NMP
(mL/kg liver)
Cumulative bile 
output at 2.5 hrs 
NMP
(mL/kg liver)
Meets both criteria 
for classification of 
good functioning liver 
during NMP viability 
testing1
SCS only
1 2.5 0.17 0.84 no
2 2.8 0.95 2.02 no
3 3.3 1.26 3.27 no
4 1.4 1.30 3.57 no
5 3.2 1.43 3.86 no
6 3.4 1.48 5.00 no
7 2.2 1.50 5.18 no
8 2.0 2.33 5.91 yes
9 2.5 2.37 7.86 yes
10 3.1 4.86 8.52 yes
11 3.2 5.53 10.20 yes
12 2.8 7.44 15.84 yes
SCS + HMP
1 2.4 2.67 6.70 yes
2 3.4 4.53 13.76 yes
3 2.9 5.41 15.15 yes
4 3.5 6.09 17.41 yes
5 3.2 21.38 49.05 yes
6# 3.0 - - -
Abbreviations used: HMP: hypothermic machine perfusion, SCS: static cold storage, NMP: normothermic machine perfusion.
1 Livers were classified as good functioning according to the following criteria: bile production of more than 2 mL/kg liver between 1.5 – 2.5 
hours of NMP, and cumulative bile production of more than 5 mL/kg liver after 2.5 hours of NMP. 




Evaluation of Hepatobiliary Injury
Release of injury markers during NMP was used to assess the degree of 
hepatobiliary injury. To correct for a wash-out effect of HMP, the relative increase 
in perfusate levels of AST, ALT, LDH, and gamma-GT during the first 30 minutes 
and after 6 hours were determined (Table 3). Except for gamma-GT, during the 
first 30 minutes of NMP, the relative increase in perfusate levels of AST, ALT, and 
LDH were significantly lower in the HMP group compared to the SCS only group. 
However, the relative increase in levels of AST, ALT, and LDH between the first 
30 minutes and 6 hours of NMP were not significantly different between the two 
groups, reflecting a similar level of hepatobiliary injury after 6 hours of NMP (Table 
3). Likewise, there were no significant differences in the biliary concentrations of 
LDH and gamma-GT after 6 hours of NMP, indicating that there was no significant 
difference in cholangiocyte injury (Table 3).  
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Figure 5: Perfusion fluid concentrations of glucose and lactate during 2 hours of oxygenated 
hypothermic machine perfusion (HMP) and 6 hours of normothermic machine perfusion (NMP). Panel 
A and B: Almost during the entire period of NMP, levels of glucose and lactate were significantly lower in 
the group of livers that first underwent 2 hours of HMP, compared to the group with only SCS preservation 
(*p<0.05). Data are represented as medians with IQR, except for the levels of lactate in the SCS only group, 
the error bars in this group illustrates the range between the 50th and 75th percentile.
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Evaluation of Hepatic Energy Status and Oxygen Consumption
Hepatic ATP concentration was used as an indicator of the cellular energy status. 
Hepatic ATP content was measured at the end of SCS, during and at the end of HMP 
and before, during and at the end of NMP, respectively (Figure 6A). In both groups, 
all livers were ATP-depleted at baseline after SCS. The median ATP concentration 
was 5 μmol/g protein in the HMP group versus 6.5 μmol/g protein in the SCS only 
group. During HMP, median ATP concentration increased >15-fold to 76 μmol/g 
protein (IQR 48-122 μmol/g protein). After 2 hours of HMP, while the perfusion 
fluid was changed, ATP concentration dropped; however, before start of NMP ATP 
concentrations were still significantly higher in the HMP group, compared to the 
SCS only group (15 μmol/g protein in the HMP group versus 6.5 μmol/g protein in 
the SCS only group). Moreover, hepatic ATP content increased more rapidly during 
the first hour of NMP in livers that first underwent HMP, compared to livers with 
SCS preservation alone. In addition, ATP levels in livers that underwent HMP 
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remained significantly higher compared to SCS only livers during the first 4 hours 
of NMP. Although not statistically significant, at the end of 6 hours of NMP, the 
median hepatic ATP content in the HMP group was 88 μmol/g protein (IQR: 12-118 
μmol/g protein), while it was only 24 μmol/g protein (IQR: 14-51 μmol/g protein) 
in the group with only SCS preservation. 
In parallel with changes in ATP concentration, the peak value of the oxygen 
consumption during NMP was significantly higher in livers that first underwent 
HMP (2.9.10-3 mL O2/min/gr liver) compared to livers with only SCS preservation 
(1.4.10-3 mL O2/min/gr liver) (Figure 6B).   
Histological Assessment 
Figure 7 provides histological evaluation of the hepatic biopsies at the end of 
the regular period of SCS and after 6 hours NMP viability testing. At baseline, 
Table 3. Biochemical Composition of the Perfusion Fluid and Bile during Normothermic Machine Perfusion (NMP) in the Groups with or 







pH 7.35 (7.30-7.40) 7.35 (7.26-7.42) 1.00
pCO2 (kPa)1 6.17 (5.20-6.64) 4.91 (4.57-5.40) 0.05
pO2 (kPa)1 63.9 (56.2-69.2) 70.2 (65.0-78.3) 0.032
sO2 (%)2 99 (98-100) 100 (0.99-100) 0.68
HCO3- (mmol/L) 25.0 (17.6-28.9) 18.7 (17.0-24.5) 0.15
Added NaHCO3 8.4% (mL)2 25.0 (2-50) 3.3 (0-10) 0.041
Injury markers3
AST Δ 0.00-0.50 hrs NMP (U/L) 4073 (2266-10,307) 605 (178-2000) 0.010
AST Δ 0.50 – 6 hrs NMP (U/L) 4268 (1928-5400) 1730 (173-4210) 0.22
ALT Δ 0.00-0.50 hrs NMP (U/L) 2558 (1236-9671) 688 (109-2133) 0.048
ALT Δ 0.50 – 6 hrs NMP (U/L) 2397 (3110-952) 775 (100-2090) 0.18
LDH Δ 0.00-0.50 hrs NMP (U/L) 8858 (3526-14,480) 1139 (314-3843) 0.010
LDH Δ 0.50 – 6 hrs NMP (U/L) 2540 (1939-4189) 1339 (317-3252) 0.21
Gamma-GT Δ 0.00-0.50 hrs NMP (U/L) 51 (21-180) 72 (26-101) 0.80
Gamma-GT Δ 0.50 – 6 hrs NMP (U/L) 14 (5-34) 51 (0-156) 0.39
Bile contents4
Biliary LDH (mmol/L) 970 (204-1927) 418 (119-1005) 0.43
Biliary gamma-GT (mmol/L) 351 (242-1155) 504 (368-1186) 0.33
Data represent median with interquartile ranges (IQR) for continuous variables
Abbreviations used: AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, gamma-GT: gamma-
glutamyl transferase, NaHCO3: sodium bicarbonate, HMP: hypothermic machine perfusion, SCS: static cold storage
1 To convert kPa to mmHg, multiply by 7.5. 
2 Oxygen saturation of hemoglobin.
2 Total mL added to the perfusion fluid during 6 hours of NMP.  
3 Relative increase in hepatobiliary injury markers during NMP, indicated for the first 0.5 hour (Δ 0.00-0.50 hrs) and 0.5-6 hours of NMP (Δ 
0.50-6 hrs). 
4 In the HMP group, one liver was excluded from the analysis of bile contents because the collected bile was mixed with blood due to hemobilia. 
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Figure 6: Hepatocellular ATP concentrations and peak oxygen consumption during oxygenated 
hypothermic machine perfusion (HMP) and normothermic machine perfusion (NMP).  Panel A: In the 
first 4 hours of NMP, ATP concentrations were significantly higher in the group of livers that underwent 
HMP, compared to livers that underwent only static cold storage (SCS) preservation (*p<0.05). Data are 
represented as medians with IQR, except for the levels of ATP in the SCS only group, the error bars in this 
group illustrates the range between the 25th and 50th percentile. Panel B: The peak oxygen consumption (mL 
O2/min/gram liver) during NMP was significantly higher in the group with HMP, compared to the group with 
only SCS preservation (*p<0.05). Data are represented as medians with IQR.
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there were no statistical differences in the degree of ischemic necrosis between 
both groups. The majority of livers had signs of ischemic necrosis grade 1 or 
grade 2 (Figure 7A). In addition, there was no major increase in the amount of 
ischemic necrosis after NMP in both groups (Figure 7B). Examples of normal liver 
parenchyma and different grades of ischemic necrosis are presented in Figure 7, 
panels C-H. In addition, no major differences between the groups were noticed in 
the degree of intrahepatic bile duct injury at the end of 6 hours NMP (Figure 8). 
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Figure 7: Comparison of the degree of ischemic necrosis between livers that underwent 2 hours of 
oxygenated hypothermic machine perfusion (HMP) after static cold storage (SCS) and those that 
underwent SCS preservation alone, and examples of different grades of ischemic necrosis. Panel A 
and B: There were no statistical differences in the degree of ischemic necrosis at the end of regular SCS 
preservation and after 6 hours of normothermic machine perfusion between the two groups. Panel C and 
D: Examples of liver parenchyma without ischemic necrosis. Panel D is a detailed picture of Panel C. Panel 
E and F: Grade 1 ischemic necrosis (0-30% of hepatocytes involved). Panel F is a detailed picture of Panel E. 
Panel G and H: Ischemic necrosis grade 2 (30-60% of hepatocytes involved). Panel H is a detailed picture of 
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Figure 8: Histological comparison of intrahepatic bile duct injury at the end of 6 hours normothermic 
machine perfusion (NMP). There were no differences in the degree of intrahepatic biliary injury between 
livers that underwent oxygenated hypothermic perfusion (HMP) after static cold storage (SCS) preservation 
and livers that underwent SCS alone. Panel A: example of intrahepatic bile duct in a liver of the SCS only 
group. Panel B: example of intrahepatic bile duct in a liver of the HMP group. White arrows point at the 
intrahepatic bile ducts. Scale bars indicate 20 μm. 
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Discussion
The aim of the this study was to assess whether 2 hours of end-ischemic 
oxygenated HMP after the regular period of SCS restores hepatobiliary function 
and reduces injury in human ECD livers, as assessed during 6 hours of ex situ NMP 
viability testing. Our study demonstrated that 2 hours of HMP after traditional 
SCS significantly improves hepatobiliary function compared to SCS preservation 
alone. These improvements in hepatobiliary function are likely explained by a 
significant increase in hepatic ATP content during HMP. Although livers that 
underwent HMP after SCS displayed better function during NMP, compared to 
livers that underwent SCS alone, we did not observe significant differences in the 
amount of hepatobiliary injury. 
The results of this study suggest that the benefit of oxygenated end-ischemic 
HMP is a result of a restoration of the oxygen debt and recovery of mitochondrial 
function prior to warm reoxygenation. By providing oxygen, mitochondria are 
able to generate ATP even if the donor liver is kept at a low temperature. Our 
study results support previous experimental studies using animal models that 
oxygenated end-ischemic HMP is able to enhance the energy status of the cold-
stored graft and subsequently improved function after warm reoxygenation (17,18). 
In our study, HMP enhanced the hepatic ATP content more than 15-fold compared 
to values immediately after SCS. Moreover, the ATP levels remained significantly 
higher during the first 4 hours of NMP in the group of livers that underwent HMP 
compared to livers that were only preserved by SCS. In parallel with the enhanced 
ATP levels in livers that underwent HMP, these livers displayed a higher oxygen 
consumption and produced significantly more bile, compared to livers that did 
not undergo HMP. The link between increased bile production and higher ATP 
levels has also been described in porcine livers (16). Bile production is an energy 
Binnenwerk_Andrie_Final.indd   155 12/20/15   11:02 AM
156
9
consuming process and sufficient hepatocellular levels of ATP are needed for the 
active secretion of bile acids, bile salts, bilirubin, cholesterol, and other organic 
molecules into bile. Similarly, higher levels of biliary bilirubin were noticed in 
livers that first underwent HMP, reflecting better hepatocellular function of these 
livers. 
Other evidence of improved hepatobiliary function after end-ischemic HMP 
was provided by stable concentrations of glucose and lactate in the perfusion 
fluid during NMP. Notably, lactate, which can be seen as a marker of anaerobic 
metabolism, did not increase during NMP of livers that first underwent HMP after 
SCS, while a clear peak in the lactate concentration was observed in the SCS alone 
group.
In contrast to the regenerated hepatic ATP and improved functional recovery in 
livers that first underwent HMP, we did not observe a reduction in the amount of 
hepatobiliary injury. There were no significant differences in the concentration 
of hepatobiliary injury markers such as AST, ALT, and LDH in the perfusion fluid 
at the end of 6 hours NMP between the two study groups. In parallel with this, 
there were no significant differences in the histological degree of hepatic ischemic 
necrosis at the end of SCS and after 6 hours NMP. Almost 70% of livers in both 
groups displayed some degree of ischemic necrosis at baseline. This is not a surprise 
as all livers were declined for transplantation and derived from donors with a high 
ET-DRI. Moreover, 15 of the 18 livers included in this study were obtained from 
DCD donors and suffered a donor warm ischemia time of more than 30 min. The 
combination of suboptimal graft quality, substantial donor warm ischemia time, 
and the subsequent period of SCS (median 7-9 hours) can explain the observed 
hepatocellular injury at baseline. It is obvious that 2 hours of end-ischemic HMP 
does not restore pre-existing hepatocellular injury; however it does restore cellular 
function of the remaining vital parts of the liver. 
Next to a better functional recovery of hepatocellular function, we also observed 
an improved cholangiocellular function in livers that first underwent HMP. An 
important aspect of cholangiocyte function is the secretion of bicarbonate into 
bile. Cholangiocytes actively secrete bicarbonate to increase biliary pH and protect 
themselves against the effects of toxic hydrophobic bile salts. This phenomenon 
has been described as the biliary “bicarbonate umbrella” (14,19). In an alkaline 
environment, bile salts are deprotonated, which is clinically relevant as protonated 
bile salts can passively enter cells by uncontrolled membrane permeation, causing 
apoptosis (14,19). Several experimental and clinical studies have shown that bile salt 
toxicity is associated with the development of NAS after liver transplantation (20-
22). Therefore, the increased secretion of bicarbonate can be seen as an important 
and promising feature of end-ischemic HMP in human liver transplantation.
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In the current study, end-ischemic HMP was performed using dual perfusion of 
both the portal vein and the hepatic artery. Bile ducts are largely dependent on 
arterial blood supply for the delivery of oxygen and nutrients and we believe that 
dual perfusion results in better preservation and functional recovery of the biliary 
epithelium than portal vein perfusion alone. It is well known that hepatic artery 
thrombosis after transplantation leads to insufficient oxygenation of the biliary 
epithelium and subsequent development of ischemic biliary strictures (23). 
Moreover, in a mouse model, we have previously shown that complete arterial 
deprivation results in a loss of bile secretory function and subsequent intrahepatic 
cholestasis (24). In the current study, cholangiocellular bicarbonate secretion was 
significantly higher in livers that first underwent HMP. We, therefore, propose that 
combined arterial and portal perfusion during HMP has a potential advantage in 
the post-ischemic recovery of the bile ducts in comparison with single perfusion 
through the portal vein alone. However, this still needs to be demonstrated in a 
separate study comparing single versus dual liver perfusion.
The aim of the current study was not to study whether HMP reduces clinical 
ischemia-reperfusion injury. Ex situ NMP was performed with perfusion fluid 
consisting of plasma, red blood cells and nutrients, but no leukocytes and 
platelets, with the aim to assess liver graft viability and function after either SCS 
or SCS followed by HMP. To examine whether HMP is not only associated with a 
restoration of hepatic ATP and hepatobiliary function prior to transplantation, but 
also reduces ischemia/reperfusion injury, a clinical trial is needed. Based on the 
favorable results of the current study, we recently initiated a clinical trial in which 
end-ischemic HMP is applied in DCD liver transplantation (Dutch Trial Register 
no. NTR 4493; www.trialregister.nl).      
In conclusion, this study demonstrates that a short period of two hours of end-
ischemic oxygenated HMP after traditional SCS of ECD livers results in a restoration 
of intrahepatic energy resources. The higher hepatocellular energy levels in 
livers that underwent HMP corresponded with a significantly better recovery of 
hepatobiliary function as assessed during ex situ NMP, when compared with livers 
that underwent only SCS preservation. Despite this better immediate hepatobiliary 
function, end-ischemic oxygenated HMP does not seem to reduce (pre-existing) 
hepatobiliary injury. The beneficial effects of end-ischemic oxygenated HMP in 
this preclinical study provide strong support for further testing end-ischemic 
oxygenated HMP in a clinical liver transplant trial. 
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End-Ischemic Machine Perfusion Reduces Bile Duct Injury 
In Donation Aft er Circulatory Death Rat Donor Livers 
Independent of the Machine Perfusion Temperature




Background: A short period of oxygenated machine perfusion (MP) after static 
cold storage (SCS) may reduce biliary injury in donation after circulatory death 
(DCD) donor livers. However, the ideal perfusion temperature for protection of 
the bile ducts is unknown. In this study, the optimal perfusion temperature for 
protection of the bile ducts was assessed. 
Methods: DCD rat livers were preserved by SCS for 6 hours. Thereafter, 1 hour of 
oxygenated MP was performed using either hypothermic (HMP), subnormothermic 
(SNP) or with controlled oxygenated rewarming (COR) conditions. Subsequently, 
graft and bile duct viability were assessed during 2 hours of normothermic ex situ 
reperfusion. 
Results: In the MP study groups, lower levels of transaminases, LDH and TBARS 
were measured compared to SCS. In parallel, mitochondrial oxygen consumption 
and ATP production were significantly higher in the MP groups. Biomarkers of 
biliary function, including bile production, biliary bicarbonate concentration 
and pH, were significantly higher in the MP groups, whereas biomarkers of 
biliary epithelial injury (biliary gamma-GT and LDH) were significantly lower in 
MP preserved livers. Histological analysis revealed less injury of large bile duct 
epithelium in the MP groups, compared to SCS. 
Conclusion: Compared to SCS, end-ischemic oxygenated MP of DCD livers provides 
better preservation of biliary epithelial function and morphology, independent of 
the temperature at which MP is performed. End-ischemic oxygenated MP could 
reduce biliary injury after DCD liver transplantation. 




Ischemic cholangiopathy, also known as non-anastomotic biliary strictures 
(NAS), is one of the most prevalent and troublesome complication after liver 
transplantation. During NAS formation, in particular, the large (extrahepatic) 
bile ducts become fibrotic and/or necrotic. Patients with NAS may suffer from 
recurrent jaundice and episodes of cholangitis and retransplantation may be the 
only curative treatment (1). The combination of ischemia and ischemia/reperfusion 
(I/R) injury has been shown to be a major risk factor for the development of NAS 
after transplantation (2). The combination of ischemia and I/R injury can lead to 
impaired regeneration of the biliary epithelium with subsequently NAS formation 
as clinical consequence (3,4).
A short period of end-ischemic machine perfusion (MP) after the regular period of 
static cold storage SCS has been shown to reduce I/R injury, compared to static cold 
storage (SCS) alone (5). Although the exact mechanisms underlying the protective 
effects of end-ischemic MP are not fully known, an important feature of end-
ischemic MP is the resuscitation of mitochondrial respiration and resynthesis of 
cellular adenosine triphosphate (ATP) (5,6). Restoration of cellular ATP improves 
metabolic function after reperfusion, making the hepatocytes and cholangiocytes 
more resistant to the effects of I/R injury (5,6). Although recent data from animal 
models and (discarded) human donor livers have provided promising results 
suggesting that end-ischemic MP has relevant protective effects on the bile ducts 
of DCD liver grafts, the most optimal perfusion temperature during end-ischemic 
MP has not been investigated (7-17). Aim of this study is, therefore, to assess the 
optimal perfusion temperature during end-ischemic oxygenated MP for protection 
of the large bile ducts against I/R injury in a DCD rat liver model. 
Materials and methods
Animals
Male Lewis rats (LEW/Han®Hsd)(290-320 g) were obtained from Harlan Labora-
tories (Boxmeer, the Netherlands). Animals received care according to the guide-
lines set by the US National Institutes of Health (1985). The study protocol was 
approved by the Institutional Animal Care and Use Committee of the University of 
Groningen, the Netherlands (IACUC-RuG).
Experimental Design
Thirty rat livers were divided into four experimental groups and a reference group 
(n = 6 per group). The four experimental groups were used to study the effects of 
end-ischemic MP, while the reference group was used for in vivo collection of bile 
during 2 hours of anesthesia (Figure 1). In the four experimental groups, livers 
were procured from DCD donors and subsequently preserved by SCS in histidine-
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Figure 1: Schematic representation of the experimental groups to examine the effects of end-ischemic 
machine perfusion (MP) at three different perfusion temperatures: hypothermic 8°C (HMP), controlled 
oxygenated rewarming 8-20°C (COR), and subnormothermic 20°C (SNP). A group of DCD livers underwent 
only static cold storage without end-ischemic MP (SCS alone). For normal values of bile composition, bile 
was collected 2 hours in vivo in the reference group. All groups contained 6 rat livers. 
10
tryptophan-ketoglutarate (HTK) preservation solution (Custodiol, Essential 
Pharmaceuticals, Ewing, NJ, USA) for 6 hours. To study the effects of end-ischemic 
MP, the 6 hours of SCS were followed by 1 hour end-ischemic oxygenated MP at 3 
different perfusion temperatures. The fourth group consisted of livers that were 
preserved by 6 hours of SCS alone (Figure 1). MP was performed at hypothermic 
conditions (8°C [HMP]), subnormothermic conditions (20°C [SNP]) or with 
controlled oxygenated rewarming [COR], using Belzer machine perfusion solution 
(MaPerSol, Bridge-to-Life, Ltd. Northbrook, IL, USA). During COR, the temperature 
of the perfusate was kept at 8°C for the first 20 minutes and then gradually 
increased from 8 to 20°C in the next 20 minutes. For the last 20 minutes of the COR 
phase, the perfusion temperature was kept at 20°C. Prior to reperfusion, all livers 
were flushed with 10 mL of cold saline and subsequently stored on a petri dish, 
covered with a wet gauze at room temperature for 60 minutes, to mimic surgical 
implantation of the liver. Subsequently, liver grafts were reperfused ex situ for 2 
hours with a perfusion fluid consisting of 25 mL human red blood cell concentrate 
(final hematocrit 25%) (Sanquin, Amsterdam, the Netherlands), 53.9 mL William’s 
Medium E solution (Life Technologies Europe, Bleiswijk, the Netherlands), 20 mL 
human albumin (200 g/L Albuman, Sanquin, Amsterdam, the Netherlands), 1 mL 
insulin (100 IE/mL Actrapid, Novo Nordisk, Alphen aan den Rijn, the Netherlands) 
and 0.1 mL unfractionated heparin (5000 IE/mL, LEO Pharma A/S, Ballerup, 
Denmark), adding up to a total volume of 100 mL.     
In vivo Bile Collection and Procurement of DCD Donor Livers
Inhalation anesthesia with isoflurane and oxygen was used before and during the 
procurement (2-3% isoflurane). First, the large bile duct was cannulated. For the 
reference groups, the rats were supported with mechanical ventilation and bile was 
collected for 2 hours in Eppendorf tubes. The procedures of DCD and in situ WIT 
(30 min) have been described previously (18). In brief, 1 mL 0.9% NaCl with 500 
IU of heparin was administered via the dorsal penile vein. After heparinization, 
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cardiac arrest was induced by external compression of the heart (tamponade) until 
contractions ceased. Subsequently, the aorta was closed using a vascular clamp 
rostral from the heart for 30 minutes. The thoracotomy and laparotomy wounds 
were covered with gauze, moistened with 0.9% NaCl. To prevent cooling, a heating 
lamp was placed above the rat. After 30 minutes in situ WIT, the hepatectomy was 
performed by ligation of the splenic vein, mesenteric artery, and mesenteric vein. 
Thereafter, the celiac trunk was cannulated. After clamping of the infra-hepatic 
vena cava and the portal vein, the portal vein was cannulated and via the portal vein 
cannula, the liver was flushed in situ with 10 mL 0.9% NaCl (37°C). Subsequently, 
the supra-hepatic vena cava was transected, followed by a cold flush out with 5 mL 
HTK preservation solution (4°C) via the portal vein cannula. The liver was removed 
and flushed with an additional 20 mL of cold (4°C) HTK via the portal vein cannula 
and 5 mL of cold (4°C) HTK via the hepatic artery (celiac trunk cannula) before 
preservation by SCS. 
Static Cold Storage, End-Ischemic Machine Perfusion and Ex situ Reperfusion 
For SCS, livers were stored in bags with ice-cold HTK (4°C) on melting ice for 6 
hours. End-ischemic MP and ex situ reperfusion of rat donor livers was performed 
with a liver machine perfusion system that enabled dual perfusion via both the 
hepatic artery and the portal vein using a closed circuit (Figure 2). Two roller 
pumps (Ismatec ISM404 + ISM719 and MS-2/6-160; IDEX Health & Science, 
Wertheim-Mondfeld, Germany) provided pulsatile flow through the hepatic artery 
and continuous flow through the portal vein. Continuous flow to the portal vein 
was achieved by the combination of elastic tubing and a pulse damper to remove 
pulses from the roller pump. Two tubular membrane oxygenators provided 
oxygenation of the perfusion solution and removal of CO2. Perfusion box and 
perfusate temperature was maintained stable at the indicated temperatures 
using a thermostat pump (Huber, Offenburg, Germany) and radiator/ventilator 
combination (Freezing Hardware, Losser, the Netherlands). The system was 
pressure-controlled by a computer algorithm allowing autoregulation of blood 
flow through the liver, with constant pressure at variable flow rates. In-line sensors 
monitored flow, pressure, and temperature. Data were displayed in real-time on a 
connected laptop.  
During HMP (8°C), the portal pressure was 3 mmHg and mean arterial pressure 
was 25 mmHg. During SNP (20°C), the portal pressure was set at 4 mmHg and mean 
arterial pressure at 40 mmHg. During the first 20 minutes of COR, the same portal 
and arterial pressure were used as during HMP. Thereafter, the perfusion solution 
was gradually warmed up to 20°C in 20 minutes and for the last 20 minutes the 
pressures were set at levels used during SNP (4 and 40 mmHg, respectively). Ex 
situ reperfusion (37°C) was performed with a mean arterial pressure of 110 mmHg 
and 11 mmHg at portal side. During end-ischemic MP and ex situ reperfusion, the 
perfusion fluid was oxygenated with 100% 02 and the pO2 was 60-80 kPa (450-
600 mmHg), as described previously (8,11,15,19).
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◀ Figure 2: Schematic presentation of the rat liver machine perfusion system providing a combination 
of arterial and portal perfusion of the liver. Two roller pumps provide a continuous flow to the portal 
vein (A) and a pulsatile flow to the hepatic artery (B). Pulses in the portal flow were eliminated with elastic 
tubing and a pulse damper (C). Two tubular membrane oxygenators provide oxygenation of the perfusion 
solution, as well as removal of CO2 (D). Several bubble traps (three-way connectors) were used to eliminate 
air bubbles in the perfusion solution (E). Flow (Φ) and pressure (P) were detected by in-line sensors and 
data were displayed and analyzed in real-time on a connected laptop (F). The perfusion temperature was 
maintained constant by two heat exchangers (G) and a radiator/ventilator combination (H), all connected 
to the thermostat pump (I). For real time control of the perfusion temperature, one in-line temperature 
sensor (T) was connected to the thermostat pump. The isolated box encapsulated the perfusion system (J) 
preventing loss of warm or cold air. The rat liver was placed into an organ chamber (K). Bile was collected in 
Eppendorf tubes (L). By the three-way connector at the portal side, samples of the perfusion solution were 
taken every 30 min for analysis of the perfusate (M).
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Biochemical Markers of Function and Injury
During ex situ reperfusion, flow, and temperature were registered every 10 minutes. 
Before reperfusion and after every 30 minutes of reperfusion, samples were taken 
from the perfusion fluid. Samples were centrifuged (2700 g for 5 min at 4°C) and 
the supernatant was collected, frozen and stored at -80°C for determination of 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate 
dehydrogenase (LDH), using standard biochemical methods.  
Bile production was measured at 60-minute intervals by weighing Eppendorf 
tubes in which bile was collected from the biliary drain. Biliary epithelial cell 
function was assessed by measuring pH and bicarbonate concentration in bile 
(20). For this purpose, bile samples were collected under mineral oil and analyzed 
immediately using an ABL800 FLEX analyzer (Radiometer, Brønshøj, Denmark). 
Biliary concentration of gamma-glutamyl transferase (gamma-GT) and LDH were 
measured as biomarkers of biliary epithelial cell injury (21), and biliary bilirubin 
concentration was measured as biomarker of hepatocellular secretory function 
(21), using standard biochemical methods. 
Thiobarbituric acid reactive substances (TBARS) were measured in perfusate 
samples after 2 hours of reperfusion, as a marker for oxidative stress. The method 
for TBARS measurements has been described previously (12).
Isolation of Mitochondria and Mitochondrial Oxygen Consumption Analysis
Mitochondria isolation and mitochondrial oxygen consumption analysis were 
performed after 2 hours ex situ reperfusion. The protocol for isolation and 
oxygen consumption measurement has been described before (22). In brief, 
oxygen consumption was measured with a Clark type electrode (Strathkelvin 
Instruments LTD, North Lanarkshire, UK). This electrode was placed in a double 
walled respiration chamber with continuous stirred suspension of the isolated 
mitochondria (2 mg/mL) and oxygen consumption buffer at 37°C. Basal oxygen 
consumption of the mitochondria (state 2 respiration) was measured after addition 
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of glutamate (10 mM) and malate (2 mM) as substrates to stimulate complex I, 
III, and IV. Maximal respiration rate (state 3 respiration) was measured after 
addition of adenosine diphosphate (ADP) (5 mM), which causes a sudden burst 
of oxygen uptake as the ADP is converted into ATP by ATPase synthase (complex 
V). Oligomycin (2.5 μM) was used to stop ATPase synthase by blocking complex 
V (defined as state 4 respiration). Rates of oxygen consumption were expressed 
as μmol O2/min/mg liver. The mitochondria respiratory control ratio (RCR) was 
defined as the ratio of state 3 and state 4. The function of the RCR is to reflect the 
viability of the mitochondria (23).
Adenosine triphosphate (ATP) Extraction and Measurement
Hepatic concentration of ATP was used as an indicator of the energy status of 
grafts after 2 hours of ex situ reperfusion. Method for extraction and measurement 
has been described previously (12). 
Histological Evaluation of the Large Bile ducts
After 2 hours of ex situ reperfusion, a segment of the large bile duct proximal from 
the tip of the biliary catheter (and therefore not mechanically injured) was dissected 
and stored in 10% formaldehyde for inclusion in paraffin. Paraffin-embedded slides 
were cut with 0.5 mm interspaces, resulting in 3 slides per bile duct. In addition, 
staining was performed with hematoxylin and eosin (H&E) staining. Large bile 
duct injury was semi-quantified using a systematic scoring system described by 
Hansen et al. (24) with adjustments according to op den Dries et al. (4). All bile 
duct sections were examined in a blinded fashion by two investigators (ACW and 
SLM) under supervision of an experienced liver pathologist (ASHG) using light 
microscopy. 
Statistical Analyses
Continuous data were presented as median and interquartile range (IQR). Mann-
Whitney U test was used to compare groups and the Kruskal-Wallis test was 
used for statistical comparison of > 2 groups. Categorical data were expressed as 
numbers and percentage and groups were compared using Pearson chi-square 
test or Fischer’s exact test where appropriate. The level of significance was set at 
a p-value < 0.05. Analyses were performed using SPSS software version 22.0 for 
Windows (SPSS Inc., Chicago, IL, USA).
Results
End-ischemic MP Provides Better Protection of Hepatocellular Function
Portal vein and hepatic artery resistance during 2 hours of ex situ reperfusion 
were influenced by end-ischemic MP treatment. At the portal side (Figure 3A), 
the vascular resistance was significant lower after end-ischemic COR and SNP 
preservation in comparison to livers only preserved with SCS. Although the 
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Figure 3: Vascular flow resistance in the portal vein and the hepatic artery during 2 hours of ex situ 
reperfusion. Panel A: During reperfusion, livers treated with end-ischemic MP controlled oxygenated 
rewarming (COR) and subnormothermic machine perfusion (SNP) had significantly lower portal vein 
resistance in comparison to liver preserved by SCS alone (*p<0.05). Livers treated with hypothermic 
machine perfusion (HMP) displayed a significantly lower portal vein resistance during the last 30 minutes of 
reperfusion, compared to SCS alone (#p<0.05). Panel B: During the last hour of reperfusion, livers that were 
preserved by SCS alone had a significant higher hepatic artery resistance compared to liver that underwent 
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portal vascular resistance after end-ischemic HMP was similar to the SCS alone 
group during the first hour of reperfusion, resistance during the second hour of 
reperfusion was significantly lower in the end-ischemic HMP group, compared 
to only SCS preservation. At the side of the hepatic artery, end-ischemic HMP, 
COR, and SNP resulted in a significant reduction of the vascular resistance 
during the second hour of reperfusion (Figure 3B). Taken the vascular resistance 
characteristics of the portal vein and hepatic artery during the second hour of 
reperfusion together, the results suggest better vascular hemodynamics after end-
ischemic MP (HMP, COR, and SNP) compared to only SCS preservation. 
After 2 hours of reperfusion, no statistically significant differences were found in 
the mitochondrial respiration and ATP production between the three end-ischemic 
MP groups. By adding ADP to stimulate ATP synthesis in the isolated mitochondria 
from livers that underwent one of the three temperature protocols of end-ischemic 
MP (HMP, COR, and SNP), the levels of oxygen consumption in mitochondria 
(state 3 respiration) were significantly higher compared to SCS alone (Figure 4A). 
In parallel, the RCR, a marker for mitochondria viability, was significantly higher 
in the three end-ischemic MP preserved groups (HMP, COR, and SNP), compared 
to preservation by only SCS (Figure 4B). In accordance with these isolated 
mitochondrial function analyses, cellular ATP levels were significantly higher in 
the three groups of end-ischemic MP compared to SCS alone (Figure 4C). 
In line with the enhanced mitochondrial function after end-ischemic MP, also 
hepatic bile production after reperfusion was significantly higher in the three 
end-ischemic MP groups (HMP, COR, and SNP), compared to the group with 
SCS alone (Figure 5A). No significant differences in bile production were found 
between the three end-ischemic MP groups. Nevertheless, in all the end-ischemic 
MP groups’ bile production during ex situ reperfusion remained lower than the 
in vivo bile production in the reference group. Biliary bilirubin concentrations 
were comparable among the three experimental groups (HMP, COR, and SNP), 
and in vivo reference group. However, the SCS preserved livers demonstrated 
significantly lower levels of biliary bilirubin (Figure 5B).
End-ischemic MP Reduces Hepatocellular Injury
Hepatocellular injury after ex situ reperfusion was significantly less in the three 
end-ischemic MP groups, compared to livers preserved by SCS alone. In the first 
30 minutes of reperfusion, markers for hepatocellular injury, including levels 
of AST, ALT, and LDH in the perfusion fluid, were significantly lower in the end-
ischemic MP groups (HMP, COR, and SNP), compared to livers preserved by SCS 
alone (Figure 6A). Similarly, after 2 hours of reperfusion, levels of the oxidative 
stress biomarker TBARS were significantly lower in the end-ischemic MP treated 
groups (HMP, COR, and SNP) (Figure 6B). 
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Figure 4: Mitochondrial respiration function and hepatocellular ATP concentrations after 2 hours ex situ 
reperfusion. Panel A: Oxygen consumption rates after the addition of adenosine diphosphate ADP (state 3 
respiration) was significantly higher in livers that underwent 1 hour end-ischemic hypothermic MP (HMP), 
end-ischemic controlled oxygenated rewarming (COR) MP, and subnormothermic machine perfusion (SNP) 
compared to livers that underwent SCS alone (*p<0.05). There were no significant differences between 
the three end-ischemic MP groups. Panel B: The respiratory control ratio (RCR) was significantly higher in 
the three end-ischemic MP groups, compared to SCS alone (*p<0.05). The RCR value was not significantly 
different between the three end-ischemic MP groups. Panel C: Cellular ATP concentration (μmol/gr protein) 
after 2 hours of reperfusion was significantly higher in livers that first underwent 1 hour of end-ischemic 
MP in comparison to SCS alone (*p<0.05). Again, there were no significant differences in ATP production 
between the three groups with different temperatures protocols for end-ischemic MP (HMP, COR, and 
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Figure 5: Bile production and bilirubin concentration in bile after 2 hours of ex situ reperfusion. Panel A: 
End-ischemic hypothermic (HMP), controlled oxygenated rewarming (COR) and subnormothermic machine 
perfusion (SNP) resulted in significantly higher bile volumes during the first and second hour of reperfusion 
compared to SCS alone (*p<0.05). There were no significant differences in bile production between the 
three end-ischemic MP groups. In general, however, bile production was significantly lower in livers that 
were preserved by HMP, COR, SNP or SCS alone, compared to values obtained in vivo (#p<0.05). Panel B: The 
concentration of biliary bilirubin was significantly lower in the group with only SCS preservation compared 
to the three MP groups and the reference group with in vivo bile measurements (*p<0.05). Between the 
three MP study groups and reference group no significant differences were measured in the biliary bilirubin 
concentration. Data are represented as medians with IQR (error bars).
10
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Figure 6: Biochemical markers of hepatocellular injury and a marker of oxidative stress (TBARS) 
measured in the perfusion fluid during 2 hours ex situ reperfusion. Panel A-C: Concentrations of AST, 
ALT, and LDH into the perfusion solution during the first 30 minutes of reperfusion. Concentrations of AST, 
ALT, and LDH during the first 30 minutes of reperfusion were significantly lower in livers that underwent 
end-ischemic hypothermic MP (HMP), controlled oxygenated rewarming (COR) MP, or subnormothermic 
MP (SNP), compared to livers that underwent only SCS (*p<0.05). There were no significant differences 
in levels of AST, ALT, and LDH between end-ischemic HMP, COR, and SNP preserved livers. Panel D: After 
2 hours of reperfusion, levels of TBARS were significantly higher in the SCS alone preserved livers versus 
the end-ischemic MP treated groups (HMP, COR, and SNP) (*p<0.05). No differences in TBARS levels were 
noted between the end-ischemic MP groups. Data are represented as medians with IQR (error bars).
10
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Figure 7: Biochemical markers of cholangiocyte function and injury measured in bile after 2 hours of 
ex situ reperfusion. Panel A and B: Markers of cholangiocyte function: bicarbonate (HCO3-) concentration 
and pH detected in bile. Biliary bicarbonate concentrations were significantly higher in livers that had 
been preserved by end-ischemic hypothermic MP (HMP), controlled oxygenated rewarming (COR) MP 
or subnormothermic MP (SNP), compared to livers that underwent only SCS (*p<0.05). There were no 
significant differences in biliary bicarbonate concentrations among the three machine perfusion groups 
(HMP, COR, and SNP).  The concentration of biliary bicarbonate collected in vivo was significantly higher 
compared to the three end-ischemic MP groups (HMP, COR, and SNP) and the SCS alone group (#p<0.05). 
Panel B: The biliary pH was in the three end-ischemic MP groups comparable with the pH measured in the 
bile samples collected from the reference group with in vivo bile collection. Moreover, the livers with only 
SCS as preservation demonstrated significantly lower biliary pH than the three MP study groups and the 
group with in vivo bile collection (*p<0.05). There were no significant differences in biliary pH between the 
three end-ischemic MP groups. Panel C and D: The biomarkers for cholangiocyte injury, LDH and gamma-GT, 
were similar in the three end-ischemic MP groups (HMP, COR, and SNP) and the reference group with in 
vivo bile collection. In bile samples of livers preserved only with SCS, significantly higher values of LDH and 
gamma-GT were measured, compared to the end-ischemic MP groups and the group with in vivo collected 
bile (*p<0.05). Data are represented as medians with IQR (error bars). 
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End-ischemic MP Improves Cholangiocyte Function and Reduces Cholangiocyte 
Injury
Biliary bicarbonate concentration after 2 hours of reperfusion was significantly 
higher in the three groups of end-ischemic MP (HMP, COR, and SNP), compared 
to the group with SCS alone (Figure 7A). No significant differences were observed 




Figure 8: Hematoxylin and eosin (H&E) staining of the large bile duct biopsies after 2 hours ex situ 
reperfusion. Panel A: SCS preservation only. Black arrows indicate biliary epithelial cell loss (epithelium 
injury grade 1). White arrows indicate mural stroma necrosis (stroma necrosis grade 2). Panel B: End-
ischemic hypothermic MP. Panel C: End-ischemic controlled oxygenated rewarming MP. Panel D: End-
ischemic subnormothermic MP. Scale bars indicate 100 μm. 
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between the three end-ischemic MP groups. However, in all four experimental 
groups (HMP, COR, SNP, and SCS alone) biliary bicarbonate concentrations after 
reperfusion were significantly lower compared to values obtained in bile samples 
from in vivo measurements (reference group). Biliary pH after 2 hours reperfusion 
was significantly higher in the three end-ischemic MP groups (HMP, COR, and 
SNP) versus the SCS alone group (Figure 7B). In fact, there was no significant 
difference in biliary pH between the three experimental MP groups and the in vivo 
reference group. 
End-ischemic MP Provides Better Preservation of the Biliary Epithelial Lining 
of Large Bile Ducts
Injury of the epithelial lining of the lumen of large bile ducts was assessed by an 
established semi-quantitative histological grading using H&E staining. Livers 
that were preserved by SCS alone displayed significantly more grade 1 (< 50% of 
the circumferential lining) epithelial cell loss and significantly higher degrees 
of mural stroma necrosis (grade 1: < 25% and grade 2: 25-50%), compared with 
livers that underwent end-ischemic MP (HMP, COR, or SNP) (Figure 8 and 9). In 
fact, large bile duct biopsies of livers that underwent end-ischemic MP revealed 
only minimal injury of the epithelial cell layer and no signs of mural stroma 
necrosis. No differences were observed in the degree of vascular injury, incidence 
of vascular thrombosis, incidence of intramural bleeding, or degree of peribiliary 
gland injury among all study groups.
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Figure 9: Overview of the distribution of epithelium injury and mural stroma necrosis of the large bile 
ducts. Panel A: Livers that were preserved by SCS displayed a significantly higher frequency of epithelium 
injury grade 1 (< 50% mucosal loss) (*p<0.05). Panel B: Livers that were preserved by SCS displayed 
significantly more mural stroma necrosis grade 1 (< 25% stroma necrosis) and mural stroma necrosis grade 
2 (stroma necrosis 25-50%), compared with the three end-ischemic MP preserved groups (hypothermic 
MP, controlled oxygenated rewarming MP, and subnormothermic MP) (*p<0.05). There were no significant 
differences in epithelium injury or mural stroma necrosis between the end-ischemic MP groups. 
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Currently, there are three different perfusion temperature conditions that are 
most frequently applied in the context of end-ischemic MP: hypothermic (<10°C), 
subnormothermic (20°C), and controlled oxygenated rewarming (8-20°C). 
However, these three methods have not been examined head to head, and it remains 
unknown which temperature protocol provides the best protection against biliary 
injury. In the current study, we, therefore, examined which perfusion temperature 
provides the best protection against bile duct injury in DCD donor livers. 
Our study demonstrates that end-ischemic oxygenated MP significantly improves 
biliary function and morphology and reduces biliary cellular injury, compared to 
conventional SCS alone. Interestingly, this beneficial effect was independent of the 
temperature protocol used during end-ischemic MP. In addition, hepatocellular 
mitochondria oxygen consumption was enhanced after a short period of end-
ischemic MP, resulting in higher cellular ATP concentrations. Moreover, end-
ischemic MP mitigated hepatocellular injury during reperfusion and lowered 
oxidative stress, again independent of the temperature protocol used. 
It is well known that biliary epithelial cells (cholangiocytes) and the bile duct 
stroma cells are very sensitive to ischemia and relatively short periods of ischemia 
result in a rapid depletion of intracellular concentrations of ATP (25,26). Due to 
ATP depletion, cholangiocytes lose their attachment to the basement membrane, 
resulting in sloughing of the epithelium layer and denudation of the bile duct 
luminal surface. In our study end-ischemic MP significantly minimized the degree 
of biliary epithelial cell loss and reduced the degree of mucosal stroma necrosis in 
the large bile ducts to a minimum, compared to only SCS preservation. Recently, 
three independent clinical studies have demonstrated that major mucosal cell loss 
(> 50% biliary epithelial injury) and mural stroma necrosis (< 50% necrotic cells) 
of the large bile duct is present in more than 80% of human donor livers (both DBD 
and DCD) at the end of SCS and subsequent reperfusion (4,24,27). Although biliary 
preservation injury is apparently almost universally present, only a minority of 
liver recipients develop NAS after transplantation. This observation has led to 
the hypothesis that insufficient proliferation and regeneration of cholangiocytes 
from the peribiliary glands are important factors in the pathogenesis of NAS (3,4). 
In the current study, we did not observe differences in injury of the peribiliary 
glands between the groups with end-ischemic MP and only SCS preservation. 
These findings are in contrast with our histological study in human donor livers 
demonstrating substantial injury of the more peripheral layers of the bile duct 
wall, including the peribiliary biliary glands, after SCS preservation (4). This 
study indicated that the severity of bile duct injury decreases from the most 
central, periluminal layers toward the periphery of the bile ducts (4). This is 
compatible with the fact that blood supply to the bile ducts enters from the 
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periphery, resulting in the lowest oxygen tension in central structures situated 
near the lumen. Peribiliary glands are situated in the peripheral layers of the bile 
duct wall. Apparently, rat liver bile ducts are more resistant to ischemic injury 
than human bile ducts. Therefore, the rat DCD liver model used in the current 
study did not cause detectable injury of peribiliary glands. Although we did not 
observe differences in injury of the peribiliary glands between the groups, end-
ischemic MP significantly minimized the degree of biliary epithelial cell loss 
and reduced the degree of mucosal stroma necrosis to a minimum, compared 
to only SCS preservation. In parallel with these differences in histopathological 
assessment, we observed significantly lower biliary concentrations of biochemical 
markers of biliary epithelial injury, such as gamma-GT and LDH in bile. Moreover, 
in contrast to livers that were preserved by SCS alone, all three groups of end-
ischemic MP revealed a normal alkalotic biliary pH and improved bicarbonate 
secretion after reperfusion. Biliary secretion of bicarbonate by biliary epithelial 
cells is considered an important protective mechanism against the cytotoxic 
effects of hydrophobic bile salts, which is known as the “bicarbonate umbrella” 
(20,28). Early recovery of the biliary function after SCS is clinically relevant since 
hydrophobic bile salts have been shown to play a role in worsening biliary injury 
and subsequent formation of NAS after transplantation (29,30). Taken together, 
these findings indicate that a short period of oxygenated MP after conventional 
SCS not only reduces the amount of biliary epithelial injury after reperfusion, but 
also contributes to an early recovery of biliary bicarbonate secretion, which helps 
cholangiocytes to protect themselves against the cytotoxic effects of hydrophobic 
bile salts. 
So far, temperature conditions for end-ischemic MP have only been examined 
in animal studies, without special focus on biliary viability (15-17). Minor and 
coworkers (15) used a pig model to study liver graft viability during 4 hours of ex 
vivo reperfusion after living donation. During reperfusion, end-ischemic MP with 
COR was identified as the most protective temperature strategy. Interestingly, 
bile production, an important marker for liver function, was only significantly 
improved by end-ischemic COR and not by HMP or SNP. Moreover, bile production 
after end-ischemic MP at hypothermic or subnormothermic conditions was almost 
similar to the group with only SCS preservation. In this respect, our findings 
are different from those made by Minor et al. as we did not observe significant 
differences in bile production between livers that underwent end-ischemic 
HMP, SNP, or COR prior to reperfusion. A possible explanation for this could be 
a difference in organ quality, due to variations in the donation models. Minor and 
colleagues used livers obtained from living donation procedures, whereas we have 
used livers from DCD donors, who had suffered a period of 30 min warm ischemia 
prior to donor hepatectomy. The main difference between a living a donor and a 
DCD donor is the inevitable period of warm ischemia after cardiac arrest in the DCD 
donor. During this period of warm ischemia the liver has to switch from aerobic 
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to anaerobic conditions for ATP production. However, anaerobic production of 
ATP is by far not enough to fulfill the metabolic demand of the liver. This results 
in a severe ATP depletion prior to cold preservation. In contrast, during living 
donation, the liver is directly flushed with cold preservation solution, reducing 
metabolism and ATP consumption (31,32). Therefore, we hypothesize that DCD 
liver grafts used in our experiment have developed a more severe oxygen debt 
and sustained more hepatocellular injury at baseline, compared to liver grafts 
from a living donor. Because of this higher degree of cellular injury in DCD grafts, 
the effects of resuscitation by end-ischemic MP may be different and even more 
pronounced, compared to end-ischemic MP in living donor grafts. Our data 
indicate that a short period of oxygenated machine perfusion after conventional 
SCS of liver grafts obtained from DCD donors results in effective restoration of 
mitochondrial function and cellular ATP concentrations, which is independent of 
the temperature at which the liver is perfused.  
Some limitations of this study should be mentioned: we did not examine the 
effects of end-ischemic MP at body temperature (normothermic, 37oC). Other 
studies have demonstrated that short periods of normothermic MP after SCS are 
not better than SCS preservation alone. In fact, a short period of normothermic 
MP after conventional SCS may not be any different from immediate implantation 
and reperfusion of a liver graft in the recipient. In both situations the whole 
cascade of I/R injury will be activated without a conditioning or protective effect 
of MP (5,33,34). Another limitation of our study is the ex situ reperfusion model. 
Although this model, which has also been used by other groups (9,12,14,15), 
allowed us to assess viability and injury of hepatocytes and cholangiocytes, we did 
not confirm our findings in a transplantation model. In particular, a longer follow-
up period is required to assess biliary complications, which can only be achieved 
in a transplantation study.  
In conclusion, this is the first study demonstrating that end-ischemic oxygenated 
MP of DCD livers provides better preservation of biliary epithelial function and 
morphology, independent of the temperature at which MP is performed. By 
significantly reducing biliary injury, especially in the large bile ducts, as well as 
restoring ATP levels in DCD liver grafts prior to transplantation, end-ischemic 
oxygenated MP could improve outcome after DCD liver transplantation.
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Background: Pre- or reconditioning of donor livers can improve organ quality 
prior to transplantation. The aim of this study was to investigate whether 
metformin as pre- or reconditioning agent is able to reduce preservation injury in 
rat donor livers and improve hepatobiliary function during ex situ normothermic 
machine perfusion (NMP).
Methods: To study the preconditioning effects of metformin, metformin was 
administered via oral gavage 12 and 2 hours before the hepatectomy. To assess the 
reconditioning effects of metformin, in 2 other groups, metformin was added to 
the NMP perfusion fluid in two different concentrations (30 and 300 mg/L). In the 
reference group, no pre- or reconditioning was carried out. In all groups, rat donor 
livers were preserved for 4 hours in preservation fluid on melting ice. Thereafter, 
NMP was performed for viability assessment.
Results: Preconditioning improved ATP production, hepatobiliary function 
(assessed by total bile production, biliary bilirubin and bicarbonate), and 
significantly lowered levels of lactate and glucose during NMP. On the other hand, 
metformin preconditioning did not reduce markers for hepatobiliary injury 
such as AST, ALT, LDH, caspase-3 activity, TBARS or biliary gamma-GT, and LDH. 
Reconditioning with metformin did not improve hepatobiliary function or reduce 
injury markers during NMP.
Conclusion: Preconditioning of rat donor livers with metformin improves 
hepatobiliary function but does not reduce preservation injury as assessed during 
3 hours of NMP. Reconditioning with metformin showed no beneficial effects.




Metformin, a well-known drug for antihyperglycemic therapy in patients with 
type II diabetes mellitus, has also been shown to have beneficial effects in reducing 
ischemia-reperfusion (I/R) injury (1,2). Several animal and human studies 
have shown that administration of metformin, either before an ischemic event 
(preconditioning) or immediately at the beginning of reperfusion (reconditioning), 
reduces tissue injury and preserves cardiac function after myocardial infarction 
(2-4). 
Although the exact mechanism of action of metformin is not fully known, one 
of the main actions of metformin is to partly and selectively block complex I of 
the mitochondrial respiratory chain (5). This inhibition of complex I has positive 
but also negative consequences. Positively, partial complex I inhibition reduces 
the level of cellular energy, which stimulates phosphorylation of the cellular 
energy sensor enzyme adenosine monophosphate protein kinase (AMPK) (6). 
An indirect consequence of AMPK activation is prevention of opening of the 
mitochondrial permeability transition pore (MPTP) in the mitochondrial inner 
membrane (7). When the MPTPs are closed, it is not possible to leak cytochrome 
c, which normally activates apoptotic death pathways (8-10). Another positive 
effect of partial complex I inhibition is a reduction in the production of reactive 
oxygen species (ROS) (11). Some ROS production normally accompanies oxidative 
phosphorylation and this increases during reperfusion. ROS avidly attack and 
degrade many cellular components including the mitochondria themselves (12). 
Inhibition of oxidative phosphorylation by metformin is coupled with lower ROS 
production and the mitochondria will be better protected against ROS-mediated 
injury (11). On the other hand, a negative effect of metformin and AMPK activation 
is the down regulation of the nuclear bile acid farnesoid X receptor (FXR) (13). FXR 
plays a central role in the control of bile salt homeostasis, maintaining the balance 
between bile salt synthesis and transport. FXR regulates expression of cholesterol 
7α-hydroxylase (CYP7A1), the rate-limiting enzyme in bile salt synthesis, and the 
bile salt export pump (BSEP), the major bile salt exporter (14). 
One of the current challenges in liver transplantation is the shortage of available 
donor livers. A widely adopted strategy to increase the number of donors is the 
use of extended criteria donor (ECD) livers (15). However, these ECD livers are 
more prone to I/R injury and are therefore related to lower graft survival rates 
(16). To enhance outcome after transplantation of ECD livers, quality of the organ 
can be improved before or after organ procurement with preconditioning or 
reconditioning strategies (17). Preconditioning of the donor can be carried out 
with pharmacological compounds administered to the donor during intensive 
care stay (18), while for reconditioning purposes machine perfusion can be used to 
“revitalize” the liver prior to transplantation (19).   
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Figure 1. Schematic representation of the experimental groups to examine the effects of pre- and 
reconditioning with metformin. All groups contained 5-6 rat livers. 
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The aim of the current study is to investigate whether metformin is able to reduce 
preservation injury of donor livers when applied as pre- or reconditioning agent. 
Hepatobiliary viability assessment was carried out during 3 hours of ex situ 
normothermic machine perfusion (NMP: perfusion at body temperature). 
Materials and methods
Animals 
Male Lewis rats (LEW/Han®Hsd) (270-300 g) were obtained from Harlan 
Laboratories (Boxmeer, the Netherlands). Animals received care according to 
the Dutch Law on Animal Experiments and the study protocol was approved by 
the Institutional Animal Care and Use Committee of the University of Groningen 
(IACUC-RuG).
Experimental Design
Rats were divided into three experimental groups and one reference group (n 
= 5-6 per group) (Figure 1). The three experimental groups were used to study 
the effects of preconditioning or reconditioning with metformin in rat donor 
livers. Metformin was purchased from Sigma-Aldrich (1,1-dimethylbiguanide 
hydrochloride, Sigma-Aldrich Inc., St. Louis, MO, USA). For assessment of the 
preconditioning effects, metformin (300 mg/kg body weight) was dissolved in 
saline (0.9% NaCl) and administered 12 and 2 hours before the hepatectomy directly 
into the stomach via oral gavage. Pretreatment with metformin in a concentration 
of 300 mg/kg body weight is in accordance with earlier rat studies in which serum 
levels were obtained that were within the therapeutic range used in humans (1-4 
mg/L) (20,21). All other groups were pretreated with saline (0.9% NaCl) on the 
same time points before the hepatectomy. 
In all study groups, rat livers were procured using a standard technique (see next 
paragraph) and subsequently preserved by static cold storage (SCS) in histidine-
tryptophan-ketoglutarate (HTK) preservation solution (Custodiol, Essential 
Pharmaceuticals, Ewing, NJ, USA) for 4 hours. Prior to NMP, all livers were flushed 
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with 10 mL of cold saline. To study the reconditioning effects of metformin, 
metformin was added to the perfusion solution during NMP in 2 different 
concentrations: 300 mg/L and 30 mg/L. A concentration of 300 mg/L corresponds 
with 1.8 mM metformin. In a recent study with hepatocyte cell cultures, 2 mM of 
metformin was the lowest effective concentration to lower the degree of apoptosis 
induced by bile acids (22). However, 300 mg/L is a toxic concentration for humans 
(23). Therefore, we examined also the effects of 30 mg/L, which can be seen as a 
non-toxic concentration for humans (metformin toxicity > 40 mg/L) (23).
The basic NMP perfusion fluid consisted of 25 mL human red blood cell concentrate 
(final hematocrit 25%) (Sanquin, Amsterdam, the Netherlands), 53.9 mL William’s 
Medium E solution (Life Technologies Europe, Bleiswijk, the Netherlands), 20 mL 
human albumin (200 g/L Albuman, Sanquin, Amsterdam, the Netherlands), 1 mL 
insulin (100 IE/mL Actrapid, Novo Nordisk, Alphen aan den Rijn, the Netherlands) 
and 0.1 mL unfractionated heparin (5000 IE/mL, LEO Pharma A/S, Ballerup, 
Denmark) adding up to a total volume of 100 mL. 
Procurement of Rat Donor Livers 
Procurement of rat livers has been described previously (24). In brief, inhalation 
anesthesia with isoflurane and oxygen was used before and during the procurement 
(2-3% isoflurane). After the laparotomy, the large bile duct was cannulated and 1 
mL 0.9% NaCl containing 500 IU of heparin was administered via the dorsal penile 
vein. Moreover, a blood sample was taken via the dorsal vein for assessment of 
the serum level of metformin in vivo. After heparinization, the hepatectomy was 
performed by ligation of the splenic vein, mesenteric artery, and mesenteric vein. 
Thereafter, the celiac trunk was cannulated. After clamping of the infra-hepatic 
vena cava and the portal vein, the portal vein was cannulated and via the portal vein 
cannula, the liver was flushed in situ with 10 mL 0.9% NaCl (37°C). Subsequently, 
the supra-hepatic vena cava was transected, followed by a cold flush out with 5 mL 
HTK preservation solution (4°C) via the portal vein cannula. The liver was removed 
and flushed with an additional 20 mL of cold (4°C) HTK via the portal vein cannula 
and 5 mL of cold (4°C) HTK via the hepatic artery (celiac trunk cannula) before 
preservation by SCS. 
Static Cold Storage and Normothermic Machine Perfusion
For SCS, livers were stored in bags with ice-cold HTK (4°C) on melting ice for 
4 hours. Ex situ NMP of rat donor livers was performed with a liver machine 
perfusion system that enabled dual perfusion via both the hepatic artery and the 
portal vein using a closed circuit (Figure 2). Two roller pumps (Ismatec ISM404 + 
ISM719 and MS-2/6-160; IDEX Health & Science, Wertheim-Mondfeld, Germany) 
provided pulsatile flow through the hepatic artery and continuous flow through 
the portal vein. Continuous flow through the portal vein was achieved by the 
combination of elastic tubing and a pulse damper to remove pulses from the 
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◀ Figure 2. Ex vivo rat liver machine perfusion system. Two roller pumps provide a continuous flow to 
the portal vein (A) and a pulsatile flow to the hepatic artery (B). Pulses in the portal flow were eliminated 
with elastic tubing and a pulse damper (C). Two tubular membrane oxygenators provide oxygenation of the 
perfusion solution, as well as removal of CO2 (D). Several bubble traps (three-way connectors) were used 
to eliminate air bubbles in the perfusion solution (E). Flow (Φ) and pressure (P) were detected by in-line 
sensors and data were displayed in real-time on a connected laptop (F). The perfusion temperature was 
maintained constant by two heat exchangers (G) and a radiator/ventilator combination (H), all connected 
to the thermostat pump (I). For real time control of the perfusion temperature, one in-line temperature 
sensor (T) was connected to the thermostat pump. The isolated box encapsulated the perfusion system (J) 
preventing loss of warm or cold air. The rat liver was placed into an organ chamber (K). Bile was collected in 
Eppendorf tubes (L). By the three-way connector at the portal side, samples of the perfusion solution were 
taken every 30 min for analysis of the perfusate (M).
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roller pump. Two tubular membrane oxygenators provided oxygenation of the 
perfusion solution and removal of CO2. Perfusion box and perfusate temperature 
were maintained stable at 37 degrees Celsius using a thermostat pump (Huber, 
Offenburg, Germany) and radiator/ventilator combination (Freezing Hardware, 
Losser, the Netherlands). The system was pressure-controlled by a computer 
algorithm allowing autoregulation of blood flow through the liver, with constant 
pressure at variable flow rates. In-line sensors monitored flow, pressure, and 
temperature and data were analyzed by and displayed in real- time on a connected 
laptop. NMP was performed with a mean arterial pressure of 110 mmHg and 11 
mmHg at the portal vein. The perfusion fluid was oxygenated with 100% O2 (1 L/
min) and the pO2 was 60-80 kPa (450-600 mmHg), as described in earlier machine 
perfusion experiments (25,26). 
Analysis of Metformin and Biochemical Markers of Function and Injury
Samples of heparinized arterial blood during hepatectomy and perfusate before 
the start of NMP and after every 30 min of NMP were centrifuged (2700 g for 
5 min at 4°C) and the supernatant was collected, frozen and stored at -80°C 
for future additional analysis. Metformin was measured by a validated liquid 
chromatography–mass spectrometry method in the laboratory of the Department 
of Clinical Pharmacy and Pharmacology of the University Medical Center 
Groningen. Serum insulin levels were analyzed using an ELISA kit (Rat/Mouse 
Insulin ELISA, Merck, Billerica, MA, USA). Determination of glucose, lactate, 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate 
dehydrogenase (LDH), was performed using standard biochemical methods.  
Bile production was measured gravimetrically at 30-minute intervals by weighing 
Eppendorf tubes in which bile was collected from the biliary drain. The density 
of bile was defined as 1 mg/mL. The hepatic bile production was expressed as mL/
gram liver. Biliary epithelial cell function was assessed by measuring pH and 
bicarbonate concentration in bile (27). For this purpose, bile samples were collected 
under mineral oil and analyzed immediately using an ABL800 FLEX analyzer 
(Radiometer, Brønshøj, Denmark). Biliary concentration of gamma-glutamyl 
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transferase (gamma-GT) and LDH were measured as markers of biliary epithelial 
cell injury (28), and biliary bilirubin concentration was measured as marker of 
hepatocellular secretory function (28), using standard biochemical methods. Total 
bile salt concentrations were measured as described before (29).
Thiobarbituric acid reactive substances (TBARS) were measured in perfusate 
samples after 2 hours of reperfusion, as a marker for oxidative stress (degree of 
lipid peroxidation of membranes). Detailed description of the method has been 
described previously (30). 
Caspase-3 Enzyme Activity Assay
Immediately after SCS and after 3 hours of NMP, caspase-3 enzyme activity 
was measured in liver homogenates using a fluorimetric assay and expressed in 
arbitrary fluorescence units (AFUs) (31). Caspase-3 enzyme activity was corrected 
for the total protein content. The total protein concentration was determined using 
a commercially available kit (Bio-Rad, Veenendaal, the Netherlands). 
RNA Isolation and Polymerase Chain Reaction (PCR)
Immediately after SCS and after 3 hours of NMP, hepatic mRNA expression of 
hepatocellular transporter protein bile salt export pump (BSEP) and cholesterol 
7α- hydroxylase (gene symbol CYP7A1) was determined by quantitative real-time 
PCR. RNA isolation, reverse transcription PCR, and quantitative PCR (qPCR) 
was performed as described previously (32) and 18S mRNA levels were used as 
endogenous control. Primers and probes are provided in Table 1. 
Adenosine triphosphate (ATP) Extraction and Measurement
The hepatic ATP content was used as an indicator of the energy status of the liver 
tissue. For this purpose, liver tissue biopsies after 3 hours of NMP were immediately 
frozen in liquid nitrogen and were processed later for ATP measurement, as 
described previously (30). 
Histological Evaluation of Liver Parenchyma 
After 3 hours of NMP, biopsies were taken from liver parenchyma and preserved 
with 10% formaldehyde. After inclusion in paraffin, slides were stained with 
periodic acid-Schiff (PAS) for evaluation of the glycogen content. 
Statistical Analysis
Continuous variables were presented as median with interquartile range (IQR) and 
were compared using the Mann-Whitney U test. The level of significance was set 
at a p-value of < 0.05. All statistical analyses were performed using SPSS software 
version 22.0 for Windows (SPSS Inc., Chicago, IL, USA).
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Table 1. Primer-probe Sets Used for RT PCR Analysis
Gene Sequence
18S Forward:     CGG CTA CCA CAT CCA AGG A 
Reversed:   CCA ATT ACA GGG CCT CGA AA 
Probe:         CGC GCA AAT TAC CCA CTC CCG A
CYP7A1 Forward:     CAG GGA GAT GCT CTG TGT TCA 
Reversed:   AGG CAT ACA TCC CTT CCG TGA 
Probe:        TGC AAA ACC TCC AAT CTG TCA TGA GAC CTC C
BSEP Forward:     CCA AGC TGC CAA GGA TGC TA 
Reversed:   CCT TCT CCA ACA AGG GTG TCA 
Probe:        CAT TAT GGC CCT GCC GCA GCA
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Results
Perfusate Levels of Metformin and Metabolic Parameters during Hepatectomy
To confirm that oral gavage with metformin led to adequate levels, serum 
metformin levels were measured during the hepatectomy. In the groups in which 
metformin was administered via oral gavage as preconditioning agent, relatively 
high metformin serum levels were achieved, while no metformin was detected in 
rats to whom only saline was administered via oral gavage (Figure 3A). Metformin 
is an oral antihyperglycemic agent and therefore can lower elevated blood glucose 
levels. Glucose levels (reference value in rat 4.5 mmol/L) during the hepatectomy 
were comparable between the group with metformin treatment before the 
hepatectomy and without metformin treatment (Figure 3B). In addition, also 
insulin levels showed no significant differences between the metformin-pretreated 
animals and untreated animals (Figure 3C).  
Metformin Concentrations during Normothermic Machine Perfusion
Levels of metformin during 3 hours of NMP are shown in Figure 4. In all groups in 
which metformin was added as extra ingredient to the perfusion solution, a drop 
in the concentration was noticed in the first 30 minutes of perfusion, indicating 
that a part of metformin remains intracellular. Thereafter, levels of metformin 
in the perfusion solution remained stable. Remarkably, in the group of rats that 
only received metformin via oral gavage before the hepatectomy and without 
metformin in the perfusion solution, a low level of metformin was observed in the 
perfusate during the entire period of NMP. 
Binnenwerk_Andrie_Final.indd   193 12/20/15   11:03 AM
194
Figure 3. Serum levels of metformin, glucose, 
and insulin during hepatectomy. Panel A: Serum 
levels of metformin during hepatectomy. Panel B: 
Serum glucose levels during hepatectomy (rat 
reference glucose levels 4.5 mmol/L). Panel C: 
Serum insulin levels during hepatectomy. Data 
are represented as medians with IQR (error bars).
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Figure 4. Metformin concentrations during 3 hours of NMP. Data are represented as medians with IQR 
(error bars).
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▶ Figure 5. Metabolic parameters for hepatobiliary function during perfusion. Panel A: Hepatic ATP 
concentrations after 3 hours of NMP. Hepatic ATP content was significantly higher in the group with 
metformin preconditioning compared to the reference group (*p<0.05). Panel B: Bile production during 3 
hours of NMP. The group with metformin preconditioning displayed a significantly higher bile production 
during the entire period of NMP compared to the reference group (*p<0.05). In addition, after the first 60 
minutes of perfusion, the group with a high concentration of metformin in the perfusion solution (300 
mg/L) displayed a significantly decrease in bile production compared to the reference group (#p<0.05). 
Panel C: Biliary bilirubin after 3 hours of NMP. Levels of bilirubin were significantly higher in the group with 
metformin preconditioning compared to the reference group (*p<0.05). In addition, bilirubin levels were 
significantly lower in the group with a high concentration of metformin added to the perfusion solution 
(300 mg/L), compared to the reference group (#p<0.05). Panel D: Biliary bicarbonate levels after 1.5 hours 
of NMP. Levels of bicarbonate were significantly higher in the group with metformin preconditioning versus 
the reference group (*p<0.05). In addition, levels of bicarbonate were significantly lower in the group with 
a high concentration of metformin added to the perfusion solution (300 mg/L) compared to the reference 
group. Panel E: Biliary pH levels after 1.5 hours of NMP. Data in panels A, C, D, and E are represented as 
medians with IQR (error bars) and data in panel B are represented as medians only. 
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Preconditioning with Metformin Improved ATP Content, Markers for 
Hepatobiliary Function, and Lowered Levels of Glucose and Lactate during NMP
Hepatic ATP concentrations after 3 hours of NMP are provided in Figure 5A. 
Interestingly, the group with metformin preconditioning had a significantly 
higher ATP production after 3 hours of NMP compared to the reference group (no 
pretreatment with metformin and normal perfusion solution without metformin). 
There were no significant differences in hepatic ATP contents between all other 
groups and the reference group. 
Bile production, an important marker for hepatocyte function, is presented in 
Figure 5B. The group with metformin preconditioning displayed a significantly 
higher bile production during the entire period of NMP compared to the reference 
group. In addition, after the first 60 minutes of perfusion, the group with a high 
concentration of metformin added to the perfusion solution (300 mg/L) displayed 
a rapid decline in bile production compared to the reference group. Furthermore, 
no significant differences in bile production were noticed between the group with 
a low concentration of metformin (30 mg/L) in the perfusion solution and the 
reference group.  
Concentrations of the total biliary bilirubin after 3 hours of NMP, another marker 
for hepatocyte function, are presented in Figure 5C. The concentrations of total 
biliary bilirubin were significantly higher after metformin preconditioning 
compared to the reference group. Moreover, in the group with a high concentration 
of metformin added to the perfusion solution (300 mg/L), bilirubin concentration 
was significantly lower compared to the reference group after 3 hours of NMP. 
Concentrations of biliary bicarbonate, a marker for cholangiocyte function, were 
measured after 1.5 hours of NMP (Figure 5D). The biliary bicarbonate concentration 
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was significantly lower in the group of livers with a high concentration of metformin 
added to the perfusion solution (300 mg/L) compared to the reference group. In 
addition, a significantly higher concentration of bicarbonate was measured in the 
bile samples after 1.5 hours in the group with metformin preconditioning versus 
the reference group. Biliary pH levels after 1.5 hours of NMP are shown in Figure 
5E. Biliary pH was not significantly different between the study groups. 
The perfusate levels of lactate and glucose during 3 hours of NMP are presented 
in Figure 6A and B. The group with metformin added to the perfusion fluid in a 
high concentration (300 mg/L) showed a significantly steeper increase in lactate 
and glucose concentrations almost over time compared to the reference group. 
Furthermore, in the group with metformin preconditioning, lactate and glucose 
levels were significantly lower than the reference group from 60 minutes onwards. 
Preconditioning with Metformin Lowered the Total Concentration of Bile Salts 
and Reduced BSEP and CYP7A1 mRNA Expression 
Concentrations of total bile salts after 1.5 hours of NMP are presented in figure 
7A. The group with metformin preconditioning displayed a significantly lower 
concentration of total bile salts after 1.5 hours of NMP compared to the reference 
group. Between the groups with metformin in the perfusion solution (high 
and low concentration) and the reference group no significant differences 
were found. Remarkably, the concentration of total bile salts in the group with 
metformin added to the perfusion solution in a high concentration (300 mg/L) 
was almost comparable to the concentration of total bile salts in the group with 
preconditioning. However, the total bile production in the group with metformin 
in a high concentration added to the perfusate was almost 4 times lower (Figure 
5B). 
Relative mRNA expression of CYP7A1 and BSEP immediately measured after SCS 
(baseline groups; rats pretreated with metformin or only saline) and after 3 hours 
of NMP are presented in Figure 7A and 7B. Metformin pretreatment significantly 
decreased mRNA levels of CYP7A1 and BSEP compared to the groups with saline 
feeding as pretreatment. In addition, after 3 hours of NMP, mRNA levels of CYP7A1 
and BSEP were significantly lower in the group with metformin preconditioning 
compared to the reference group. 
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Figure 6. Lactate and glucose during 3 hours of NMP. Panel 6A: Lactate concentrations during 3 hours of 
NMP. Panel 6B: Glucose concentrations during 3 hours of NMP. Almost during the entire period of NMP, 
levels of lactate and glucose were significantly higher in the group with metformin added to the perfusion 
solution in the high concentration (300 mg/L) compared to the reference group (*p<0.05). Furthermore, in 
the group with metformin preconditioning, lactate and glucose levels were significantly lower after the first 
hour of NMP in comparison with the reference group (#p<0.05). Data are represented as medians.
11
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◀ Figure 7. Total concentration of bile salts and mRNA expression of CYP7A1 and BSEP.  Panel A: Total bile 
salts production after 1.5 hours of NMP. Levels of total bile salts were significantly lower in the group with 
metformin preconditioning compared to the reference group (*p<0.05). Panel B: Relative mRNA expression 
of CYP7A1. Panel C: Relative mRNA expression of BSEP. Messenger RNA expression of CYP7A1 and BSEP 
in baseline biopsies immediately after static cold storage (SCS) showed that metformin pretreatment 
significantly decreases mRNA levels of CYP7A1 and BSEP compared to the groups with saline feeding as 
pretreatment. In addition, after 3 hours of NMP, mRNA levels of CYP7A1 and BSEP were significantly lower 
in the group with metformin preconditioning compared with the reference group. Data are represented as 
medians with IQR (error bars). 
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Pre- and Reconditioning with Metformin Did Not Lower Preservation Injury 
during NMP
Markers for hepatocellular injury, AST, ALT, and LDH measured in the perfusate 
after 3 hours of NMP showed no significant difference between the groups with 
metformin pre- or reconditioning and reference group (Figure 8A-C). In addition, 
levels of TBARS, a marker for oxidative stress, were not significantly different 
between groups after 3 hours of NMP (Figure 8D).
Markers for cholangiocyte injury, LDH and gamma-GT, measured in bile after 3 
hours of NMP are provided in Figure 8E and F. The concentrations of biliary LDH 
and gamma-GT were also not significantly different between the groups with 
metformin pre- or reconditioning and the reference group. 
Figure 8G presents caspase-3 activity, a marker for apoptosis, immediately 
measured after SCS (baseline groups; rats pretreated with metformin or only 
saline) and after 3 hours of NMP. Interestingly, caspase-3 activity was significantly 
lower in the group with metformin pretreatment compared to the group with only 
saline pretreatment. However, after 3 hours of NMP no significant differences 
were found in caspase-3 activity between the groups with metformin pre- or 
reconditioning and the reference group. 
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▲▶ Figure 8. Markers for hepatobiliary injury. Panel A: Perfusate AST levels after 3 hours of NMP. Panel 
B: Perfusate ALT levels after 3 hours of NMP. Panel C: Perfusate LDH levels after 3 hours of NMP. Panel D: 
Perfusate TBARS levels after 3 hours of NMP. Panel E: Biliary gamma-GT after 3 hours of NMP. Panel F: 
Biliary LDH after 3 hours of NMP. Panel G: Caspase-3 activity immediately after static cold storage (SCS) 
(baseline biopsies) and after 3 hours of NMP. The caspase-3 activity was significantly lower in the group 
with metformin pretreatment compared to the group with only saline pretreatment in baseline biopsies 
(*p<0.05). Data are represented as medians with IQR (error bars). 
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Figure 9. Histological evaluation of glycogen content after 3 hours of NMP. Panel A: Low color intensity of 
PAS staining of liver parenchyma after 3 hours of NMP in the group with metformin added to the perfusion 
solution in a high concentration (300 mg/L). This low color intensity indicates glycogen breakdown. Panel 
B: Example of high color intensity of PAS staining of liver parenchyma in all other study groups at the end 
of 3 hours NMP. This indicates higher glycogen contents in all other study groups compared to the group 
mentioned under panel A. The central vein is marked with an asterisk. Scale bars indicate 100 μm.
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Metformin Reconditioning Lowered Glycogen Content during NMP
The group with metformin added to the perfusion solution in a high concentration 
(300 mg/L) displayed a breakdown of the liver glycogen content during 3 hours 
of NMP, as indicated by PAS staining (Figure 9A). In contrast, the PAS stains of 
all other study groups indicated higher glycogen levels in liver tissue (Figure 9B). 
Discussion
The aim of the current study is to examine whether metformin is able to reduce 
injury when it is administered before the period of ischemia, as preconditioning 
agent or as reconditioning agent when it was added as extra additive during 
NMP. Our study demonstrates that preconditioning with metformin significantly 
improved ATP content, markers for hepatobiliary function (total bile production, 
cumulative levels of biliary bilirubin and bicarbonate), and lowered levels of 
glucose and lactate during 3 hours of NMP. However, metformin preconditioning 
also lowered total bile salt secretion and expression of the FXR target genes 
CYP7A1 and BSEP. In addition, metformin preconditioning did not lower markers 
for hepatobiliary injury such as AST, ALT, LHD, TBARS, biliary gamma-GT, biliary 
LDH, and caspase-3 activity, a specific marker for apoptosis. With respect to 
the reconditioning effects of metformin, examined in two different perfusate 
concentrations (30 and 300 mg/L), our study did not show beneficial effects in 
improving hepatobiliary function or reducing hepatobiliary injury. In contrast, 
metformin added to the perfusion solution in a high concentration (300 mg/L) had 
adverse effects as it significantly increased levels of lactate and glucose, decreased 
bile production, and reduced glycogen content during 3 hours of NMP. 
As described in the introduction, metformin partly blocks complex I of the 
respiratory chain. Inhibition of complex I during ischemia and in the beginning 
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of reperfusion can lower I/R injury via two different pathways. Firstly, partial 
blocking of complex I stimulates AMPK activation, inhibition of opening of the 
MPTP, a depressed release of cytochrome c and ultimately less apoptosis (8-10). 
Secondly, partial inhibition of complex I is related with lower production of ROS 
(11). Some ROS are normally generated during oxidative phosphorylation (12). 
However, when the oxidative phosphorylation is partly blocked by metformin, 
less ROS will be produced (11). ROS are an important cause for cellular and in 
particular mitochondrial injury as ROS are extremely unstable and react with 
several cellular components (12). In our experiments, we found evidence that 
preconditioning with metformin significantly improved mitochondrial function, 
as reflected by higher ATP content and lower levels of lactate in the perfusate 
during 3 hours of NMP compared to the reference group. In addition, our data also 
showed that metformin preconditioning lowered the degree of apoptosis. Hepatic 
caspase-3 activity was significantly lower immediately after SCS in the group with 
metformin preconditioning compared to the reference group. However, levels of 
TBARS after 3 hours of NMP, a marker for lipid peroxidation of membranes due 
to ROS injury, were not significantly different between the group with metformin 
preconditioning and the reference group. 
With respect to the reconditioning effects of metformin, no significant differences 
were obtained in ATP content, lactate levels, and caspase-3 enzyme activity 
compared to the reference group. The observation that reconditioning with 
metformin has no obvious beneficial effect may have two possible explanations. 
First, metformin was not present intracellularly in time to inhibit complex I 
during early reperfusion. It has been shown that closing of the MPTP via complex I 
inhibition should be performed immediately during reperfusion to lower apoptosis 
(2,8). Late inhibition of complex I during reperfusion has no effect in the reduction 
of apoptosis (2,8). Another possible explanation might be that complex I was 
inhibited too strongly during the entire period of NMP, which may have nullified 
the potential beneficial effects of metformin during early reperfusion. It is known 
that toxic inhibition of complex I as occurs in patients with a metformin overdose, 
suppresses the oxidative phosphorylation with lactic acidosis as a consequence 
(23). Although in our study reconditioning with metformin in two concentrations 
(30 and 300 mg/L) did not significantly suppress ATP content, lactate levels in the 
group with metformin in the high concentration (300 mg/L) were significantly 
higher compared to the reference group, indicating that also anaerobic glycolysis 
was necessary for ATP production. 
Metformin is widely used for lowering gluconeogenesis in patients with type II 
diabetes (1,2). In our study, we observed significantly lower glucose levels in the 
group with metformin preconditioning. Remarkably, this was not the case in the 
groups with metformin reconditioning. In the group with a high concentration 
of metformin in the perfusion solution (300 mg/L) considerable increases in 
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glucose levels were observed. In addition, evaluation of PAS staining revealed 
a lower glycogen content after 3 hours of NMP, which indicates a higher degree 
of glycogenolysis in this group. Apparently, the increases in glucose levels were 
generated from hepatic glycogen stores. A higher rate of glycogenolysis was also 
shown in earlier studies where rat livers were perfused with high concentrations 
of metformin (5 mmol/L or 825 mg/L) (33). However, the exact mechanisms how 
metformin reduces gluconeogenesis but also can stimulate glycogenolysis are not 
fully known (34).  
Another effect of AMPK activation is suppression of FXR transcriptional activity 
(13). In turn, FXR plays an important role in the control of bile salt homeostasis, 
inducing BSEP expression and inhibiting CYP7A1 expression (35,36). In our study, 
in particular in the groups with metformin preconditioning, we observed that 
metformin reduces the mRNA levels of both CYP7A1 and BSEP. Therefore, our study 
could not confirm the association between AMPK activation by metformin and 
FXR suppression. A possible explanation for this might be the low concentration of 
metformin used in our experiment during preconditioning. With preconditioning 
we obtained circulating metformin levels of 6 mg/L in vivo, while in experiments 
with cultured hepatocytes concentrations of 165 mg/L were used and FXR 
suppression was observed (13). 
One interesting finding was the relatively higher concentration of total bile salts in 
the group with metformin added to the perfusion solution in a high concentration 
(300 mg/L) compared to the group with metformin preconditioning. Levels of 
total bile salts were almost similar between both groups, while the group with 
metformin preconditioning produced almost 4 times more bile. Therefore, the 
question rises if bile in the group with metformin preconditioning was diluted. 
Bile flow into the bile canaliculi is dependent of the osmotic gradients caused by 
bile salts (bile salt dependent bile flow) and other solutes (bile salt independent 
bile flow) (37). With respect to the bile salt independent bile flow, it has been 
shown that biliary bicarbonate as solute increases the osmotic gradient, allowing 
water to passively follow into the canaliculi (38). In the group with metformin 
preconditioning significantly more bicarbonate was produced during 3 hours of 
NMP. As a result, the higher bicarbonate production could play a role in the diluted 
bile production in the group with metformin preconditioning. 
Contrary to expectations, metformin preconditioning or reconditioning was not 
able to significantly reduce preservation injury in our heart beating donation 
model. Therefore, it is still interesting to assess in a model with more severe 
injury at baseline (e.g. in a donation after circulatory death model) whether 
metformin preconditioning will be able to lower preservation injury and improve 
hepatobiliary function. However, it should be noticed that levels of total bile salts 
as well as mRNA expression of CYP7A1 and BSEP are of interest in these future 
experiments.
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Taken together, our results illustrate that preconditioning of rat donor livers 
with metformin significantly improves hepatobiliary function but does not 
reduce injury as assessed during NMP viability assessment. Reconditioning with 
metformin showed no beneficial effects. Further research should be undertaken 
to investigate whether metformin is able to reduce preservation injury in a model 
with more severe ischemic injury at baseline.  
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Summary and General Discussion
The studies in this thesis have provided evidence for new strategies to improve 
outcome after transplantation of extended criteria donor (ECD) livers. Especially, 
the chapters in which the applications of machine perfusion were investigated 
confirm previous findings and contribute additional evidence that machine 
perfusion has the ability to lower preservation injury and improves organ quality 
of ECD livers before transplantation.
In this chapter, the results of this PhD thesis are summarized and discussed, 
followed by a section on future perspectives. 
Chapter 1 provides a short introduction to this thesis and the aims of this thesis 
are discussed.  
Part A: Strategies to Improve Outcome after Transplanta-
tion of Extended Criteria Donor Livers in Clinical and Ani-
mal Studies
In chapter 2 we examined whether donor livers with advanced age (≥ 65 years) 
can be used safely for transplantation compared to a control group that received 
a graft from younger donors (< 65 years). We performed this retrospective study 
together with the other two liver transplant centers in the Netherlands. We 
demonstrated that transplantation of livers from elderly donors does not result in 
inferior patient/graft survival rates or a higher incidence of biliary complications 
such as non-anastomotic biliary strictures (NAS). A plausible reason for the good 
outcomes after transplantation of elderly donor livers could be the short cold 
ischemia times obtained in this cohort. However, it should be noticed that the 
elderly donor livers were transplanted in recipients with minimal additional risk 
factors (low MELD [model for end-stage liver disease] score, no high urgency, no 
hepatitis C cirrhosis) and other donor related risk factors such as donation after 
circulatory death (DCD), split livers, or steatosis were avoided. 
In chapter 3 we assessed whether short cold ischemia times during transplantation 
of moderate (30-60%) macrovesicular steatotic donor livers can lead to similar 
postoperative outcomes compared to transplantation of nonsteatotic donor livers. 
In 19 patients who received a moderately steatotic donor liver, similar patient 
and graft survival rates were observed in comparison to a control group of 95 
patients that were transplanted with a nonsteatotic liver. Likewise, no differences 
were found in the incidences of primary non-function, retransplantation, or NAS 
formation. In addition, we have shown that liver function, reflected by prothrombin 
time and serum bilirubin was comparable between the two groups. Similarly, no 
differences were observed in postoperative lactate levels. However, recipients of a 
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moderately steatotic liver suffered from more postoperative complications such as 
respiratory or kidney dysfunction, which necessitated intensive care treatment. 
In chapter 4 and 5 we analyzed whether the diffuse reflectance spectroscopy 
(DRS) system of Philips Healthcare was able to quantify steatosis in liver tissue of 
humans and mice. Both studies demonstrated that the DRS can measure steatosis 
accurately and in-real time. A good agreement was shown between DRS analysis 
and pathological assessment (gold standard) of the degree of steatosis. Moreover, 
we showed that DRS is also able to differentiate between mild and moderate/severe 
steatotic livers with high sensitivity and specificity. As a result, we suggest that 
the DRS can be used to assist the surgical team in the assessment of the hepatic 
fat content during donation and/or transplantation procedures. However, it was 
not possible to discriminate between macrovesicular and microvesicular steatosis 
with the DRS system. With the DRS device it was only possible to measure the total 
hepatic fat content. 
We explored in chapter 6 whether transplantation of ECD livers is associated 
with higher need for blood transfusions during transplantation. A donor liver was 
classified as ECD when the donor risk index (DRI) was 1.7 or higher. ECD livers were 
used in 115 of the 318 primary adult liver transplant recipients (36%) of this cohort. 
In 95 (30%) of all recipients no red blood cell concentrate (RBC) was administered 
during transplantation. After uni- and multivariate analysis the following variables 
were found to be independently associated with postreperfusion RBC transfusion 
requirements: DRI ≥ 1.7, female recipient, recipient age, and no aprotinin 
administration. The increased blood loss after graft reperfusion in ECD livers could 
be related to the higher susceptibility of ischemia/reperfusion (I/R) injury in ECD 
livers. It has been shown that increased reperfusion injury is associated with the 
release of fibrinolytic proteins from the donor graft, which results in premature 
breakdown of hemostatic blood clots. 
Part B: Machine Perfusion as a Strategy to Improve Hepa-
tobiliary Viability of Extended Criteria Donor Livers
Chapter 7 provides a general overview of biliary complications after liver 
transplantation. In particular we focussed on the role of machine perfusion as a 
potential technique to lower biliary complications after liver transplantation. 
In a recent study performed by our group, it has been shown that injury to 
the peribiliary glands during static cold storage (SCS) is associated with the 
development of NAS after transplantation (1). Therefore, we aimed in chapter 8 
to study whether the peribiliary glands are also injured in the late stages of severe 
NAS. Another aim of this study is to hypothesize new starting points for protection 
of the bile duct epithelium with machine perfusion. To study whether the 
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peribiliary glands are injured in late stages of severe NAS, we analyzed large bile 
duct biopsies of explants of patients retransplanted for severe NAS. Large bile 
duct biopsies of explants from patients without concomitant biliary pathology 
were chosen as controls. Our study demonstrated that the peribiliary glands are 
significantly more injured in patients retransplanted for severe NAS compared to 
patients retransplanted without concomitant biliary pathology. In addition, also 
significantly more biliary epithelial injury was observed in large bile duct biopsies 
of patients retransplanted for severe NAS compared to control patients. Therefore, 
our study supports our earlier hypothesis that injury to the peribiliary glands 
during SCS increases the risk for the development of NAS after transplantation. 
Furthermore, we postulate that these ongoing injuries to the peribiliary glands 
and consequently insufficient regeneration of the biliary epithelium are important 
contributing factors in the pathogenesis of NAS. Additionally, in another recent 
study, it has been shown that it is possible to isolate stem cells from the peribiliary 
glands. Moreover, the same study showed that therapy with these stem cells in two 
patients with liver cirrhosis, improved the functionality of their cirrhotic liver 
(2). Besides, it has been suggested that normothermic machine perfusion ([NMP] 
perfusion at 37°C) can function as vehicle for the delivery of stem cells (3-5). Hence, 
the combination of NMP and stem cell therapy may be an interesting approach to 
reduce bile duct injury after transplantation of ECD livers.
In chapter 9 we investigated whether 2 hours of end-ischemic machine perfusion 
was able to improve liver viability of human ECD livers after regular SCS. During 
machine perfusion, the inflow temperature was set at 120C (hypothermic condi-
tions) and the perfusion fluid was actively oxygenated. The liver was perfused 
through both the portal vein and hepatic artery. After 2 hours of oxygenated hy-
pothermic machine perfusion (HMP), livers were perfused using NMP at 37°C for 
6 hours, to evaluate hepatobiliary viability. NMP was performed with a perfusion 
solution enriched with an oxygen carrier (RBCs) and nutrients. Livers with only 
SCS preservation and NMP served as control group. Our study demonstrated that 2 
hours of HMP significantly increased hepatic ATP content as well as liver function-
ality, as seen by a better cumulative bile production and improved composition of 
bile (more bicarbonate secretion) compared to livers with only SCS preservation. 
However, HMP treatment did not lower markers of hepatobiliary injury such as 
transaminases, lactate dehydrogenase (LDH), biliary LDH, and biliary gamma-glu-
tamyl transferase (gamma-GT) after 6 hours of ex situ viability testing using NMP. 
A possible explanation for the similar level of hepatobiliary injury markers can 
be the almost equivalent degree of pre-existing injury in the two groups. Immedi-
ately after SCS, in the majority of ECD livers, a substantial degree of parenchymal 
ischemic necrosis was observed. This substantial degree of injury can be explained 
by the combination of suboptimal graft quality, substantial donor warm ischemia 
time, and the subsequent period of SCS (median 7-9 hours). Likewise, after 6 hours 
of NMP, the patterns of ischemic necrosis were comparable and no increase in in-
jury was observed between the group with HMP and only SCS preservation. 
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The study in chapter 10 assessed the optimal end-ischemic machine perfusion 
fluid temperature for protection of the bile ducts. We performed this study with 
DCD rat livers. Three temperature conditions were compared: hypothermic 
(8°C), subnormothermic (20°C), and gradual rewarming, or so-called controlled 
oxygenated rewarming (8-20°C). In the control group no end-ischemic machine 
perfusion was performed. After 1 hour of oxygenated end-ischemic MP, the livers 
were 2 hours reperfused ex situ at 37 degrees for hepatobiliary viability assessment. 
Independently of the machine perfusion temperature, end-ischemic machine 
perfusion improved markers of biliary function, such as bile and bicarbonate 
production, and reduced markers of biliary injury as well as biliary histological 
injury. In addition, end-ischemic machine perfusion reduced hepatocyte injury 
markers (transaminases and LDH) and improved mitochondrial function, all 
irrespective of the perfusion temperature. 
In chapter 11 we examined whether pharmacological pre- or postconditioning of 
rat donor livers using metformin, was able to improve hepatobiliary function and 
reduce preservation injury as assessed during 3 hours of NMP. Metformin was 
administered 12 and 2 hours before the hepatectomy via oral gavage (precondi-
tioning), or was added to the perfusion fluid in two different concentrations (300 
mg/L and 30 mg/L) (reconditioning). Rats who were pretreated with only saline 
in combination with NMP without metformin administration served as control 
group. Three hours of NMP was used as method to assess hepatobiliary viability. 
The study demonstrated that metformin, as preconditioning agent, significantly 
improved ATP production, markers for hepatobiliary function (total bile produc-
tion, biliary bilirubin and bicarbonate), and significantly lowered levels of lactate 
and glucose during NMP. On the other hand, metformin preconditioning lowered 
total bile salt secretion and expression of the FXR target genes CYP7A1 and BSEP. 
Furthermore, metformin preconditioning did not reduce markers for hepatobili-
ary injury such as AST, ALT, LDH, caspase-3 activity, TBARS or biliary gamma-GT 
and LDH. In addition, reconditioning with metformin did not improve hepatobi-
liary function or reduce hepatobiliary injury markers during NMP. In contrast, 
metformin added in a high concentration to the perfusion solution (300 mg/L) had 
adverse effects as it significantly increased levels of glucose and lactate, decreased 
bile production and reduced glycogen content during 3 hours of NMP. Contrary 
to expectations, in this study, metformin preconditioning or reconditioning was 
not able to significantly reduce preservation injury. A possible explanation for this 
may be that the reference group (heart beating model) did not show major injury 
after 4 hours of SCS. Therefore, it still remains unknown whether metformin pre-
conditioning is also able to lower preservation injury in a model with more severe 
injury at baseline (e.g. donation after circulatory death model). 12
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Future Perspectives
The current strategy to optimize the use of ECD livers is to find a balance between 
additional donor related risk factors and recipient factors. Although no strict 
guidelines are available for the allocation of ECD livers, a couple of models are 
useful that can help with balancing of risks between the recipient and the donor. 
These models are able to predict recipient patient/graft survival when ECD livers 
are used for transplantation. Examples of such models are the donor risk index 
(DRI) (6) or DRI adjusted for the Eurotransplant registry (ET-DRI) (7), donor 
age combined with model for end-stage liver disease (D-MELD) score (8), and 
balance of risk (BAR) score (9), all using donor related risk factors whether or not 
combined with recipient risk factors. Although these models are applicable for risk 
assessment, usage of these models will not lead to a major increase of ECD livers 
that are necessary to reduce waiting list mortality (10). In addition, the common 
perception is that availability of suitable donor organs is getting worse due to the 
increased prevalence of diabetes type II and obesity in the general population. As 
a consequence, other strategies are needed to improve postoperative outcomes of 
transplantation of ECD livers.
A possible way to reduce preservation injury compared to the current preservation 
method SCS is the application of machine perfusion as preservation method. In 
the last years, substantial evidence, mainly in animal experiments and studies 
using (discarded) human donor livers, have shown that machine perfusion is 
a very promising method to lower preservation injury and improve function of 
ECD livers (11-19). In two clinical studies, Guarrera et al. and Dutkowksi et al. 
have reported that human recipients of an end-ischemic hypothermic machine 
perfused liver showed less early allograft dysfunction, fewer biliary complications, 
and shorter length of hospital stay compared to recipients with a liver, which was 
only preserved with SCS (11,12,19). Although these reports included a relatively 
small numbers of recipients, the results are very encouraging and support the 
initiation of randomized clinical trials with hypothermic machine perfusion 
(HMP). For subnormothermic machine perfusion (SNP) and NMP the first (proof-
of-principle) clinical studies have yet to be published. 
Despite recent substantial improvements in machine perfusion of the liver, several 
basic parameters of this technology are still subject to ongoing (pre)clinical 
research, including temperature of the perfusion fluid, timing of perfusion, 
pressure, single or dual perfusion, nature of perfusion solution, oxygenation of 
perfusate, and suitable biomarkers for hepatobiliary injury in the perfusate. In the 
next section of this chapter, these parameters will be discussed and directions for 
further research will be given. 
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Timing and Duration of Perfusion
Machine perfusion can be performed at different time points between organ 
procurement and transplantation. Machine perfusion can be carried out in the 
donor (normothermic regional perfusion) (20), immediately after procurement, 
during transport, or at the end of transport (so called end-ischemic machine 
perfusion) (21). Depending on the perfusion temperature, some time intervals 
are not beneficial such as a short period of NMP at the end of SCS (end-ischemic 
NMP) (22-24). Because machine perfusion during the transport phase is a logistic 
challenge, most experience has been gained with a short period (1-2 hours) of end-
ischemic MP in the transplantation hospital under hypothermic, subnormothermic 
or controlled rewarming conditions. However, a combination of machine perfusion 
during different phases between organ procurement and transplantation will 
synergistically act to make the effects of single periods of machine perfusion more 
powerful (21).   
Temperature of the Perfusion Fluid
As mentioned previously, machine perfusion can be performed under different 
temperature conditions such as HMP (4-12°C), SNP (20-30°C) and NMP (37°C). In 
addition, gradual warming-up of the perfusion solution (controlled oxygenated 
rewarming; COR) from 8 to 20 degrees Celsius has also shown to be a feasible 
temperature strategy (25-27). In our study, performed with DCD rat livers, as 
described in chapter 10, we found no differences between the three temperature 
conditions HMP, COR, and SNP. However, in a previous study using a porcine 
model, Minor et al. indicated that COR might be the best perfusion temperature for 
the preservation of liver grafts after living donation (25). A possible explanation 
for the dissimilarity in the results between the study of Minor et al. and our study, 
could be next to the various donation models (DCD versus living donation), also the 
difference in specific liver mass. A porcine liver has a higher weight and therefore 
the influence of slowly rewarming might be more intensive than in a rat liver, 
which has a relatively small liver mass. In addition, in the field of ex vivo lung 
perfusion, it is known that gradual rewarming of the lung after SCS provides the 
best results (28,29). Clinical trials with COR are therefore strongly recommended. 
Interestingly, Minor and coworkers already initiated such a study; six ECD livers 
were recently transplanted after COR. All recipients showed a good liver function 
with a median peak aspartate aminotransferase (AST) level within the first 7 days 
of 564 (305-1525) U/L (D. Hoyer et al. presented at World Transplant Congress, 
Philadelphia 2015). The final outcomes of this study are awaited with great interest. 
With respect to NMP, a short period of NMP prior to reperfusion has shown no 
beneficial effects compared to only SCS preservation. During a short period of NMP, 
the full cascade of I/R injury will be activated without a conditioning or protective 
effect of NMP (22-24). The general hypothesis is that NMP is only beneficial if it 
is performed during the entire preservation period or for a couple of hours after 
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SCS to washout the effects of preservation injury (5). The results of a clinical study 
using NMP during the entire period of preservation are expected soon (study 
performed under supervision of Professor Peter Friend, Controlled-Trials.com ID: 
ISRCTN14355416, OrganOx, Oxford, UK). In addition, another advantage of NMP 
is that liver viability can be assessed prior to transplantation (4,30). We used this 
application of NMP in experiments described in this thesis. A disadvantage of 
NMP is that an interruption of the perfusion or a failure of the perfusion system 
may cause substantial tissue injury like an “ex situ DCD” procedure. Moreover, the 
available machines for NMP do not have a built-in cold storage back-up system to 
prevent tissue injury when the perfusion is interrupted. 
Pressure of Perfusion 
During perfusion it is necessary to find a balance between optimal tissue perfusion 
and shear stress induced endothelial injury. A low pressure can lead to incomplete 
perfusion, while a high pressure can cause injury to the endothelial cells. It is well 
known that high portal pressure disrupts endothelial sinusoidal cell integrity 
(31). For HMP and NMP, studies have given directions to the optimal perfusion 
pressure (4,32). However, the ideal pressure for SNP has to be determined. So 
far, experiments with SNP are only performed under flow-controlled conditions 
(no pressure control used) or the pressures during these SNP experiments were 
similar to hypothermic conditions (13,14,18,25,33). In our experiment described 
in chapter 10, we perfused rat livers under subnormothermic conditions with a 
pressure of 40 mmHg on the arterial and 4 mmHg on the portal side. However, it 
has yet to be established whether this pressure is the most optimal.     
Single or Dual Perfusion 
It is known that under physiological conditions, perfusion through the hepatic 
artery is necessary to perfuse the microcirculation (peribiliary vascular plexus) 
around the bile ducts (34). In our experiments, in particular during HMP, 
we perfused through the portal vein and hepatic artery. However, Dutkowksi 
and coworkers who have extensive expertise in perfusion under hypothermic 
conditions, perfuse the liver only through the portal vein (12,15,35). Nonetheless, 
more research is required to determine whether only portal vein perfusion is 
suffient enough to adequately preserve the biliary epithelium. 
Nature of Perfusion Solution
Depending on the perfusion temperature and the corresponding degree of liver 
metabolism, it is necessary to adjust the ingredients of the perfusion solution. 
The available machine perfusion solutions are mainly based on a colloid with 
electrolytes to mimic the normal physiological osmolarity. However, amino 
acids or glucose are absent in these solutions. During SNP, the liver has a higher 
degree of metabolic activity compared to HMP. Consequently, it is questionable 
if the currently available perfusion solutions contain sufficient amounts of 
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nutrients to fulfill the metabolic demand during SNP. Experimental studies with 
a perfusion fluid based on William’s Medium E (hepatocyte growth medium) and 
with or without an artificial oxygen carrier have shown its feasibility during 
SNP (18,33). Therefore, future studies are needed to examine the ideal perfusion 
fluid for SNP. In addition, because during NMP normal physiological conditions 
are mimicked, it is definitely necessary to add nutrients and an oxygen carrier 
to the perfusion fluid. In our NMP experiments, we used human RBCs as oxygen 
carrier. However, given the expectation that the frequency of NMP will rise in 
the upcoming years, the request for human RBCs will consequently also increase. 
RBCs are not unlimitedly available; therefore the expectation is that studies on the 
use of artificial oxygen carriers such as hemoglobin-base oxygen carriers (HBOCs) 
added to NMP perfusion fluids, will appear in the next years. Furthermore, NMP 
opens new opportunities to repair preservation injury by adding pharmacological 
compounds or even mesenchymal stem cells (3-5). Recently, an animal study has 
shown that a cocktail of defatting agents lowered the amount of steatosis during 
NMP (36). However, these results have to be confirmed in clinical studies with 
severe steatotic (discarded) donor livers.  
Active Oxygenation of the Perfusate
For HMP with human donor livers it is not known if oxygenation of the perfusion 
fluid is beneficial. In two clinical series, Guarrera et al. (11,19) did not actively 
oxygenate the perfusion solution, while Dutkowski et al. used 100% oxygen (12). 
Only in animal studies it has been shown that perfusion with 100% oxygen during 
HMP improves the functional recovery after ischemia, compared to perfusion 
with 20% or 0% oxygen (37,38). Advocates of perfusing with oxygen emphasize 
that oxygen is needed for improvement of the mitochondrial function before 
reperfusion and that perfusion without oxygen, only can be seen as flush out of 
injury markers (39). In contrast, proponents of perfusion without oxygen claim 
that oxygenation increases oxidative stress during reperfusion (39). However, the 
effects of HMP whether or not with actively dissolved oxygen in the perfusion fluid 
has to be explored with (discarded) human donor livers. 
Biomarkers for Biliary Injury
During SNP and especially NMP, it is possible to assess the viability of the bile 
ducts by analyzing biomarkers in perfusate and bile (4,18). The current markers for 
biliary injury are changes in bile composition such as low glucose concentrations 
(< 1.0 mmol/L), or release of injury markers like gamma-GT or LDH into bile 
(40). In addition, also histological analysis of large bile duct biopsies can be used 
to predict the development of biliary injury, in particular NAS (1). Recently, 
Verhoeven and colleagues have reported that specific microRNA profiles in the 
preservation solution during SCS are associated with the development of NAS 
(41). It is therefore very interesting to study if these profiles of microRNAs are also 
measurable during machine perfusion and whether these profiles correlate with 
more established markers of hepatobiliary injury and/or histological assessment 
of the biliary tract. 
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Nederlandse samenvatting
Tijdens een levertransplantatie wordt de zieke lever vervangen door een gezonde 
lever van een orgaandonor. Veel voorkomende oorzaken van niet te genezen 
leverziekten zijn cirrose door chronische hepatitis, galwegaandoeningen of 
overmatig alcoholgebruik. Jaarlijks worden in Nederland, afhankelijk van het 
aanbod, tussen de 110 en 140 levertransplantaties uitgevoerd om mensen te genezen 
van hun eindstadium leverfalen. Helaas is de vraag naar geschikte donorlevers 
groter dan het aanbod van geschikte donoren. Hierdoor sterven in Nederland 
jaarlijks tientallen mensen vroegtijdig, die mogelijk gered hadden kunnen worden 
met een nieuwe lever. Een manier om het donoraanbod te vergroten is het accepteren 
van donorlevers die naar verwachting een mindere kwaliteit hebben. Deze 
donorlevers worden ook wel suboptimaal genoemd en worden in de internationale 
literatuur aangeduid als Extended Criteria Donor (ECD) levers. Donorlevers met 
een verwachte mindere orgaankwaliteit zijn vooral afkomstig van oudere donoren 
(> 60 jaar) of donoren met overgewicht. Mensen met overgewicht hebben een 
grotere kans op leververvetting. Daarnaast worden donorlevers die gedoneerd zijn 
nadat de donor is overleden aan een circulatiestilstand gerekend tot ECD levers. Een 
potentieel nadeel van suboptimale donorlevers is dat deze levers extra kwetsbaar 
zijn voor de periode van zuurstoftekort, die optreedt als de lever op ijs bewaard 
wordt tijdens transport. De huidige manier van het vervoeren van de donorlevers 
bestaat namelijk uit het bewaren van de lever in een zak met preservatievloeistof, 
in een doos met ijs. De donorlever krijgt zo voor een periode van gemiddeld acht tot 
tien uur niet voldoende zuurstof, waardoor allerlei schadelijke processen optreden. 
Suboptimale donorlevers zijn door hun mindere kwaliteit extra gevoelig voor dit 
zuurstoftekort. Naast de gevolgen van het zuurstoftekort krijgt de donorlever 
een extra klap te verwerken als deze wordt aangesloten in het lichaam van de 
ontvanger. Het opnieuw doorbloeden van de lever zorgt wederom voor allerlei 
schadelijke processen, ook wel ischemie/reperfusieschade genoemd (in het Engels: 
ischemia/reperfusion injury). Donororganen van relatief jonge donoren kunnen 
de klappen van het zuurstoftekort en het opnieuw doorbloeden van het orgaan 
redelijk goed verwerken, echter donorlevers van suboptimale donoren kunnen 
dit minder goed. Daarom gaan transplantaties met suboptimale donorlevers vaker 
gepaard met minder goede uitkomsten na transplantatie. Relatief gezien is er bij 
een suboptimale donorlever een grotere kans dat deze niet goed gaat werken in de 
ontvanger. Voornamelijk galwegafwijkingen zijn een belangrijke oorzaak voor het 
opnieuw falen van de lever. Alles valt en staat bij goed functionerende galwegen 
na een transplantatie. In het bijzonder het ontwikkelen van niet-anastomotische 
galwegstricturen (in het Engels: non-anastomotic biliary  strictures, afgekort als 
NAS) zorgt vaak voor het opnieuw krijgen van eindstadium leverfalen. Een nieuwe 
transplantatie is dan dikwijls de enige geschikte behandeling voor deze niet-
anastomotische galwegstricturen. 
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Dit proefschrift beschrijft strategieën die de kwaliteit van suboptimale donorlevers 
kunnen verbeteren voordat deze levers getransplanteerd worden. In deel 1 (part A) 
van dit proefschrift zijn studies beschreven die hebben onderzocht of een korte 
koude ischemietijd (de periode tussen het koelen van de lever in de donor en het 
aansluiten in de ontvanger) ook kan leiden tot gunstige postoperatieve uitkomsten, 
in met name oudere donorlevers en donorlevers met matige leververvetting. 
Andere hoofdstukken in het eerste deel hebben als doel te onderzoeken of 
spectrometrie ook als handig hulpmiddel kan dienen voor het meten van de mate 
van leververvetting. In het laatste hoofdstuk van het eerste deel is onderzocht of 
transplantatie van suboptimale donorlevers ook gerelateerd is aan toegenomen 
bloedverlies en het gebruik van meer bloedproducten tijdens transplantatie. In 
het tweede deel van dit proefschrift (part B) zijn studies beschreven die hebben 
onderzocht of machineperfusie als nieuwe preservatiemethode, in plaats van 
alleen het vervoeren op ijs, ook de mate van bewaarschade (de zogenaamde 
preservatieschade) in suboptimale donorlevers kan verminderen en uiteindelijk 
ook de functie van deze organen kan verbeteren.
Hieronder volgt een korte samenvatting van het eerste deel van het proefschrift. 
Hoofdstuk  1 dient als algemene inleiding en beschrijft de opzet van dit proefschrift. 
In de hoofdstukken 2 en 3 hebben we onderzocht wat de uitkomsten zijn 
na transplantatie van levers van oudere donoren (> 65 jaar) en matig vette 
donorlevers (30-60% leververvetting). In beide hoofdstukken komt naar voren dat 
goede uitkomsten behaald kunnen worden met deze suboptimale donorlevers als 
de periode van koude ischemie zo kort mogelijk wordt gehouden. Het is daarbij 
wel belangrijk te vermelden dat deze oudere en matig vette donorlevers in relatief 
minder zieke ontvangers getransplanteerd moeten worden. Ook is het belangrijk 
dat de frequentie van andere donorgerelateerde risicofactoren laag is als oudere of 
matig vette donorlevers gebruikt worden voor transplantatie. 
In de hoofdstukken 4 en 5 hebben we samengewerkt met Philips Eindhoven 
(afdeling In Body Systems) en het Antoni van Leeuwenhoek Ziekenhuis in 
Amsterdam om te onderzoeken of een door Philips ontwikkelde spectrometer 
nauwkeurig en snel de mate van leververvetting (steatose) kan meten. Het 
exact meten van de mate van steatose tijdens de donatieprocedure is vaak lastig. 
Donatieprocedures vinden meestal ’s nachts plaats en pathologische expertise is 
zodoende niet altijd aanwezig. Ook andere technieken waarmee de hoeveelheid 
steatose gemeten kan worden, zoals CT of MRI, zijn niet altijd inzetbaar, omdat 
metingen met deze apparaten relatief teveel tijd kosten in de korte tijdsperiode 
waarin donatieprocedures gewoonlijk plaatsvinden. Tevens is gebleken dat de 
inschatting van de hoeveelheid steatose door het chirurgisch uitnameteam niet 
voldoende nauwkeurig is. Op het oog worden soms levers afgekeurd die uiteindelijk 13
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minder vet blijken te zijn. Het exact beoordelen van de mate van steatose is van 
belang, omdat mild steatotische levers (0-30% leververvetting) wel gebruikt 
kunnen worden voor levertransplantatie. Voor matig en vooral ernstig steatotische 
donorlevers (> 30% leververvetting) gaat dit niet op. Het transplanteren van 
deze levers is sterk gerelateerd aan ongunstige uitkomsten na transplantatie. Uit 
de gezamenlijke onderzoeken is gebleken dat de spectrometer van Philips snel 
en nauwkeurig de mate van steatose kan meten. Daarbij kan het apparaat ook 
onderscheid maken tussen mild en matig-ernstig steatotische levers. Uit deze 
resultaten concluderen wij dat de spectrometer een waardevolle aanwinst kan zijn 
om de beoordeling van het percentage leververvetting sneller en nauwkeuriger te 
laten verlopen tijdens de donatieprocedure.
Het doel van hoofdstuk 6 was om te onderzoeken of transplantatie van 
suboptimale donorlevers ook gepaard gaat met meer bloedverlies en een 
grotere transfusiebehoefte tijdens de transplantatieprocedure. De ernst van het 
bloedverlies en/of de hoeveelheid gegeven bloedproducten om het bloedverlies 
te compenseren zijn beide gerelateerd aan een groter risico op postoperatieve 
complicaties. De resultaten uit deze studie laten zien dat het transplanteren 
van een suboptimale donorlever gepaard gaat met het toedienen van meer 
bloedproducten in de reperfusiefase (als de lever is aangesloten in de ontvanger). 
De toegenomen vraag naar bloedproducten kan waarschijnlijk verklaard worden 
doordat suboptimale donorlevers over het algemeen, door hun slechtere kwaliteit, 
meer bloedstollingsproblemen geven tijdens transplantatie. 
In het tweede deel van het proefschrift is de toepassing van machineperfusie 
als preservatiemethode voor suboptimale donorlevers onderzocht. Tijdens 
machineperfusie wordt de donorlever aangesloten op een pompsysteem en 
doorspoeld met perfusievloeistof waarin zuurstof is opgelost. Dit zogeheten 
oxygeneren (zuurstof geven) van de lever en galwegen heeft als doel de donorlever 
makkelijker door de preservatieperiode heen te loodsen. Door oxygeneren 
ontwikkelen de donorlevers minder weefselschade dan wanneer ze alleen op 
ijs worden bewaard. Op basis van de temperatuur van de perfusievloeistof kan 
machinepreservatie onderverdeeld worden in hypotherme machineperfusie (HMP; 
temperatuur 4-12°C), subnormotherme machineperfusie (SNP; temperatuur 
20-30°C) en normotherme machineperfusie (NMP; temperatuur 37°C). Tijdens 
NMP wordt de normale fysiologische situatie zo goed mogelijk nagebootst door 
de lever naast zuurstof ook voldoende voedingstoffen te geven. De lever gaat als 
het ware opnieuw functioneren, alleen vindt dit niet in het lichaam plaats, maar 
in een perfusieopstelling. Een groot voordeel van NMP ten opzichte van SNP en 
HMP is dat de kwaliteit van de lever beter onderzocht kan worden. Een belangrijke 
parameter die de leverfunctie goed weergeeft, is de mate van galproductie. Een 
ander voordeel van NMP is dat medicijnen die de lever kunnen repareren aan 
de perfusievloeistof toegevoegd kunnen worden. Een nadeel van NMP is dat een 13
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korte onderbreking van de perfusie al snel onomkeerbare weefselschade kan 
geven. Dit risico op schade door een falende perfusie is lager bij HMP en SMP. 
HMP en SMP hebben vooral tot doel de lever en galwegen van zuurstof te voorzien. 
HMP en SMP worden vaak toegepast aan het einde van de preservatieperiode. 
De donorlevers worden in eerste instantie vervoerd op ijs, maar worden voor 
de transplantatie nog even kort doorspoeld (geperfundeerd) met zuurstof. De 
korte periode van machineperfusie aan het einde van de preservatieperiode 
(zogenaamde eind-ischemische machineperfusie) heeft als doel de mitochondriën, 
de energiefabriekjes van de cel, van zuurstof te voorzien. Met zuurstof kunnen 
de mitochondriën energiemoleculen maken voor de levercellen. Deze levercellen 
kunnen hierdoor als het ware opstarten voor de transplantatie en zijn zo beter 
voorbereid om de periode van ischemie/reperfusieschade met zo min mogelijk 
schade te doorstaan. 
Hieronder volgt een korte samenvatting van het tweede deel van het proefschrift. 
Hoofdstuk 7 vormt een algemene inleiding over galwegcomplicaties die 
kunnen optreden na levertransplantatie. Verder beschrijven we de toekomstige 
mogelijkheden om  deze galwegcomplicaties met machineperfusie te verminderen 
dan wel te voorkomen. 
Het doel van hoofdstuk 8 was om de kennis over de mechanismen van het 
ontstaan van niet-anastomotische galwegstricturen (NAS) na transplantatie te 
verbreden. Zoals eerder beschreven zijn galwegafwijkingen na transplantatie een 
belangrijke oorzaak voor het falen van de donorlever. Eerder onderzoek waarbij 
biopten van galwegen ten tijde van transplantatie zijn onderzocht, heeft laten 
zien dat schade aan de peribiliaire klieren in de galwegen gerelateerd kan zijn 
aan de latere ontwikkeling van NAS (1). De peribiliaire klieren zijn als het ware 
nestjes waaruit nieuwe galwegepitheelcellen kunnen groeien. Om de bevindingen 
van deze eerdere studie te bevestigen, is het ook van belang om te onderzoeken 
of met name de peribiliaire klieren zijn aangedaan in de late fases van NAS, als 
patiënten zich met klachten van zieke galwegen presenteren. Om galwegen van 
patiënten met ernstige NAS te onderzoeken, hebben we galwegbiopten bestudeerd 
van patiënten die geretransplanteerd zijn wegens ernstige NAS. Deze patiënten 
werden dus voor de tweede keer getransplanteerd. Galwegbiopten van patiënten 
die geretransplanteerd waren voor een andere oorzaak dan galwegziekten 
vormden de controlegroep. Uit deze studie kwam naar voren dat in galwegbiopten 
van patiënten die geretransplanteerd waren voor ernstige NAS, meer schade 
te zien was in de peribiliaire klieren ten opzichte van de controlegroep. Deze 
resultaten bevestigen de eerdere hypothese dat schade aan de peribiliaire klieren 
tijdens transplantatie een belangrijke factor kan zijn in de pathogenese van NAS. 
In een andere recent verschenen studie zijn stamcellen uit de peribiliaire klieren 
gebruikt om de kwaliteit van cirrotische levers te verbeteren (2). Daarnaast is in 13
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andere artikelen de hypothese geponeerd dat NMP ook kan dienen als methode 
om stamcellen af te leveren in de donorlever (3-5). Op basis van deze inzichten 
suggereren wij dat de combinatie van NMP en stamceltherapie met cellen uit de 
peribiliaire klieren wellicht een waardevolle combinatie kan zijn om in de toekomst 
schade aan de galwegen van (suboptimale) donorlevers te kunnen reduceren.
In hoofdstuk 9 hebben we onderzocht of twee uur eind-ischemische HMP de 
hoeveelheid preservatieschade kan verminderen en de functie kan verbeteren van 
zes suboptimale humane donorlevers. De controlegroep in deze studie bestond 
uit twaalf suboptimale donorlevers zonder twee uur HMP. De gebruikte humane 
donorlevers in deze studie waren afgekeurd voor transplantatie en hadden tijdens 
het transport naar het Universitair Medisch Centrum Groningen (UMCG) alleen 
op ijs gelegen. In beide groepen werd de kwaliteit van het orgaan getest na het wel 
of niet toepassen van HMP middels zes uur NMP. De perfusies werden uitgevoerd 
met de Liver Assist, een machineperfusie-opstelling speciaal ontworpen voor 
donorlevers, van de firma Organ Assist uit Groningen. De studie toonde aan dat 
twee uur eind-ischemische HMP de leverfunctie van de suboptimale donorlevers 
kan verbeteren. De functie van de lever werd o.a. onderzocht door de galproductie 
te meten, de samenstelling van de gal te beoordelen en de zuurstofopname van 
de lever te bepalen. Twee uur eind-ischemische HMP was echter niet voldoende 
om ook de mate van preservatieschade te verminderen. In beide groepen was de 
concentratie schademarkers in de preservatievloeistof en de gal gelijk na zes uur 
NMP. Ook werden geen verschillen waargenomen in de histologische beoordeling 
van de donorlevers in beide groepen. Dat HMP niet de hoeveelheid weefselschade 
kon verminderen kan mogelijk verklaard worden doordat de levers al veel 
weefselschade hadden opgelopen voordat ze met HMP werden gepreserveerd. 
In eerste instantie waren de levers al afgekeurd voor transplantatie. Daarnaast 
was een groot deel van deze donorlevers gedoneerd na een lange periode van 
circulatiestilstand in de donor en was de gemiddelde koude ischemietijd zeven 
tot negen uur. Echter, het verbeteren van de leverfunctie middels twee uur 
eind-ischemische HMP is zeker een belangrijk resultaat. Het toont aan dat eind-
ischemische HMP in staat kan zijn om suboptimale donorlevers een zogenaamde 
‘jumpstart’ te geven voordat de donorlever wordt aangesloten in de ontvanger. 
In hoofdstuk 10 hebben we onderzocht wat de optimale machine-
perfusietemperatuur is om de galwegen te beschermen. De studie werd uitgevoerd 
met donorlevers van ratten. De machineperfusie van de rattenlevers werd 
uitgevoerd op een specifiek ontworpen opstelling, aanwezig in het Chirurgisch 
Onderzoekslaboratorium in het UMCG. In deze studie hebben we drie verschillende 
temperatuurstrategieën onderzocht: HMP, SMP en het langzaam opwarmen van 
de perfusievloeistof van 8 tot 20°C, ook wel controlled oxygenated rewarming 
(COR) genoemd. De functie en mate van schade aan de lever en galwegen 
hebben we onderzocht met twee uur ex situ reperfusie, uitgevoerd op hetzelfde 13
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perfusiesysteem. Het doel van ex situ reperfusie is om de echte reperfusiefase (dus 
als de lever is aangesloten in de patiënt) na te bootsen. De controlegroep in dit 
experiment bestond uit rattenlevers met alleen twee uur ex situ reperfusie, zonder 
eind-ischemische machineperfusie. Aan het einde van twee uur ex situ reperfusie 
hebben we ook de mitochondrieën geïsoleerd en de functie van deze celorganellen 
gemeten. Uit dit experiment bleek dat de temperatuur van de perfusievloeistof 
tijdens eind-ischemische machineperfusie geen verschil maakte. Wel reduceerde 
eind-ischemische machineperfusie de hoeveelheid ischemie/reperfusieschade en 
verbeterde het de functie van de lever en galwegen. Ook lieten de mitochondrieën 
een verbeterde functie zien onder machineperfusie, in vergelijking met de 
controlegroep waarbij geen machineperfusie werd uitgevoerd.
Hoofdstuk 11 had als doel te onderzoeken of metformine, toegevoegd aan de 
preservatievloeistof ten tijde van drie uur NMP, de functie van de lever en galwegen 
kan verbeteren en de hoeveelheid preservatieschade kan reduceren. Zoals eerder 
beschreven biedt NMP de mogelijkheid om met medicijnen de leverfunctie 
na donatie te herstellen, en de mate van preservatieschade te verminderen. 
Metformine is een veel gebruikt medicijn bij diabetes mellitus type II om de 
bloedglucosespiegel te verlagen. Een minder bekend effect van metformine is dat 
het ook de mate van ischemie/reperfusieschade kan verlagen. Dit experiment 
werd uitgevoerd met rattenlevers en op dezelfde perfusieopstelling als het 
experiment beschreven in hoofdstuk 10. Een ander doel van dit experiment was 
om te onderzoeken of metformine al een effect kan hebben als het aan de donor 
wordt gegeven voordat de donorprocedure plaatsvindt. De gedachte hierachter is 
dat de lever met (intracellulair) metformine aan boord al beter beschermd is tegen 
preservatieschade. Om dit te onderzoeken werd metformine oraal toegediend aan 
de ratten voorafgaand aan de donatieprocedure. Ook deze groep onderging drie uur 
NMP, om zo de functie van de lever en galwegen te onderzoeken. Het belangrijkste 
resultaat van dit onderzoek was, dat wanneer metformine werd toegediend 
voorafgaand aan de donatieprocedure, de functie van de lever en galwegen 
verbeterde (meer galproductie en betere kwaliteit van de gal). Helaas gold dit niet 
wanneer metformine alleen werd toegevoegd aan het perfusiemedium. Dit bleek 
niet voordelig te zijn ten op zichte van perfusievloeistof zonder metformine. 
Toekomstperspectieven 
Tot nu toe zijn er twee klinische studies verschenen waarbij machineperfusie 
(eind-ischemische HMP) is toegepast bij suboptimale donorlevers die ook al 
geaccepteerd waren voor transplantatie (6-8). Ook al zijn de studies uitgevoerd 
met een klein aantal patiënten, de resultaten zijn veelbelovend. Patiënten die een 
donorlever ontvingen die eerst hypotherm gepreserveerd was, hadden minder 
aanwijzingen voor ischemie/reperfusieschade in vergelijking met patiënten die 
een lever ontvingen zonder eind-ischemische HMP. Door minder weefselschade 13
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verbleven de patiënten minder lang in het ziekenhuis en ontwikkelden ze 
minder galwegcomplicaties (o.a. NAS). Echter, om goed te onderzoeken of 
machinepreservatie de incidentie van galwegcomplicaties kan verminderen, zijn 
grootschalige gerandomiseerde klinische studies noodzakelijk. Initiatieven voor 
dergelijk onderzoek zijn onlangs genomen, o.a. in het UMCG, in samenwerking met 
(inter)nationale transplantatiecentra. Daarnaast is de verwachting dat met NMP 
de kwaliteit van suboptimale donorlevers verbeterd kan worden als medicijnen 
of stamcellen aan de perfusievloeistof worden toegevoegd. Dit zal in de komende 
jaren verder worden onderzocht.
13
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Dankwoord
Promoveren doe je niet alleen. Wellicht een van de meest voorkomende zinnen 
waarmee een dankwoord wordt begonnen, maar ook zeker waar voor mijn 
proefschrift. Het leukste van samenwerken vind ik dat je veel van elkaar kunt 
leren. Bij deze wil ik dan ook graag diegenen bedanken die met mij hebben 
samengewerkt om dit proefschrift te kunnen voltooien.
Prof. dr. Robert Porte, beste Robert, zonder jouw ideeën en je support was het mij 
niet gelukt om dit proefschrift te schrijven. Ik wil je dan ook graag bedanken voor 
de mogelijkheden die je mij geboden hebt en het vertrouwen dat je in mij had om 
het MD/PhD traject succesvol te kunnen doorlopen. Ik denk graag terug aan onze 
besprekingen, waarbij als ik een keer was vastgelopen in de analyses, jij mij weer 
in de juiste richting dirigeerde. Daarnaast heb ik bewondering voor de manier 
waarop jij het werk als chirurg, onderzoeker, hoofd van de HPB chirurgie, hoofd 
van de JSM en diverse rollen in het Groninger Transplantatie Centrum succesvol 
kunt combineren. Ik heb veel van je geleerd. 
Prof. dr. Ton Lisman, beste Ton, jij weet als geen ander wat erbij komt kijken 
om succesvol onderzoek te kunnen doen, daarin succesvol te zijn en succesvol te 
blijven. Als jonge onderzoeker loop je met je hoofd in de wolken, omdat er vele 
manieren zijn om iets te kunnen onderzoeken. Na jouw scherpe blik wordt eerst 
een pas op de plaats gemaakt en daarna sta je weer met beide benen op de grond. 
Niet te moeilijk doen is je credo en dit waardeer ik aan jou. Ook in het schrijven van 
artikelen; niet te veel poespas, gewoon simpel houden. Dat wil ik graag meenemen.
Prof. dr. Henri Leuvenink, beste Henri, ik wil je bedanken voor de kansen die 
je mij hebt gegeven om in het Chirurgisch onderzoekslaboratorium samen met 
Paria de rattenlever- en nierperfusies te kunnen doen. Je expertise in perfusie-
experimenten was zeer waardevol. Ook heb ik bewondering voor je capaciteit 
om ‘out of te box’ te kunnen denken. Als voorbeeld noem ik het koelen van de 
perfusiebox: dit hebben we toch mooi opgelost door een computerventilator en 
radiator te combineren!
Prof. dr. Annette S.H. Gouw, beste Annette, eigenlijk ben jij mijn vierde promotor, 
jammer dat er maar drie promotores mogen zijn. Jij hebt me vaak geholpen met de 
(histologische) analyses voor diverse artikelen. Samen hebben we vele uren door 
de microscoop gekeken naar leverparenchym en galwegen. Bij de beoordeling van 
de coupes legde je ook veel uit. Ik vond het erg interessant om te zien hoeveel jij 
al kon vertellen over wat er met de lever aan de hand was geweest, zonder op de 
hoogte te zijn van het bijbehorende klinische verhaal. 
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De leden van de beoordelingscommissie; prof. dr. Herold Metselaar, prof. dr. 
Klaas Nico Faber en prof. dr. Michel Struys ben ik zeer erkentelijk voor het 
beoordelen van dit proefschrift. 
Ook bedank ik de Junior Scientific Masterclass, onder leiding van oud-voorzitter 
prof. dr. Janneke Kluin-Nelemans, voor de mogelijkheden om te kunnen 
promoveren tijdens en na mijn studie Geneeskunde. 
Het personeel van het centrale proefdierenlaboratorium (CDP) en de 
dierenexperimentencommissie (DEC) onder leiding van dr. Catriene Thuring 
zijn belangrijk geweest voor het welslagen van mijn promotietraject. Bij deze 
wil ik hen ook graag bedanken voor de expertise en hulp bij de uitvoering van 
proefdierexperimenten. 
Analisten van het Chirurgisch Onderzoekslaboratorium! Petra, Janneke, 
Suzanne, Jacco en Jelle. Jullie werk en ondersteuning is erg belangrijk geweest 
voor dit proefschrift. Het lab zag ik als een grote speeltuin waar altijd wat te doen 
was en waar ik ook zeer welkom was om iets te onderzoeken. Jacco Zwaagstra, 
beste Jacco, in het begin moesten we aan elkaar wennen. We hebben wel eens een 
meningsverschil gehad over het dragen van twee handschoenen in de box van de 
rattenleverperfusie set-up. Echter, aan het einde van mijn promotieperiode belde 
je mij vaak op om te lunchen. Alleen is het mij nog steeds niet duidelijk of je dit deed 
om niet als enige man met een groep dames in het personeelsrestaurant te hoeven 
zitten. Petra Ottens, beste Petra, mijn waardering voor jou is groot vanwege alle 
hepatectomieën die je hebt uitgevoerd voor de rattenlever perfusie-experimenten. 
Het was fijn dat jij ’s ochtends vroeg de ratten voorbehandelde met metformine, 
zodat ik wat later kon beginnen (dus wat later kon opstaan). Samen met Suzanne 
heb je mij ook goed geholpen met de regelgeving rondom dierproeven. Bedankt voor 
je begeleiding daarin. Suzanne Veldhuis, beste Suzanne, je hulp was onmisbaar 
op het CDP ten tijde van het muizenexperiment met Golnar en Fernanda. Bedankt! 
En bedankt voor het zijn van een fijne collega! Janneke Wiersema-Buist, beste 
Janneke, zonder jouw snij- en kleurkwaliteiten van de weefselblokjes, stond ik 
nu nog met lege handen. Jij hebt me ook ontzettend vaak geholpen met andere 
analyses. Niets meer dan lof. Last but not least Jelle Adelmeijer, beste Jelle, 
bedankt voor alle (on)gevraagde adviezen.
Mede-promovendi en studenten van het Chirurgisch Onderzoekslaboratorium, 
veel dank voor de verrijkende momenten op het lab maar ook daarnaast. De 
‘werksfeer’ in het lab en het Triadegebouw was altijd erg leuk en gezellig. In 
het bijzonder wil ik dr. Sanna op den Dries bedanken voor het zijn van de 
eerste ‘dakpan’. Ik heb verder kunnen bouwen op wat jij hebt opgezet. Ik geef 
graag het stokje door aan de volgende dakpannen in de onderzoeksgroep voor 
levermachinepreservatie. I would also like to thank Negin Karimian, Fernanda 
Binnenwerk_Andrie_Final.indd   245 12/20/15   11:03 AM
246
Bomfati, dr. Golnar Karimian and Paria Mahboub for their cooperation in the 
lab experiments. I wish you all the best in your future careers!
Voor de verscheidende hoofdstukken heb ik samengewerkt met onderzoekers uit 
allerlei (wind)richtingen. Hier in het UMC Groningen wil ik graag mijn waardering 
uitspreken voor de samenwerking met dr. Marieke de Boer, Henk-Jan Mantel, 
dr. Maarten Nijsten, dr. Herman Hendriks, Manon Buist, prof. dr. Han 
Moshage, prof. dr. Daan Touw, Ben Greijdanus, Jan Bottema, Linda Albronda 
en Ernst Buiter. Vanaf deze plek een diepe buiging als dank voor jullie support!
De (oud)medewerkers van Organ Assist in Groningen, Martin Kuizinga, Ton 
Mulderij, Leonie Venema en dr. Arjan van der Plaats, fijn dat jullie altijd 
beschikbaar waren voor hulp tijdens de humane perfusie-experimenten, ook vaak 
‘s nachts, en jullie kennis wilden delen over de opzet van de apparatuur.
To Eindhoven, dr. Benno Hendriks and dr. Vishnu Pully, researchers of Philips 
Healthcare. Dear Benno and Vishnu, I am grateful for all your efforts in the human 
and mice study where we examined the applicability of the DRS system. We 
published two articles together! In addition, I greatly appreciate the cooperation 
with dr. Danny Evers and prof. dr. Theo Ruers from the Netherlands Cancer 
Institute Amsterdam. Thanks a lot for your contribution in the human study.
De andere Nederlandse levertransplantatiecentra en de Nederlandse Transplantatie 
Stichting ben ik ook veel dank verschuldigd. De onderzoekers in het Erasmus MC 
te Rotterdam onder leiding van prof. dr. Herold Metselaar, in het LUMC Leiden 
onder leiding van prof. dr. Bart van Hoek en Cynthia Konijn van de Nederlandse 
Transplantatie Stichting, bedankt voor jullie fijne samenwerking betreffende het 
multicenter onderzoek naar donorleeftijd. 
Julius von Martels en Jaap Euwema, wat fantastisch dat jullie mijn paranimfen 
willen zijn. Julius, ik vind het erg knap van je hoe je met alles bent omgegaan de 
laatste jaren en ben trots dat jij naast mij staat tijdens de verdediging! Op naar je 
promotie!
Jaap, onderzoek doen is niet jouw ding maar mensen helpen des te meer. Als zeer 
kundige jonge arts ligt de wereld aan je voeten. Fijn dat je de rol als paranimf wilt 
vervullen, hulde!
Lieve familie, vrienden, ouders Dick en Corry en broer Jos, ik kan jullie niet 
genoeg bedanken voor de onvoorwaardelijke steun in alles wat ik onderneem.
Allerliefste Annet, gewoon bij jou zijn of samen reizen, fietsen, bankhangen, 
koken, krant lezen… dat maakt mij al heel gelukkig! Laten we dat nog héél lang 
samen doen!
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Groningen, he studied one year at the Maritime Institute ‘Willem Barentz’ on the 
island Terschelling and one year of Pharmaceutics at the University of Groningen 
(first year diploma cum laude). In his second year of medical school he started with 
a pilot project in the research group of professor dr. Ton Lisman and professor dr. 
Robert Porte. In the same year he joined the Junior Scientific Masterclass (JSM) 
research week on the island Schiermonnikoog. In 2009, Andrie wrote his first paper 
about blood loss during liver surgery in cirrhotic patients together with professor 
dr. Ton Lisman and professor dr. Robert Porte. After the period of clinical rotations 
(Martini Hospital Groningen, Medical Center Enschede, Academic Hospital 
Paramaribo in the Republic of Suriname, and the University Medical Center 
Groningen) he continued his research during the scientific research internship 
and was accepted for the MD/PhD program in 2012. In 2013 Andrie graduated 
cum laude from medical school and also finished the basic teaching qualification 
in education for medical students (Basiskwalificatie Onderwijs voor Studenten; 
BKO-S) under supervision of professor dr. Ineke Molenaar. After two-and-a-half 
years of full-time research, Andrie started in October 2015 with the training to 
become an anesthesiologist at the University Medical Center Groningen under 
supervision of dr. J. K. G. (Götz) Wietasch.   
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